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9Preface	
Personalized Healthcare has seen great growth in the past decade and is believed to continue so forth.
Coming from working for Delft University of Technology as a Bioproduct Designer, we were trained
towards bridging the gap between academics and industry and translating technologies in real time to
industrial application as well as working with patents. We were quite focused on the commercialization
of academic knowledge and patents and were contracted with industry and academic groups to
commercialize or develop business plans of their in-house patents. To us the bridged gap between
academic research and industry and the subsequent market penetration was the end goal. We did not
think beyond those parameters as profit and success for the projects seemed inevitable.
Coming to Maastricht University, I was exposed to a totally new field of research, public health genomics
and health policy research. For me, these were unheard terms and activities. With a background in
Biotechnology, I was generally interested in genome-based technologies and initially wanted to integrate
my past expertise at Delft with the current research. I noticed from now working in these new areas of
research, healthcare implementation or diffusion was a totally different world in itself and as a
Bioproduct Designer, such issues were not addressed.
On further investigation, I noticed that several of the bioproducts or genome-based technologies being
commercialized for market penetration and generating good profits are in fact not implemented in
healthcare or have delayed diffusion rates.
This gave birth to the title and work of this thesis. I hope that the reader will be intrigued by the present
work and its importance regarding the issues the thesis addresses. Based on my now combined
background, the preface can end on the following quote:
“No discipline seems pleasant at the time, but painful. Later on, however, it produces a harvest of
righteousness and peace for those who have been trained by it”
Hebrews 12:11 NIV
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Background	
Outline
Within public health, and especially in Public Health Genomics, personalized health interventions have
become of great importance recently and will be in the future. However, their applications and
implementation in healthcare systems seem limited and/or delayed. Consequently both industry and
individuals are at disadvantage here as a result. This issue defines the importance of this work. The thesis
aims to address the issue of this bottleneck by developing a conceptual framework and demonstrating its
potential implementation for public health. In the process it aims to resolve the bottleneck of
personalized health application. This will be further emphasized in the subsequent paragraphs. This
chapter will start off with some background on Public Health Genomics and on how personalized
healthcare was derived through the complexity of biology, which gave rise to the ‘omics’ sciences and
eventually systems biology leading to the demand of personalized medicine and beyond. The chapter
then will define the state of the art of the various tools and activities used in translational research for
moving personalized healthcare from bench to healthcare. This will be followed by elaborating on the
problem statement, i.e. the backlog of personalized health applications, and will then define the
objectives of the thesis.
Omics, Systems Biology to Personalized Healthcare
Molecular biology in combination with other basic sciences as supplements, both human and non-
human research has greatly contributed not only to medical and applied research as well as directly to
medicine and drug discovery, but also to healthcare as a whole. Historically this has been well
documented from the early times for example the advent of genetics to disease, molecular coding,
viruses and the molecular mechanism of infection, protein structure, etc. [1] to examples in modern
application, like diabetic complications. For example, glucose mediated vascular damage has been
attributed to four pivotal molecular mechanism providing a potential for drug discovery [2]. However,
only in the past few decades, due to the birth of the concept of genomics and other ‘omics’1 we have
come to know beyond what was possible with just basic molecular biology largely due to the potential of
computational power [3, 4]. Similarly drug discovery applications historically have been influenced
significantly through genomics [5]. This led to the hype of the future of genomics research [6, 7]. As a
1 Omics encompass all types like Genomics, Proteomics, Metabolomics, Transcriptomics, etc.
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consequence of this expansion, we have come to know about the complexity of biology bringing in more
questions than answers, in this huge network of molecular interactions resulting in functional
consequences [8, 9].
These collective ‘omics’ including their interactions with environmental factors (exposome, epigenomics,
microbiome, lifestyle, etc.) and the complex knowledge generated demanded for a more holistic systems
approach and large scale models to evaluate information and to understand function [10] propelling the
concept of systems biology. Systems biology is defined as an integrative, interdisciplinary approach to
biological science that is built around the concept of close integration of computational methods,
technology development (including -omics) and global measurement and analysis of biological systems
[11].
The drive of systems biology and ‘omics’ power has inclined medical research towards a more
personalized approach to healthcare [11, 12]. With the advancement of ‘omics’ and access to
information via the internet and social media, the individual is demanding a more personalized approach
to his/her treatment [13] given we now know that every person is unique. Such advancement has led to
the development of the field of personalized medicine and healthcare, which is defined as the use of
genome-based2 information and technologies3 for providing more stratified and precise (and possibly
truly personalized) interventions [14]. Through the systems approach to medicine, medical application is
moving towards a more predictive, personalized, preventive and participatory (P4) approach [15]. As a
result, in 2009 alone, the U.S personalized medicine market was at $232 billion and is projected to reach
$452 billion by 2015 [16]. Consequently, in this post-genomic era through systems biology and ‘omics’,
personalized healthcare which also includes personalized medicine is becoming the way to move forward
in prevention and treatment of disease in a healthcare setting.
State of the Art for Translational Research
To realize P4 medicine or personalized healthcare, one must move this knowledge from the laboratory
into healthcare systems for daily practice. Translational research is defined as the effective translation of
2 Genome-based is in a synonymous with Omics as everything deriving from the human genome is genome-based,
i.e. transcriptomics, metabolomics, etc.
3 Information also includes omics interactions with the environment and technologies can include a diagnostic
application, intervention, technique, process, methodology, clinical application, and technology in the general
sense
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new knowledge, mechanisms and techniques generated by advances in basic science research into new
approaches for prevention, diagnosis and treatment of disease essential for improving health [17].
Translational research is considered pivotal for the realization of shift from bench to bedside and
beyond, i.e. to healthcare, of personalized health interventions. There are several methodologies or the
state of the art in translational research at different stages of the transition from bench to healthcare,
which will be described in the subsequent paragraphs. This is divided into two sections, namely
valorization focusing on the commercialization to the market and then the healthcare implementation
tools focusing on the integration aspects into healthcare.
Valorization
In translational research, valorization is a term commonly found responsible for bringing research ideas
into science-based businesses onto the market (bench to market). Valorization can be defined as the
transformation of knowledge into concrete new products, services and processes [18]. The term is
generally associated with commercialization of knowledge/technology from an academic or industrial
environment. Through systems biology and ‘omics’ research, we see the knowledge generated is being
valorized into personalized health applications on the market through the biotechnology sector [19-22].
Valorization as such does not have a defined methodology rather a concept put into action using other
methods. Terms or methodologies related or overlapping with valorization are regional valorization
systems, open innovations, technology transfer, spin-offs and drug discovery, all of which will be
emphasized on in the following paragraphs.
Regional Valorization Systems
To achieve knowledge valorization, there is no defined methodology. However, one related conceptual
framework for knowledge valorization is called a Regional Valorization System. The idea is that
interactions  between  different  regional  actors  will  streamline  knowledge  transfer  from  academics  to
business and subsequent policy development for such knowledge valorization to business. A Regional
Valorization System [23] is a framework, which aims to achieve knowledge valorization between
academia and the business sector by providing support at different sub-systems as well as to make
aware important areas and interactions. Furthermore, it aims to involve local and regional governing
bodies to recognize the urgency on the direction of knowledge based development and subsequent
policies. Smooth interaction between the different sub-systems leading to knowledge valorization from
academics to business can be seen as the success of this framework. The actors required and available to
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facilitate this framework include interactions of people from multiple disciplines for example, basic and
applied university researchers, industrial partners, hospitals, contract researchers, venture capitalists,
funding agencies including both non and governmental, human resource department, policy makers and
local government. The expectation of the stakeholders within this framework is consistent and clear
communication and interactions between the different players involved to facilitate knowledge
valorization.
Open Innovations
Another term related to valorization is open innovation. Open innovation [24] can be defined as to profit
from external knowledge without making heavy internal investment in long term research. This may
include any form of cooperation with third parties that can contribute to improve the long term
performance of a company as well as grants both governmental and NGOs. Cooperation with third
parties, for example contracted research to private institutes, companies or universities will help in
avoiding substantial investment in one’s own infrastructure to do research to develop say a product.
Licensing production is another example. Stakeholders expect minimal amount of investment with
maximal  amount  of  returns.  Consistency  can  vary  from  case  to  case  as  well  as  organization  to
organization. Current trends (patents, trademarks and trade secrets among others) limit the full
potential for open innovation.
Technology Transfer
Valorization also closely associates with another term called Technology Transfer (TT). Technology
Transfer aims to transfer technology from one organization to another organization. TT is seen as an
activity of the migration of early discoveries in any setting (e.g. private sector, academia) to useful
application in the development of marketable products or processes (adapted from [25]). Again this is on
the business side of translational research and overlaps with the concept of valorization but generally
has defined methods.  Various TT methodologies are well known and actively utilized by the commercial
sector to move ideas from the lab onto the market. For an example see figure 1 [26]. Furthermore, TT
offices exclusively also exist both in academics as well as private sector just to help in commercializing an
idea or patent or technology. Other resources include investors as well as development of business
models. Staff activities can involve coming up with a concept which addresses a market need and
subsequently developing that concept. The concept of TT is well established and proven [27].
Stakeholders expect that the product developed through the TT pipeline is eventually rolled into the
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market and successfully commercialized for return on investment. Consistency of this performance is
based on a case by case basis and the market need. For example, in the biopharmaceutical industry, it
does not have such a high success rate, whereas in the medical devices and electronics markets it has
more consistency in the same order. It is to be noted that TT is differentially applied and may not have
the same order as figure 1 below.
Spin-offs
Spin-off is a term, which partly overlaps with the concept of valorization in the specific setting of
academia, although does not have an absolute defined methodology. Spin-offs have been extensively
researched can be considered an emerging field of work focusing on the process of creating, discovering
and exploiting technological and scientific opportunities created by academic research through the
development of an independent company created from an existing part or person of the academic
institution or company. Spin-offs can be considered almost synonymous with SMEs (Small Medium
Enterprises) as SMEs generally are the companies, which are created as a result of the endeavor.
Therefore, spin-offs can be defined as firms whose products or services develop out of technology-based
Figure 1: A  sketch  of  an  example  of
technology  transfer  taken  from  [26].  The
idea is that research in the lab leads to an
idea, which is developed into an invention
and assessed for its feasibility. After or
during the development of the
technology, the technology is protected
by patenting, thereby marketing the
technology to customers. These
customers  can  take  the  license  of  the
technology to sell it to other customers or
can be skipped. This results in products
and services eventually leading to return
on investments.
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ideas or scientific/technical know-how generated in a research setting by a member of the research
institution, staff or student who founded (or co-founded with others) the firm [28]. The term firm can be
replaced with the term SMEs. Spin-offs are related to technology transfer or even overlapping greatly
with technology transfer in some instances based on the latter’s methodology. For spin-offs in some
cases, academic resources may be required or not for conceiving the initial research idea based on the
market need or creating the need. Investments like from venture capitalists, grants, etc. in the
development of a business model for a company based on the concept of the product are generally
required. Technology transfer offices (TTOs) are available for such a venture and spin-offs generally
require approval from the research institution.
Drug Discovery
Knowledge valorization also relates to the development and discovery of biopharmaceuticals. Moving a
drug from the lab to the market is generally done in phases, which seem to overlap again with the above
mentioned concepts. Drug discovery phases can be seen from figure 2 [29] below. Like TT, drug discovery
has a defined yet subjective methodology. After preclinical research, a medical target is identified which
can be exploited for drug development purposes. Thereafter, the feasibility of the target for drug
development is assessed leading to preclinical development and eventual creation of the drug. Phase I
concerns the test of the drug for safety, administered amount and side-effects in a volunteered small
healthy group of subjects. Phase II is concerned with effectiveness as well as safety in a volunteered
small healthy group of subjects. Phase III involves testing the drug on a large group of volunteered
subjects. This is to establish the effectiveness as well as to observe side-effects and compare to currently
used treatments. Phase IV is done when the drug is approved and use has started. The concept is to
gather and analyze data on risks, benefits and best usage.
Figure 2: The different stages of drug discovery and development. Taken from [29]
Healthcare Implementation Tools
The above mentioned terms generally define the most generally used mechanisms in the
commercialization of knowledge and technologies. However, only technology transfer and drug
discovery have a defined methodology, which overlaps in concepts between the remainder of terms as
| INTRODUCTION
22
can be seen. So there seems to be a possibility of interchangeable terms in the process of
commercialization. On the other hand of translational research, implementation or integration of
technologies into healthcare beyond commercialization has several activities such as Health Needs
Assessment (HNA), Health Technology Assessment (HTA), Health Impact Assessment (HIA), ACCE, EGAPP,
T1-T4, Public Health Genomics Enterprise, and the Public Health Wheel. These will be elaborated upon in
the subsequent paragraphs.
Health Needs Assessment
Major tools used by decision makers directly or indirectly include Health Needs Assessment (HNA),
Health Technology Assessment (HTA) and Health Impact Assessment (HIA) [30].  HNA is ‘a systematic
method of reviewing the health issues facing a population, leading to agreed priorities and resource
allocation based on the needs of the population that will improve health and reduce inequalities’ [31].
HNA can use epidemiological, qualitative and comparative methods to this end to address the above
definition [32]. HNA works towards influencing policy through logical decision making, promoting
interagency collaboration and advance prioritized R&D [33]. The methodology of HNA involves first
estimating the frequency of health issues in a given population and then evaluating the proof for the
positive and negative effects of the technologies per health issue [34]. In the process, HNA addresses the
impact, changeability, acceptability and resource feasibility with respect to maximum positive impact the
technology can have on the health of a population, i.e. targeting whole populations, subpopulations as
well as individuals [31].
Health Technology Assessment
Health Technology Assessment (HTA) is considered a very important tool looked at by decision makers.
HTA can be defined as a ‘multidisciplinary process that summarizes information about the medical,
social, economic, legal and ethical issues related to the use of a health technology in a systematic,
transparent, unbiased, robust manner’ [35]. HTA strives for the best possible value and also works on
informing in the development of effective and safe (health) policies that are focused on the
patient/citizen [35]. As this applies HTA’s involvement in interventions and appraisals it is considered as
an  important  information  tool  for  decision-making  [30].  According  to  Battista  [36]  HTA  could  be
perceived to bridge the gap between decision-making and research, however, it is perceived to be based
in scientific method [35]. Policy analysis, (health) economic evaluation and evidence-based medicine play
a pivotal role in HTA. This is also extended to humanities/social sciences as well [37]. HTA is
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complimented by horizon scanning (HS - identifying emerging and new technologies) [38] and
Constructive Technology Assessment (CTA). The latter addresses the issue of technologies being highly
dynamic [39]. Historically HTA was developed from the need of healthcare systems and/or decision
makers to identify relevant technologies for their usage [40, 41]. An example of the HTA process can be
seen from figure 3 below [42].
Figure 3: A simplified example of an HTA process. Taken from [42]. Different agencies can do HTA differently. It is to
be noted that the HNA part of HTA is different from the general HNA.
Health Impact Assessment
Like HNA and HTA, Health Impact Assessment (HIA) is a good evaluation tool used by decision makers.
HIA is ‘a combination of procedures, methods and tools by which a policy, program, or project may be
judged as to its potential effects on the health of a population, and the distribution of those effects
within the population’ [43]. In other words, HIA gives decision makers insights of the full spectrum of
consequences of genome-based technologies (GBTs) or policies as a result, as well as informs about
unpredictability [44]. HIA, as a tool first investigates and determines various polices which can positively
or negatively impact health. This is followed by considering both, direct as well as indirect health effects,
thereby determining, which populations are affected as a result and on what basis. This is followed by
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reporting the findings to decision makers and finally evaluating the result of actual implementation [32].
HIA originated partly from environmental policy development, health equity and a social view of health
[45]. In conclusion, HNA identifies ‘health priorities for a given population’, HTA evaluates the
‘performance of health care technologies’ and HIA assesses the ‘effects of policies, programs or projects
on the population’s health’ [32]. There are professionals and organizations, some designated by policy
makers working on these separate 3 yet overlapping tools to develop recommendations for decision
makers.
ACCE
On the other hand, the ACCE (Analytical Validity, Clinical Validity, Clinical Utility, Ethical, Legal, and Social
Implications, see figure 4) is considered a benchmark framework to evaluate specifically emerging
genetic tests [46]. Supported and developed by CDC, USA, it aims to inform decision makers by
presenting data on genetic tests in an updated readable format for them to make decisions [47].  From
ACCE, Analytical Validity defines ‘how accurately and reliably the genetic test measures the genotype of
interest’ [47]. Clinical Validity defines ‘how consistently and accurately the test detects or predicts the
intermediate or final outcomes of interest’ [47]. On the other hand, Clinical Utility defines ‘how likely the
test is to significantly improve patient outcomes’ [47]. The last ‘E’ in the ACCE stands for ELSI (Ethical,
Figure  4: Sections of the ACCE model and their
details. The figure shows what falls under
analytical validity, clinical validity, clinical utility
and ELSI. Taken from [47]
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Legal, and Social Implications) and forms an important part of the ACCE framework as implications may
arise in context of using the genetic test [47]. The ACCE methodology includes gathering data, assessing
it and interpreting the results followed by reporting that data to decision makers in an understandable
updated read for them to come to a decision. This data is generally about DNA-related testing or genetic
disorders  [47].  A  standard  set  of  44  specific  questions  comprises  the  model.  These  44  questions  are
divided into 5 sections namely, disorder/setting (7 questions), analytical validity (10 questions), clinical
validity (8 questions), clinical utility (16 questions) and ELSI (3 questions). Some of these 5 sections are
also further divided into subsections [47].
EGAPP
EGAPP (Evaluation of Genomics Applications in Practice and Prevention) established in 2004 [48], can be
in a way considered as the successor to the ACCE model as it builds upon ACCE and was also developed
by CDC, USA. The EGAPP working group aims at the development of a ‘systematic, evidence-based
process for assessing genetics tests and other applications of genomic technology in transition from
research to clinical and public health practice’ [48]. The methodology constitutes existing
recommendations based on population-based epidemiological studies as well as knowledge from prior
initiatives [48]. EGAPP consists of independent multidisciplinary panel of 15 experts sanctioned through
CDC. The general methodology involves selecting potential topics for review through horizon scanning
and feedback, and then defining disorders of interest, specific tests and clinical scenario. This is followed
by brief summaries of identified tests and a preliminary review and prioritization of topics using specific
criteria ending in voting. The next step involves the EGAPP evidence review process. This starts with
formulation of key questions and analytical framework for evidence review followed by a systematic
evidence review either in the direction of comprehensive EPC (Enhanced Primary Care) reports or
Rapid/Targeted reviews. After this, the EGAPP reviews the evidence reports, considers contextual issues
and may consider other sources of evidence, and as a result a draft recommendation peer-reviewed
statement is developed and published. This ends with the dissemination to stakeholders. Detailed step
by step can be found in the document [49] CDC published.
T1-T4
Khoury et al. [50] propose a framework for the continuum of multidisciplinary translation research based
on population-based epidemiological studies. Although not part of the assessment used by decision
makers, this framework has received attention [32]. The authors divide their framework into 4 phases.
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Phase 1 translation research (T1) aims to move a ‘basic genomic discovery into a candidate health
application’. This is followed by phase 2 (T2), which ‘assesses the value of a genomic application for
health practice leading to the development of evidence-based guidelines’. Phase 3 (T3) moves from
‘evidence-based guidelines to health practice’. The final phase 4 (T4) evaluates in practice the health
outcomes the genomic application. T1 to T4 can have feedback loops [50]. Khoury et al. compares their
phases with drug discovery and ACCE mentioned above as we as the Human Genome Project (HuGE),
which can be seen from figure 5 below.
Figure  5:  Giving  an  example  of
T1 to T4 over different tools like
ACCE and drug discovery. Taken
from [50]. It should be noted
here however, T1 to T4 does
not have a defined
methodology.
The Public Health Genomics Enterprise
The Public Health Genomics (PHG) Enterprise (see figure 6 below) is a composite ‘for effective translation
of genome-based knowledge and technologies into improved population health’ [51]. The consensus was
developed by an international expert workshop held in Bellagio, Italy in 2005, with 18 experts from US,
Canada, Germany, UK and France. Although not part of the assessment process by policy makers, it
nonetheless contains important components and overlaps with tools previously mentioned. The PHG
Enterprise’s knowledge integration is considered pivotal [51]. It can be defined as ‘the process of
selecting, storing, collating, analyzing, integrating and disseminating genome-based information both
within and across disciplines for the benefit of population health’. This can also constitute
methodological progression as well [51]. Further information can be seen from figure 6 below.
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Figure 6: The PHG Enterprise - Blue represents the scope of the enterprise, yellow indicates creation of knowledge
through research and red indicates genome-based science and technology playing a pivotal role. Green indicates
society in its widest sense including stakeholders, activities, etc. Two sided arrows indicate dynamic and interactive
nature of the enterprise. As can be seen the PHG enterprise has four main activities, viz. communication and
stakeholder engagement, informing public policy, developing and evaluating preventive and clinical health services
as well as education and training. Research identifies gaps with differentiation between basic and applied research
being blurred. Also the generated knowledge is modulated by the results of its own output. This includes a cycle of
analysis, strategy, action, evaluation, which is widely regarded in public health practice. Taken from [51].
The Public Health Wheel
The Public Health Wheel [52] can be seen from figure 7. The PHG Wheel demonstrates the integration of
genome-based information and technologies into public health by addressing the 10 essential tasks of
public health in the translation of the technology in question.
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The Problem Statement
The above mentioned tools summarize the most popular activities or tools for translational research of
health interventions from bench (lab) through the market to bedside and beyond (healthcare). As earlier
stated in the outline of this chapter and the subsequent paragraphs, it is seen that the importance of
personalized healthcare and its exponential market is being realized. Furthermore, there are various
tools, some of which overlap that can bring personalized health applications from bench to healthcare.
Still however, the timely implementation of these applications depending upon the type of technology
seems apparently delayed. This is evident from large amount of scientific data in the market [21, 22] and
also in terms of literature [53], patents [54, 55] and publications compared to the uptake by hospitals
and  the  healthcare  system  [56].  There  seems  to  be  a  backlog  of  technological  integration  into  the
healthcare system. As a result, by the time a new genome-based technology arrives in practice, it
becomes outdated. Even though the technology may get part/whole of the job done, there is always a
newer technology waiting to be used, which may get the same/better results more efficiently in terms of
time, accuracy, specificity and costs (notwithstanding the cost of the technology itself) and this makes
the difference in the quality of life. Even guidelines developed tend to focus on handling and use
genome-based information no matter by what type of technology the information was produced.
Figure  7: The Public Health
Wheel which divides 10 essential
tasks of public health over the
domains of assessment, policy
development and assurance
with research at its core. The
idea is that by addressing these
10 essential tasks, integration of
genomics into public health can
be possible. Taken from [52].
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Public Health Genomics is the responsible and effective translation of genome-based knowledge and
technologies into public policy and health services for the benefit of population health [51]. It is an
emerging field with increased demands of integration of genome-based information into public health
due to the prior’s increasing value and relevance in the latter. The field of Public Health Genomics based
on its definition exactly answers the problem. This issue of genome-based technologies, (which include
personalized health interventions), delayed translation and implementation in healthcare is an important
problem to be addressed. Both healthcare and industry is as a loss here, if relevant technologies are not
transferred in real time to the healthcare settings. For example, patients can benefit from the latest
personalized medicine applications if provided on time, possible focusing on early prevention rather than
only cure, thus possibly alleviating the burden of disease. Also industry can generate larger profits if
timely  interventions  reach  the  patient  or  citizen  as  compared  to  delayed  sales  or  limited  sales.  It
becomes indeed a pity if the boom of personalized healthcare including personalized medicine with its
huge market and promises is delayed. Therefore the aim of this thesis is to address this backlog through
the concept and still relatively new field of public health genomics.
The Missing Link
The thesis approaches the issue with the concept of bringing valorization in public health genomics to
complete the picture. Reason being valorization addresses the business side of things including
commercialization, whereas the definition of public health genomics concentrates on the translation into
public policy and health services. Also cross-integration of different concepts has been suggested [57] to
bring in the effective and efficient real-time integration of genome-based technologies. Based on the
problem statement, there seems to be a rabbit and turtle pace between the two enterprises, namely,
the science-based industry and healthcare system respectively when it especially comes to personalized
healthcare applications. The thesis will address the problem of the backlog and bottleneck of the real
time effective and efficient integration of genome-based information and technologies (including
personalized medicine and healthcare applications) from the bench (lab) through the market to the
healthcare covering the whole spectrum of translational research of health interventions.
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General	Aims	
The thesis aim to address the issue of the backlog and bottleneck of the effective and efficient
integration of genome-based information and technologies from the first idea, through the market, to
implementation in healthcare covering the whole spectrum of translational research. The hypothesis is
that given the exponential increase in genome-based technological innovation, systems in place for
technological integration into healthcare practice still have a backlog in real time. The thesis therefore
projects to gain knowledge about current methodological apparatuses in place, identification of
gaps/problems and issues in healthcare systems, see possible integration of relevant tools and give
recommendations. Furthermore, certain existing concepts and ideas have overlaps and the thesis also
aims to develop a consistency of the relation of different tools to avoid confusion thereby bringing in
new concepts in valorization. In addition the current existing guidelines are not compatible for
implementation of genome-based technologies; therefore the thesis will also aim to contribute to the
development of the European best practice guidelines in this field (through PHGEN II). The objectives of
the thesis can be summarized as follows:
· Identify the reason behind the backlog or bottleneck of effective and efficient real time
integration of health innovations/interventions (genome-based technologies)
· Address the issue of this bottleneck by proposing a framework covering the whole spectrum of
translational research possibly through integration and development of (new) concepts
· Demonstrating reasons why certain tools are not relevant to the framework
· Defining the concept of valorization in public health genomics
· Addressing the confusion behind different concepts in translational research and showing the
relations between them including conceptual development of the placement of tools within the
translational research pipeline
· Developing the step by step methodology of the developed framework
· Giving examples where the new framework can be implemented
· Contribution to the development of the European best practice guidelines on genome-based
information and technologies
Conclusively the thesis aims to develop a conceptual framework for the whole pipeline of translational
research using the concept of valorization in public health genomics.
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Overview	of	Thesis	Chapters	
The thesis is divided into 5 sections namely, General Introduction (Section 1),  Chapters  (Section  2),
General Discussion (Section 3), Concluding Remarks and Future Prospects (Section 4) and Miscellaneous
(Section 5). With respect to the aims mentioned above in the General Introduction, Section 2 (Chapters)
is divided into two parts namely Part  A that includes chapters I, II, III and IV which deals with the
development of theoretical concepts; and Part  B that includes chapters V, VI, VII and VIII which deals
with the potential implementation scenarios of the developed framework.
Chapter  I deals with setting the stage of the issue and defining the concept of valorization in Public
Health Genomics, identifying the bottleneck and addressing it by developing a conceptual framework.
Chapter II elaborates on all the widely used concepts of translation and implementation of genome-
based health innovations. It clarifies the concepts of different tools and demonstrates the place of
different tools within other concepts and clears the confusion. It also demonstrates why certain tools
were  left  out  of  the  developed  framework  in  chapter  I  as  well  as  why  the  framework  is  overarching.
Chapter III develops the complete detailed protocol/methodology on how to use the model and
addresses related issues. Chapter IV gives the general conclusion of Part  A based on the specific
objectives defined. Chapter V describes  the  complexity  of  biology  as  a  result  of  ‘omics’  and  the
introduction of systems biology and its relation to personalized healthcare. It proposes the
implementation of the developed framework using an example of a current EU flagship pilot project ICT
Future of Medicine (ITFoM). Chapter VI gives a review of literature on Chlamydia trachomatis and its
relevance to tubal pathology and infertility and the recent development of the potential of developing a
diagnostic kit based on an ongoing series of single nucleotide polymorphisms (SNP) markers. Possibly
through an SME the developed kit will supplement traditional tests and the thesis’s developed
framework is proposed here to address the bottleneck mentioned in Part A with this diagnostic kit.
Chapter VII contributes to the development of the European best practice guidelines for quality
assurance, provision and use of genome-based information and technologies and clears certain
concepts. Here the thesis demonstrates the incorporation of the developed framework in the policy
guidelines on the European level. Chapter VIII gives the general conclusions of Part  B based on the
specific objectives defined.
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Section 3 discusses in detail the conceptual development of the framework and discusses the issues of
the previous chapters and conceptualizes beyond the status quo. Section 4 derives and simplifies the
conclusions over the complete thesis. Section 5 gives the summary of the thesis, the CV of the thesis
author as well as list of publications and acknowledgements.
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Specific	Aims	
This part of the thesis deals with developing the theoretical foundations based on the problem
statement of the bottleneck of the real-time effective and efficient integration of genome-based
technologies into healthcare as stated in the introduction chapter. The part however first deals with
identifying and addressing the problem and building around theoretical concepts and the protocol to
execute the solution as well as defending the solution’s overarching reach. In relation to the general
objectives stated in the introduction chapter, this part relates to the following mentioned general
objectives:
· Identify the reason behind the backlog or bottleneck of effective and efficient real time
integration of health innovations/interventions (genome-based technologies)
· Address the issue of this bottleneck by proposing a framework covering the whole spectrum of
translational research possibly through integration and development of (new) concepts
· Demonstrating reasons why certain tools are not relevant to the framework
· Defining the concept of valorization in public health genomics
· Addressing the confusion behind different concepts in translational research and showing the
relations between them including conceptual development of the placement of tools within the
translational research pipeline
· Developing the step by step methodology of the developed framework
Deriving from these general objectives, the specific aims of Part A are as follows:
· Chapter I
o Presenting the problem statement of the bottleneck of integration of genome-based
technologies into healthcare
o Identifying the rationale behind the problem statement
o Introducing  tools to resolve the problem statement
o Defining valorization in public health genomics
o Developing the framework to close the gap – the LAL model
· Chapter II
o Elaborating on various concepts used in the field and arguing the exclusion/inclusion of
them with respect to the developed framework
43
o Resolving the issue of overlapping tools and defining them with relation to each other
o Argumentation why the solution framework is the answer
· Chapter III
o Elaboration on the defined steps of the solution framework
o Addressing issues still to be resolved
· Chapter IV
Deriving conclusions based on the specific objectives
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CHAPTER	I	PUBLIC	HEALTH	AND	VALORIZATION	OF	GENOME-BASED	TECHNOLOGIES:	A	NEW	MODEL	
Published as:
Lal JA, Schulte in den Bäumen T, Morré SA, Brand A.
Journal of Translational Medicine 2011, 9:207.
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Abstract	
Background: The success rate of timely translation of genome-based technologies to commercially
feasible products/services with applicability in health care systems is significantly low. We identified both
industry and scientists neglect health policy aspects when commercializing their technology, more
specifically, Public Health Assessment Tools (PHAT) and early on involvement of decision makers through
which market authorization and reimbursements are dependent. While Technology Transfer (TT) aims to
facilitate translation of ideas into products, Health Technology Assessment, one component of PHAT, for
example, facilitates translation of products/processes into healthcare services and eventually comes up
with recommendations for decision makers. We aim to propose a new model of valorization to optimize
integration of genome-based technologies into the healthcare system.
Methods: The method used to develop our model is an adapted version of the Fish Trap Model and the
Basic Design Cycle.
Results: We found although different, similarities exist between TT and PHAT. Realizing the potential of
being mutually beneficial justified our proposal of their relative parallel initiation. We observed that the
Public Health Genomics Wheel should be included in this relative parallel activity to ensure, all
societal/policy aspects are dealt with preemptively by both stakeholders. On further analysis, we found
out this whole process is dependent on the Value of Information. As a result, we present our LAL
(Learning-Adapting-Leveling) model, which proposes, based on market demand; TT and PHAT by
consultation/bi-lateral communication should advocate for relevant technologies. This can be achieved
by public-private partnerships (PPPs). These widely defined PPPs create the innovation network, which is
a developing, consultative/collaborative-networking platform between TT and PHAT. This network has
iterations and requires learning, assimilating and using knowledge developed and is called absorption
capacity. We hypothesize that the higher absorption capacity, higher success possibility. Our model
however does not address the phasing out of technology although we believe the same model can be
used to simultaneously phase out a technology
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Conclusions: This model proposes to facilitate optimization/decrease the timeframe of integration in
healthcare. It also helps industry and researchers to come to a strategic decision at an early stage, about
technology being developed thus, saving on resources, hence minimizing failures.
Keywords: Technology Transfer, Health Technology Assessment, Public Health Genomics, Health Needs
Assessment, Health Impact Assessment, Valorization, Translational Research, Healthcare, Health Policy,
Genomics
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Background	
Over time we have seen enormous transition of genome-based/life science research from the lab to
products and technologies [1-3] on the market [3-6] as a result of knowledge valorization and spin-offs
[2,3,7,8].  This  can  be  attributed  to  the  concept  of  translational  research,  which  is  the  effective
translation of new knowledge, mechanisms and techniques generated by advances in basic science
research into new approaches for prevention, diagnosis and treatment of disease essential for improving
health  [9].  However,  we  notice  that  the  timely  translation  of  genome-based  technologies  to
commercially feasible products with practical applicability or direct implementation in health care
systems is quite low [10]. This is evident by the large amount of data present in literature [11], patents
[12,13] and the market [3,5] compared to what actually is being used in hospitals [10,14]. We identify,
based on our experience as well as derivatively, three phases of translation. The first phase includes
translation from lab to industrial application (see T1 of Khoury et al.) [15], the second phase being from
industry to market penetration [16] and the third phase being, shift from the market to integration in
health policy (see T3 of Khoury et al.) [15]. We believe both academia and industry focus only on one or
maximum two of the three translational phases.
In addition, methodologies in place for translation generally focus on the first two phases or the last
phase  and  as  per  our  knowledge  we have  not  seen  a  combination  of  the  three,  overlaps  or  jumps  in
general. For example, Technology Transfer (TT) mainly addresses the first two phases mentioned above.
TT is seen as an activity of the migration of academic discoveries to useful application in the
development of marketable products or processes [17]. TT can involve several steps from organization to
organization and can have separate offices specialized in this activity. For example, universities have a TT
office or valorization center responsible for TT activities of university research. Basically, the TT activity
initiates from an invention of an innovative idea, through the development of the idea into a pilot to the
creation of the technology based on the idea followed by patenting the technology in question and ends
after the technology maturation process. The maturation process involves the return on investment and
exit strategy of a company with respect to the technology concerned. A simplistic example can be seen
from Figure 1 below [18]. TT is the most widely used activity [1] in business development of academic
research and spin-offs [19]. It should be noted here however, TT can be considered as an activity,
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methodology, tool  or technique depending on the user.  However from the objective of our paper,  we
will consider this as an activity.
Figure 1: The Technology Transfer Process. The basics include the start from research and development based on
market pull or push, successfully inventing a product based on that research, patenting the product, thereby
marketing and licensing and going through the technology maturation process. Taken from the North Carolina
Agricultural and Technical State University [18].
The most common procedures used by decision makers (DM) and health professionals in phase three
mentioned above involve the traditional public health evaluation instruments [20], which include Health
Needs Assessment (HNA), Health Technology Assessment (HTA) and Health Impact Assessment (HIA).
HNA is a systematic method of reviewing the health issues facing a population, leading to agreed
priorities and resource allocation that will improve health and reduce inequalities [20]. Correspondingly,
HTA is a multidisciplinary process that summarizes information about the medical, social, economic and
ethical issues related to the use of a health technology in a systematic, transparent, unbiased, robust
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manner. Its aim is to inform the formulation of safe, effective, health policies that are patient focused
and seek to achieve best value [21]. This implies to interventions as well as HTA’s involvement in
appraisals. Thus, HTA is a powerful tool to inform policy making. According to the World Health
Organization, HIA is a combination of procedures, methods and tools by which a policy, program, or
project may be judged as to its potential effects on the health of a population, and the distribution of
those effects within the population [22]. To summarize, HTA evaluates the performance of health care
technologies, HIA assesses the effects of policies, programs or projects on the population’s health, and
HNA identifies health priorities for a given population [20]. For our convenience, we will use the term
Public Health Assessment Tools (PHAT) for the collective reference to HNA, HTA and HIA in the text.
It becomes apparent from above, that the translational phases 1-2 and 3 mentioned above are
investigated by two separate entities, namely, the academia-industry infrastructure [23] and the
governmental  bodies  respectively.  This  is  the  key  reason  why  the  two  operate  as  separate  functions.
While TT aims to facilitate the translation of ideas into products, HTA for example, assesses the
translation of products and services into healthcare. As per content, they both seem inseparable in the
order stated, however to our knowledge have never been connected. As a result, there is a backlog of
relevant technologies to be integrated in Public Health and healthcare in general in a timely as well as
effective and efficient manner [10,24,25]. Even by the time a technology is introduced in the health care
system, it is in a way deemed redundant as more effective and efficient technologies become available in
the market. Redundancy is from the perspective of the potential of existing technologies on the market
compared to the previously introduced one in the hospital. Efficiency measures whether healthcare
resources are being used to get the best value for money [26]. Therefore, efficiency can be seen in terms
of added value, speed and cost, although costs can vary. According to Ostrower [27], effectiveness has
several varying definitions but one of the common ones used by institutions includes the component of
‘having an impact’. On the other hand (clinical) effectiveness is the extent to which specific (clinical)
interventions do what they are intended to do, i.e. maintain and improve the health of patients securing
the greatest possible health gain from the available resources [28]. In other words, effectiveness and
also in our case, refers to the achievement of the overall goal (the effect). We identify the non-synergy
between TT and PHAT, as the bottleneck of technological integration in the health care.
This brings in the new field of Public Health Genomics, which is the responsible and effective translation
of genome-based knowledge and technologies into public policy and health services for the benefit of
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population health [29]. It is an emerging field with increased demands of integration of genome-based
innovations i.e. genome-based knowledge and technologies, into Public Health due to the prior’s
increasing value and relevance in the latter. Within the concept of Public Health Genomics and keeping
in mind the bottleneck mentioned above, we aim to propose a new model to facilitate valorization of
genome-based technologies into the healthcare system in real time.
The term valorization can vary depending upon the user (say either the economist or entrepreneur).
According to the Merriam-Webster online dictionary [30], one definition of valorize states ‘to assign
value  or  merit  to’.  On  the  other  hand,  the  term  valorization  can  be  defined  as  the  transformation  of
knowledge into concrete new products, services and processes [31]. Deriving from these two definitions
and keeping in mind the definition of Public Health Genomics, valorization in Public Health Genomics can
be seen as the ‘process of realization’ of relevant added value ‘bioproducts’ in the domain of Public
Health for benefit of the population and healthcare systems. Here we consider realization in terms of
understanding the importance, impact or potential benefit and implementing it. The term bioproduct
may have varying definitions [32,33], here again based on the user or source. According to the working
definition submitted to the British Columbia Bioproducts Working Group [34] with the background of
agro-forestry, bioproducts are sustainable, environmentally friendly novel products, or products
satisfying novel applications and generated from renewable (living) bioresources based on
technologically advanced eco-efficient conversion processes. Within our scope of usage focusing on
integration of genome-based technologies/life sciences into healthcare, we define bioproducts as
sustainable novel products or products satisfying novel health applications derived or inspired from
genome-based information or technologies. We define a product as a system, device, technique or
process or application. Genome-based technologies encompass all -omics initially deriving from the
(Human) Genome.
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Methods	
The methodology we used to develop the model is based on the Basic Design Cycle [35] and the Fish
Trap model [36] as can be seen from Figure 2 and 3 respectively. The general methodologies mentioned
above are used mainly in designing products for commercial exploitation. In our case, the methodologies
have been adapted to fit our purpose, which can be seen in Figure 4 below. We use this adapted design
technique to address a Public Health and health policy issue, the integration of genome-based
technologies into healthcare in the concept of a new model. In the subsequent paragraphs we briefly
explain the two models from which our methodology derived from followed by the derived methodology
itself.
The Basic Design Cycle (BDC) is stated to be the most fundamental model
of designing. The intended behavior or function of the product is the start
of product design as can be seen from Figure 2. Broad statements on the
function/properties (use) are made in order for the designer to know
what needs to be designed. In the analysis phase the problems
surrounding a new product idea are identified (also called the problem
statement), thereby criteria are formulated from general to specific ones
over iterations, which the solution should satisfy. The next step is the
development of a provisional design via the synthesis phase (combining
things) [35]. This phase is based on human creativity and is considered the
moment of externalization and description of an idea on any form. The
next phase is simulation phase, which is considered a deductive process.
Simulation in essence is forming an image of the behavior and properties
of the designed product through testing, reasoning, etc. and results in
anticipation of the real
properties or conditional
predictions for the new product.
The next phase is the evaluation
in which the value of the design
is established. This is based on
Figure 2: The basic design cycle. The most
basic design methodology used. All design
problems have one way or the other went
through this design directly/indirectly. See
text for description. Taken from
Roozenburg et al. [35].
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comparison of previously mentioned set specific criteria (see Figure 2) and actual properties in the
design. The last phase is the decision phase whether to continue or reconsider. There is the possibility
that the designer may need to return to the analysis or synthesis with subsequent iterations and
feedback loops [35].
The Fish Trap Model (FTM) (can be considered to be called as to catch a final solution) is a systematic
process of designing a product form. As can be seen in the Figure 3, the fish trap is illustrated in two
ways, (Figure 3A) to visualize the divergence and convergence as well as to show the occurrence of
various solution types at each level [36]. Once possible variants are created through
curiosity/possibilities, they are categorized according to solution type. Thereafter, one or more variants
are chosen to be developed into a concept, which indicates a specific solution type. Again, from here
more concrete solutions are derived from the chosen variants thus diverging again. This narrows down
to one or few options to go forth with [36].
As can be seen from Figure 3B, the FTM is represented in a step by step or phase format. Since the
model pushes the designer to discover alternatives on 3 levels, namely topological, typological and
morphological, it is considered a systematic process as can be seen in the figure. Following step by step
Figure 3B, in order to develop the ‘structural concept’ the ‘basic structure’ functional components need
to be defined in advance through ‘visualization of context’. One can develop or ‘generate’ multiple
variants with these components that may differ in their respective spatial placement. These divergent
are then clustered (convergence) or ‘categorize’ and a representative variant are selected to be
developed into a ‘structural concept’. Again, selection of these structural concepts will be based on
evaluation criteria and need to be put into context. For the development of a ‘formal concept’, one or
more structural concepts are taken [36]. From these selected structural concepts, geometric
constructions via sketching are made leading to different classes of form (generate step). These sketches
are evaluated based on their viability and categorized into groups based on form, and improvements can
be still made and evaluated. Thereafter, promising candidates are further developed into one or more
‘formal concepts’. Similar to above, further materialization of one or more formal concepts is done with
a diverging exploration process again looking at a detailed level at the solution [36].
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Figure 3: The fish trap model. (A) The convergence-divergence illustration. ‘Sa and Sb’ refer to structural concept a
and structural concept b respectively. Similarly, ‘Fa and Fb’ refer to formal concept a and formal concept b
respectively. ‘M’ refers to material concept. (B) the phase or step-wise illustration of the fish trap model. See text
for description. Taken from the Delft Design guide [36].
Our methodology was adapted from the above two mentioned models. As can be seen in Figure 4 the
first phase is the problem phase derived from the concept of the ‘problem statement’ of the analysis
phase of the Basic Design Cycle (BDC). In our model the problem phase includes both stating the
problem (statement) of the BDC as well as identification of the intended behavior or function of the
product which in our case is a framework. This phase not only deals with identifying the problem which
needs to be solved but as well as understanding it. As a result the intended function of the final solution
is cleared from the beginning.
The next step in our methodology is the analysis phase, which is derived partly from the remainder of
the analysis phase in the BDC and the structural concept phase of the Fish Trap Model (FTM). From the
latter, the basic functional components are taken into our analysis phase. In other words, we look at the
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problem and its potential components and factors in more detail and analyze the data. Additionally,
from the BDC concept, our analysis phase also includes developing criteria for the analysis and can
include possible iterations and feedback.
Figure 4: The methodology adapted from the Fish Trap Model and the Basic Design Cycle. The first phase is called
the ‘Problem phase’. This phase deals with identifying the problem, which needs to be solved, and understanding
it. The next phase is the ‘Analysis phase’. In this phase we look at the problem in detail and analyze relevant data
per se. Next comes the ‘Idea phase’. This phase derives possible solutions based on the analysis phase coming up
with the possible options, directions or ideas to proceed with and can overlap with the analysis phase. Following
the idea phase is the ‘Concept Phase’. From the list of options generated, based on merits, one or few are selected
to work on further detail or conceptualize it. Thereafter the conceptualization, the product is materialized or
brought forth and implemented. This is followed by the evaluation of the product. The whole process can have
iterations and moves from a large set of options and narrows down to a single idea to be implemented. Adapted
from the Basic Design Cycle [35] and the Fish Trap Model [36].
As a result of the analysis phase several options are generated/developed to go forward with, which we
call the idea phase and is the next step in our methodology. The components of this phase are derived
from the synthesis phase of the BDC, which is based on human creativity (and describes the idea on any
form) and the divergence concept (several possibilities) of the FTM. Also, from the FTM, the basic
functional components previously defined in our analysis phase are developed into multiple variants and
clustered forming a structural concept. This step is considered the externalization of several relevant
ideas.
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The concept phase is the follow-up step of the idea phase in our methodology and is based on the
simulation step of the BDC to develop the provisional design and is a deductive process as one or more
options are chosen from a list (in the idea phase) based on the context it can solve. Also, the concept
phase influentially derives from the formal concept step of the FTM, which include assessing one or
more structural concepts from our idea phase as well as geometric sketches. From these sketches
through iterations and feedback loops one final version is selected.
The above mentioned steps in our adapted methodology (see Figure 4) in line with the BDC and the FTM,
initially quantify the data down to a single qualitative product or in our case, a model. This is achieved
through iterations and feedback loop, which include diverging and converging of data or components. In
other words development initiates with several ideas and through the process and feasibility analysis
narrows down from a quantity of data to one final option good in quality. The scope of our methodology
includes and ends at the concept phase since based on the fact the model we propose is a theoretical
framework. Nonetheless, validation or proof of principle and evaluation are logically the next steps
although not within the scope of this paper. Therefore we keep these two points in the to-be final two
steps of our methodology mentioned below.
Materialization phase will be the next step of our methodology although not utilized in the paper. This is
derived directly from the materialization phase of the FTM and may include diverging exploration if
necessary. The implementation of the product or in our case the model/framework is considered the
completion of this phase. The final to-be phase is the evaluation phase, which is a direct derivation of the
decision phase of the BDC with a modified approach to evaluate rather than to come to a decision.
However this evaluation can lead to further adaption of the model.
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Results	
On further analysis, we identified that the mainly used activity in transfer of academic knowledge to
industry/market is TT [1,19]. On the other hand, the system used by decision makers to come to a
decision regarding implementation of technologies in the healthcare system is the PHAT. For simplicity,
we will take one example of the PHAT, i.e. HTA with references to other components when seemed
appropriate. As known HTA is initiated by the need and identification of technologies which can reduce
the burden of illness and through its steps, prioritize those with importance and relevance [37,38] and
eventually come up with recommendations for DMs. Taking into account the HTA process [37] as can be
seen in Figure 5 below, it has several steps. The TT activity however, similar to HTA in its complexity of
dynamic steps,  varies from organization to organization. For our case we will  use the simple example,
given by North Carolina Agricultural and Technical State University, [18] as shown in Figure 1 above. As
we can see from the Figures 1 and 5, there are quite some similarities or overlaps between the two
different approaches as well as per definitions of the two seem inseparable in the order stated.
However, after comparing Figure 1 and 5 above, it seems that TT should move in parallel with HTA rather
than one after the other. Below are suggested relations between the two:
1. HNA/HTA initiates with the identification of current health needs and prioritizes accordingly. On
the other hand, TT, kick-starts with research and development, which in part is motivated by the
current  needs  in  the  market  (market  pull)  or  creates  a  need  based  on  scientific  data  (market
push). It should be noted here that literature suggests a significantly large amount of scientific
data relevant and applicable to health [11] which is not implemented in the same [10], therefore
justifies market push in health and medicine. The key word here being ‘need’ is the common
ground of motivation for both TT and HNA/HTA initiation, suggesting the reason for both of
them to start in parallel unlike what their respective definitions suggestion of one after the
other. In other words, HNA and HTA identify the gaps in the needs of healthcare technology and
its subsequent requirement of investigation respectively, and TT capitalizes on this need.
2. It should be stressed that consultation with external experts form a core component of HTA
during the prioritizing of relevant technologies. Generally speaking, experts in the field develop
the technology in the TT process, and with regard to medical technologies, take feedback from
the end-consumers.
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3. The core component of HTA is the assessment phase (including the economic, ethical, legal and
social implications) of the technology in question and can also include Horizon Scanning (can be
considered part of HNA and early stages of HTA) [39]. Horizon Scanning is defined as a
systematic  process  for  objectively  evaluating  the  status  of  potential  benefits  of  foreseeable
technological developments based on contemporary research and evidence [40]. It also implies
that it may be used as a type of SWOT (Strengths, Weaknesses, Opportunities and Threats)
analysis [40]. Assessment of the feasibility of the invented technology is a given in TT before
patenting or placing it in the market and this generally includes SWOT analysis. This also brings
forth the HIA, where the impact of potential technology to be used is assessed, which also
related to the TT’s strategy before introducing the technology concerned in the market. It seems
logical that TT should encompass Horizon Scanning within the aspect of HNA and HTA.
4. Another point is that both fields identify related stakeholders during the process.
Figure 5:  A general  outline of  the HTA procedure. The picture displays how HTA investigation initiates and the
different steps involved followed by dissemination or recommendation to Government officials, for example
whether or not to go forward with the technology in question in health policy implementation. Taken from the
Canadian Coordinating Office for HTA [37].
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It is not of the reasons above that the two (PHAT and TT) should start off together. Rather the essence of
the story lies in the fact that both separate fields can and should benefit from each other and en-route
streamline the integration process in order to properly address the whole innovation pipeline. Based on
the authors’ experience working with, in and around the Biotech industry, the bottleneck of technology
integration is rooted in the fact that the industry neglects the policy aspects [41] (can include but not
limited to market authorization, reimbursement and market penetrance) of technology which is an
important factor in determining technology use in Public Health and healthcare at the end of the
technology maturation process. Similarly, DMs only assess existing mature technologies to cover the
aspects of current need, which results in the untimely introduction of relevant or upcoming technologies
that can solve the ‘need’ issue more effectively and efficiently. With this flow of thought, the above
mentioned points which suggest the anonymous inter-relations between TT and PHAT bring forth a new
window of opportunity to use these pre-existing respective setups to expand the bottleneck for
sustained flow of technological integration in the healthcare system through simultaneous initiation of
these methods rather than one after the other.
Based on the above, our model should include relative parallel initiation of TT and PHAT with a
sustainable infrastructure or network for the two to communicate bi-laterally and mutually benefit. On
further research, we found that the Public Health Genomics Wheel (PHGW) [42], which describes Public
Health components or areas that can be addressed by genome-based information and technologies,
seems suitable to fit in our model. Furthermore, we identified that the Value of Information (VOI), the
amount a person is willing to pay to come to a decision on a subject [43], seems appropriate for our
model.
As a result of our investigation, we present our model which we call the ‘LAL Model’ as can be seen in
Figure 6 below and stands for ‘Learning-Adapting-Leveling’. As we know, TT is driven by either market
pull or market push and PHAT is driven by market pull. A technology (or market) push implies that a new
invention is pushed through research and development, production and sales functions onto the market
without proper consideration of whether or not it satisfies a user need [44]. In contrast, an innovation
based upon market pull has been developed by the research and development function in response to
an identified market need [44]. Also it is known that market push can lead to market pull and vice-versa.
It  should  be  noted  here  when  talking  in  terms  of  PHAT  market  pull  is  not  motivated  due  to
commercialization although TT may recognize it in that way, but rather by requirement or health need.
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Figure  6: The  LAL  Model  -  Learning  Adapting  Leveling.  The  model’s  core  consists  of  two  components,  the  TT
activity and the PHAT process (used by DMs). This model proposes bi-lateral communication, collaboration and
advocating for relevant technologies during and between the (early-mid) TT activity and PHAT process both of
which are driven by market pull/push (common denominator). This is achieved possibly through PPPs. The two
components/entities (TT & PHAT) use the PHGW as a reference point to see that all policy and societal aspects are
covered. This ongoing interaction through PPPs develops the innovation network for the current and future
collaborations which is a network or platform through which common goals can be achieved. This innovation
network is dependent on the VOI, i.e. the actual relevance (including added value) of the technology in question,
the exclusivity (patent, license, etc.) of the technology to be integrated including possible hindering factors as a
result, and the processing ability or understandability of user (say health professional or doctor, etc.) with respect
to the technology and its impact. Over the process, the two core components (TT and PHAT), learn and adapt from
each other within the innovation network and level out differences in approach and concept through PPPs (in
essence learning-adapting-leveling) through feedback loops and iterations. This can be achieved over multiple or
repetitive PPPs. Each network has a threshold of optimal capacity for such a learning curve, which we call the
absorption capacity. The model indicates the right balance between profit and timely interventions.
However, the (market) pull or need is the common ground which fuels both PHAT (in particular
HNA/HTA) and TT respectively. When we talk about TT, it moves from quantitative to qualitative output.
In other words, research and development initiates with several ideas and through the process and
feasibility analysis, quantifies down to a single qualitative product to be commercialized. This is
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represented in our Figure 6 as TT being an inverse triangle. What also can be noticed is that the TT
triangle and PHAT bar are standing in parallel, with the prior starting a bit earlier than the latter. TT
identifies possibilities of commercialization via market pull/push based on sound scientific knowledge.
The initial stages of TT start in the lab with research and development. At this stage, the research is
motivated on market dynamics and cannot clearly identify with the PHAT’s Health Needs Assessment;
hence the reason of this kind of leveling or kick-off.
Based on the previous common grounds identified in the two fields, the idea of cross cutting
collaboration starting from the equal leveling of PHAT and TT (as shown in Figure 6 above) is  the next
step. The starting point is market pull. Market pull/push demonstrates the inter-dependability of new
technologies of the PHAT pipeline (in particular HNA and HTA) with TT activity. TT should work two-fold,
using its traditional ‘opportunity identifying’ needs methodology fuelled by market demand and bi-
lateral communication through evidence-based advocating for relevant (or upcoming) technologies in its
activity with the PHAT organizations and DMs. This can be made possible through public-private
partnerships (PPP). According to Laane et al. [45], academics, industry (in our case the academic-
industrial complex) [23] and government join forces in PPPs to translate basic science into marketable
applications with social and economic value. These PPPs can take different forms as it can be on a one-
on-one basis or it can involve multiple parties (large to small medium enterprises) or universities to
(semi) public or private research organizations and/or involve charities and government. Laane et al. [45]
further states that PPPs can have physical locations or be virtual (with researchers from different
organizations/locations) or it can be entirely different. PPPs are considered to be collaborative (partners
work together contributing knowledge/resources), precompetitive (exclusivity not an issue in
collaboration) and they are partnerships in which the risks/rewards, funding and intellectual properties
are shared. PPPs are supposed to:
i. Bridge the gap between the academic-industrial complex and policy makers
ii. Pool knowledge and resources
iii. Catalyze innovation through translational research
iv. Transmit momentum and gear social/market pull to technology push
v. Multiple investments
vi. Align academic-industrial research agendas with social priorities
vii. Concentrate focus and mass on areas of social priority in which the parties are strong
viii. Increase social and economic returns of basic research
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In our case PPPs also involve consultation. The industry should get involved in the subsequent steps of
PHAT, including identifying the current and potential future needs, assessment, impact and prioritizing
among others and should involve a feedback loop with communication two-way. This is a good strategy
to ensure flexibility and adaptability by both parties leading to higher chances of success both
commercially and policy-wise, which is principle of communicating vessels. For example, the
health/market need and technology could be identified by the industry and possibly via consultation
with the end users and DMs (say HNA). After initial research and development, the industry can
approach the HTA professionals and DMs with their proposal to fulfill the need and collaborate through
the HTA steps and vice versa. This also includes the assessment of the impact the technology will have on
society (HIA) in mutual collaboration. In hindsight, this can help covering areas critically ignored by both,
the industry and the health care system.
This combination brings into the picture the PHGW, which demonstrates the integration process of
Genomics into Public Health and healthcare in general [42]. Beskow et al. [42] divides Public Health tasks
within three key domains of Public Health (Genomics), viz., Assessment, Policy Development and
Assurance. The industry and DMs should systematically and in parallel go through these domains at an
early stage within our model and integrate it in their respective strategies of product development and
development of evidence based guidelines. This is in addition to the TT and PHAT inter-dependability, to
ensure areas to be covered or gaps are not neglected in their technology development and policy
respectively. Thus all critical economic, policy and societal aspects are dealt with pre-emptively which
are generally put aside. As a result, the timely as well as effective and efficient transition of relevant
technological integration in policy and the health care system can be ensured.
As a consequence of these interactions and setups being developed, it is important that a sustainable
infrastructure is in place which can accommodate these interactions since the major component of our
strategy involves complex communication. Furthermore, the stakeholders involved should use the
concept of this infrastructure to push forward their respective agendas within our ‘LAL Model’. Keeping
in mind this infrastructure, our model proposes to use/develop and gives rise to the (innovation)
network which is an evolving mutual dependency system based on resource relationships in which their
systemic character is the outcome of interactions, processes, procedures and institutionalization.
Activities within such a network involve the creation, combination, exchange, transformation, absorption
and exploitation of resources within a wide range of formal and informal relationships [46,47]. This
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network is dependent on the VOI (Value of Information). VOI is the maximum price one should pay for
knowing the actual value of an uncertainty before deciding on a course of action [43] (see legend of
Figure 6). In our case this can be a technology or technique in question to be integrated in health policy
and healthcare. According to Oestreich [43] and adapted to our model, the VOI is dependent on three
factors, namely relevance to the consumer, processing ability of the current infrastructure (the
innovation network-developed through PPP between the academic-industrial complex and government,
to understand say its clinical utility or utility in healthcare) and exclusivity to the provider (patent for
example). This is a learning process with continued iterations and feedback loops, and requires the
ability to learn, assimilate and use knowledge developed elsewhere through a process that involves
substantial investments especially of an intangible nature and is called the absorption capacity [47,48].
| CHAPTER I
64
Discussion	
Based on our model, we believe the higher the absorption capacity, the higher the possibility of success
as can be seen from Figure 7A below. The y-axis represents the progress and development of the
innovation network. The numbers on this axis are percentage units of the expansion of the innovation
network with 0.1 being 10% and 0.8 being 80%. The x-axis represents time in years, which corresponds
to the timeline of the TT activity. This graph in ideal situations corresponds with the development of
upcoming or new technologies. With regard to relevant technologies already in the market, the same
can apply, however the years may be shorter. The gradient represents the absorption capacity, which in
our case is the function of the innovation network with respect to time which in turn in dependent on
the VOI. The threshold or optimal possibility of the absorption capacity is marked at 80% in (say) 5 years.
It can also be noticed that the absorption capacity gradient does not start at year 0 but rather a bit later.
As  earlier  mentioned,  the  initial  stages  of  TT  start  in  the  lab  with  research  and  development  and  the
research is motivated on market dynamics and cannot clearly identify with the PHAT’s Health Needs
Assessment, which in turn is the necessary partner (HTA) of TT, required for the expansion of the
innovation network. Therefore progression cannot start at this stage. After this step, within the TT
pipeline, the innovation network becomes activated. Below is the proposed idea of the progression:
1. Identification of the health need (market pull/push) by industry and subsequent research
and development. We mark this as 0% innovation network.
2. After initial research and development, contact is made with the relevant authorities in
HNA/HTA and policy. We consider this 10% development of the innovation network, which
starts from 0%.
3. A proposal is developed either jointly (PHAT and industry) or individually (say academia-
industry) and it is advocated. Networking is the key here. We consider this 20% development
of the innovation network.
4. Initiation of PPP of the industry with policy through the PHAT authorities. Partnership can be
in terms of collaborations, knowledge sharing, joint investigations, etc. This is a major
milestone; therefore we consider this 40% capacity of the innovation network.
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5. Over time the innovation network is developed and expanded as the industry collaborates
with decision-makers through the process of the PHAT and TT activity pipelines which can
look like a pseudo-merger. We consider this 60% network capacity.
6. Finally, the innovation network has matured enough to integrate relevant technologies into
healthcare systems and policy in real time as a consequence and evaluate the impact using
HIA. We believe the innovation network at 80% functionality and are considered the
threshold of the absorption capacity of this apparatus.
Figure  7: Absorption Capacity as a function of the innovation network and time.  A  hypothetical  schematic
representation from top counter-clockwise of achieving threshold capacity for technological integration in (A) ideal
circumstances, (B) for a newly introduced technology in a non-existing innovation network with the network
development hindered through bureaucracy and skepticism of the new infrastructure, (C) of an already tested
innovation network moving through a 2nd round of new technological introduction.
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The steps  take  into  consideration  the  PHGW.  The  value  of  1.0  or  100% seems not  feasible  as  this  is  a
learning process and there will be always room for improvement apart from the fact that there will be
always unforeseen internal and external developments. This example shows emerging technology
integration via the development from a non-existent innovation network being expanded. The remaining
20% is an ongoing process with feedback loops, within the already now developed innovation network
(above 6 steps) for more new or relevant technology integration; thus having a dynamic absorption
capacity. This would be considered ideal in the development of the innovation network; however,
depending on the technology to be integrated [49] the graph can and will be represented differently for
different people/organizations over time as shown in Figure 7B and 7C below.
The involvement of various stakeholders is an essential in order for this model to work. Ideally,
government driven regulatory requirements would greatly benefit the model by stimulating the adoption
of the model for the right reasons. PPPs, for example, act as a cog in the larger innovation system
conveying momentum from one part to the other and are best if the push is from technology and the
pull  is  from  social  and  market  demand  [45].  As  of  now  the  right  level  of  intervention  settings  and
involvement is not ideal. Currently, it is up to the industry to voluntarily advocate and/or implement the
model in their settings to benefit. In the process, and as the model indicates, PPPs will bolster the
involvement and perhaps future government driven regulatory requirements. Likewise, if decision
makers identify the benefits of this model they can voluntarily indicate it to the industry to follow suit.
Either way, in realistic setting, one core stakeholder has to take the initiative to kick-start the framework.
The core stakeholders to initiate the model are basically the industry (including scientists in other
settings) and government decision-makers including PHAT professionals. Other important stakeholders
to sustain the process are the patient groups, hospitals and health professionals (including doctors).
It should be emphasized here that since this process involves advocating and PPP, the model’s ultimate
goal is to benefit the end-consumer, the patient, in a timely and effective manner, and in the process
stopping the rightful profit backlog of relevant or upcoming technologies that generally do not reach the
patient. As earlier stated, this is dependent on the relevance to the end-consumer combined with the
processing ability of the information generated through PPP with exclusivity to the provider. For
industry, profit is primary motivation behind innovation research in medicine or healthcare in general.
This is not wrong as long as the health of the patient is not compromised through misguided facts of
(ir)relevant technologies diffused into the health care apparatus thus affecting the policy-making as a
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whole. This may or may not arise from market push. In order to avoid this, the industry is encouraged to
consider ethical behavior when embarking in this model. To keep this in check, HTA professionals and
DMs should always have a third advisor. The first being industry, second being the HTA experts and their
sources (neutral or evidence-based recommendations), and the third being a combination of neutral
external experts, healthcare providers (e.g. doctors) and patient interest groups. The reason to keep it in
this order of recommendations is to encourage the pseudo-merger of TT and PHAT. The industry can
advocate for relevant or upcoming technologies in its pipeline based on sound scientific data and health
needs through consultation with doctors and patients, in the PHAT pipeline. As a result, the industry
needs to positively influence the DMs and HTA professionals to push forward the correct agenda for
timely interventions. This can be possible if the industry communicates with the PHAT professionals
evidently, hence the first opinion. However, the PHAT infrastructure should not compromise its own
recommendation. The third opinion(s) being the most important and the motivation of the target group
is self-explanatory as it is the patient group and they aim for improving quality of life through improving
health and reducing burden of disease.
As a result, the model promotes an ethical balance between profit and improving health through timely
and effective interventions. It should be noted here, however, the classical PHAT apparatus or
methodology needs to be compatible with the current trends, which is not the case at the moment.
Although revised versions of HTA like ‘core HTA’ [50] have been established, nonetheless, they have not
proven sufficient enough to solve current issues. Therefore, a more innovative approach [51] compatible
with our model is required, which will be our next step of investigation. Also TT may need to adapt to
HTA as well. However, this is within the concept of innovation networks.
A possible limitation of the model may or may not include its lack of addressing the phasing out of an
obsolete technology. Depending upon the stakeholder this may be of importance. Phasing out a no
longer required technology may not be of concern for an industrial player looking to capitalize on the
market with their new technology and seems to be the general perception based on the authors’
experience. A very simple example can be microarrays. To our knowledge we have never seen a
microarray company phasing out its previous best seller over a newer version (although they phase out
the production internally depending upon demand). Rather they simultaneously sell both until the older
version fades away. Reason being at the end of the day it boils down the amount of sales. This phasing
out of obsolete technologies rather falls on the ears on hospital management, policy makers among
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others. For them phasing out is equally important as phasing in a new technology. On the other hand it
can be argued that industry should pay to a certain extent attention on phasing out obsolete technology
parallel to their diffusion of own technologies. This can probably ensure a smooth integration process in
healthcare as it will develop a good case for integration of emerging technologies in the healthcare and
policy. Our LAL model itself does not address this important issue rather focuses on the phasing in or
diffusion of a new technology in healthcare and policy. Nonetheless, our hypotheses is that the same
model framework could be used simultaneously while phasing in a new technology, to phase-out an
obsolete version, but still has to be experimented, which is like-wise for the phasing in concept itself.
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Conclusions	
The LAL model proposes to facilitate and/or speed the valorization process of new and relevant
technologies within healthcare systems with less chances of failure through early on involvement of
stakeholders (within TT and PHAT). The aforementioned early on involvement of stakeholders can help
the industry to come to an advance decision whether or not to continue with the developing/emerging
technology or consider upgrading it before introducing it in the market. This can be based on for
example the technology’s clinical utility (is a measure of the health care value provided by the
technology) [52] among others (HTA, etc.) thus saving on resources. Our model has potential to guide
valorization in context with integration in health policy and healthcare systems resulting in the timely as
well as effective and efficient introduction of relevant genome-based technologies.
Valorization generally neglects the policy side, hence the generally fewer successes of investments by
Venture Capitalists in business models targeting healthcare. This new model proposes to bring in fresh
components to the valorization process of scientific breakthroughs not only to the bedside but also to
the healthcare system as a whole; thus making the process more efficient in real-time, by solving the
backlog of relevant technologies in healthcare before they become outdated due to introduction of
upgraded or newer technologies. The added value of this model is that it brings together, as per our
knowledge for the first  time, two separate entities (TT and PHAT) to early on involvement.  As a result
this can benefit both health care policy and industrial profit. It encourages a large amount of networking
and communication with relevant stakeholders in order to be successful, demonstrates the inter-
dependability and parallel initiation of policy and technological innovation. This network builds on the
ongoing absorption capacity of the apparatus through an ethical balance between profit and timely
interventions for the benefit of the population health. In simplistic terms it is a process of ‘Learning,
Adapting and Leveling’, which in essence is the LAL model.
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Abstract	
Introduction
Recently  there  has  been  substantial  increase  in  relevant  genome-based  technologies  to  market.
Compared to its utilization in healthcare systems, we notice a huge gap. In order to address this
bottleneck we previously developed the Learning-Adapting-Leveling (LAL) model. In this article we aim to
demonstrate the overarching reach of the model for translation to market and implementation into
healthcare systems moving towards personalized healthcare.
Methods
We use qualitative logical reasoning with the LAL model as reference.
Results
We see that Technology Transfer, Health Needs Assessment, Health Technology Assessment and Health
Impact Assessment are justified for their inclusion. In addition, the Public Health wheel is justified as a
good reference frame along with value of information.
Conclusions
We conclude that as the LAL model covers all dimensions and tools for translation and implementation in
a defined method, therefore can be considered as the overarching framework for translation and
implementation in healthcare integration.
Keywords
Translational research, Personalized Healthcare, Health Needs Assessment, Health Technology
Assessment, Health Impact Assessment, Learning-Adapting-Leveling, Public Health Genomics, Public
Health Wheel, ACCE/EGAPP, Technology Transfer.
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Introduction	
The dynamic nature of biological systems at a molecular level is highly intricate. Computational power
has greatly contributed to the partial elucidation of such systems and resulted in technological
innovations like genome-based technologies (GBTs) [1, 2] for personalized healthcare application [3].
Genome-based constitutes all –omics deriving from the human genome and including its interacting with
environmental factors. Technology can also include an intervention, technique, process, methodology
and diagnostic kit/application as well as technology in the general sense [2]. In the past decade we have
seen an exponential growth in these GBTs on the market [4-6] [101]. This is considered as a consequence
of knowledge valorization and spin-offs [4, 7-9]. Valorization can be defined as ‘transformation of
knowledge into concrete new products, services and processes’ [10]. Spin-offs can be defined as ‘firms
whose products or services develop out of technology-based ideas or scientific/technical know-how
generated in a university setting by a member of the faculty, staff or student who founded (or co-
founded with others) the firm’ [11].
Knowledge valorization and spin-offs have become ‘the’ way in translation to the market, as there have
been numerous studies [11-14] to interface the initially considered gap between the academic
environment and the industry. This has to a substantial extent been achieved and is generally referred to
as the academic-industrial complex [2]. However transitioning a technology from the lab to the market is
not the only issue, as coverage and reimbursement among other issues need to be addressed in the
whole translational research pipeline [102]. Consequently, integration and implementation seem as
important terms when it comes to transfer of knowledge attributed to applied research and valorization
of technologies beyond the market resulting in diffusion to healthcare systems. As generally known, this
diffusion of GBTs takes quite some time to be readily taken up in daily practice unlike market
penetration (5-10 years) [15]. The average of such diffusion depending upon the type of technology can
be ranging on average from 10 years up to 20 years [16, 17]. From this perspective it can be safely said
that  by  the  time  the  technology  reaches  widely  accepted  daily  practice  it  can  be  considered
comparatively irrelevant as a more effective and efficient technology becomes available on the market
[2], the latter of which is not being implemented at that moment into healthcare and should be
however, but will have to go again through the same process of the former. And by the time it does go
through the process and is implemented, another better technology appears in the market. This plays
| CHAPTER II
78
out repetitively in our observation to be what we like to call the ‘circle of destination’. Competition of
technologies to survive in the market is indeed healthy for the economy, however if they do survive as
the best, their implementation procedures are another issue, which is the circle of destination as they
become irrelevant by the time they are implemented when compared to potential in the market.
Learning-Adapting-Leveling model
To this end, we had developed the LAL (Learning-Adapting-Leveling) model (see figure 1), which we
previously published [2] of which a follow-up regarding the steps on how to use the model in a timeline
has been recently accepted to personalized medicine [3]. This model identified the bottleneck for this
circle of destination as the non-synergy between the academic-industrial complex and decision makers
(policy) offering a solution framework. The model works on the pretext that the academic-industrial
complex is developing a relevant technology, which could be beneficial to the healthcare system. It
should be noted here that there are two types in academia, on the basic scientist producing knowledge
and the other applied scientist resolving practical problems which can be done through development
and commercialization of a product possibly resulting in a spin-off company in order to realize the
solution’s application. For the academic-industrial complex here, we denote the applied scientist from
academia. However, sometimes the basic scientists’ ouput can lead to the applied scientist’s work.  It is
to be also noted here that although the academic-industrial complex defines the combination of
academics and industry, it is also known that industry can develop (health related) technologies without
involving academics at times. For the sake of simplicity, we refer to both these instances as synonymous
with the academic-industrial complex; after all the people working in industry graduated in academics.
This however true, can be an over-generalization. Nonetheless, this distinction is not necessary for the
model as either combined or separated, they will eventually interact in the model and play the same role
with the same aim for developing a relevant technology, which could be beneficial to the healthcare
system, although motives may be diversifying. The business intentions of academics and industry when
separated do not affect the functioning of the model, which is described subsequently. From henceforth,
whether separated or together, the work of the academics together with industry or industry alone will
be referred to as the academic-industrial complex.
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Figure 1: The LAL Model taken from [2] is based around the pseudo-parallel initiation of technology transfer (TT)
and the public health assessment tools (PHAT). Pseudo-parallel is from the sense that the exact parallel can vary
from  case  to  case  of  the  technology  being  considered.  Also  TT  starting  a  bit  earlier  than  PHAT  indicates  that  TT
starts with basic research in the lab and at its preliminary stages, cannot be assessed with PHAT. TT is an inverse
triangle indicating that basic/applied research starts in the lab with several feasible options and narrows down to a
single concrete product to be developed. Both TT and PHAT are driven by the (market) need either by market push
(developing a new need, mostly used by TT) or pull (addressing a need and penetrating that market). Market pull
can lead to market push and vice-versa. These interactions are within a platform we call the innovation network
and it is aspired that this possibly leads to developing broadly defined public-private partnerships (PPPs) through
which TT lobbies for uptake of relevant technologies for healthcare through evidence-based reasoning. PPPs are
eventually developed and improved upon which eventually reaches a critical mass we call the absorption capacity.
Coming back to the model (figure 1), at its core the model revolves around the pseudo-parallel initiation
[3] and cross-talk of the Technology Transfer (TT) activity and the Public Health Assessment Tools (PHAT)
[2]. TT in simplistic words is the development and transfer of the technology from the lab to the market
for commercialization. It can be considered the de facto used by the academic-industrial complex, which
we will come back on in the subsequent paragraphs. The PHAT [2] comprises of Health Needs
Assessment (HNA), Health Technology Assessment (HTA) and Health Impact Assessment (HIA). PHAT is
used to assess the current needs of the population, the technology and the impact the technology has on
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society respectively. Consequently, these determine the policy guidelines’ development, reimbursement
strategy, acceptance and implementation thus the integration of such technologies in healthcare [2, 3].
Although these may be ideal but such evidence-based health policies are not descriptive of the actual
innovation process. Decision makers (DM) use PHAT recommendations to develop these policies for
healthcare. Due to this pseudo-parallel initiation of TT and PHAT, the model encourages real time and
early on involvement of all stakeholders (patient groups, insurance, industry, policy makers, investors,
doctors, HTA professionals, academics, etc.) [2] as a result of these interactions. It can be noted here that
through TT (which covers moving a technology from the lab to the market) and PHAT (which in a way
moves the technology from the market to healthcare systems based on recommendations), the whole
pipeline of non-synergy and translational research is aimed to be addressed.
In addition to its core and distinct advantage of early involvement of all stakeholders through the TT
pipeline, the LAL model also constitutes and assesses the Value of Information (VoI). This VoI is divided
into three parts (see figure 1) namely, evaluating the ‘processing ability’ of the end user (patient, doctor,
etc.) with respect to understanding and using the technology, assessing the technology’s ‘relevance’ to
the target (population, patient, doctor, etc.), and understanding restrictions (exclusivity) due to
intellectual property rights (IPR - limiting is wide usage), thereby developing solutions around these
issues via consultation, cross-talk and public-private partnerships [2]. The model (figure 1) uses the 10
essential Public Health Tasks (within the domains of assessment, assurance and policy development) as
developed first by the Institute of Medicine (IOM) in 1988 [18] and adopted later in 2001 to the field of
Public  Health  Genomics  [19].  This  (known as  the  public  health  genomics  wheel)  is  used  as  a  reference
frame to do control analysis of possible additional gaps (in parallel to PHAT) in technology conformity
overlooked for public health integration [2].
So, in summary, the model assesses the feasibility of the developing technology from the start to near
the end of the technology maturation process for real-time uptake by healthcare systems and policy
guidelines. Thereby giving real-time recommendations to compensate for any gaps in the process prior
to launching the product. As an output it builds and establishes partnership with policy and conforms the
technology to be readily taken up by healthcare. This should not be considered as a business model
rather a framework. The model applies differentially to settings when e.g. university hospitals directly
implement their finding within their boundaries and related networks however are integrative when
they venture outside their boundaries. Nonetheless, this is beyond the scope of the article. As earlier
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stated the model works on the pretext that the academic-industrial complex is developing a relevant
technology, which could be beneficial to the healthcare system.
Current status of the Learning-Adapting-Leveling model
The  LAL  model  has  been  integrated  in  the  EU  commissioned  DG  SANCO  project  PHGEN  II
(www.phgen.eu) for development of the first edition of ‘European Best Practice Guidelines for Quality
Assurance, Provision and Use of genome-based information and technologies’ [20] and is being
implemented in various European DG Research project
1 and SMEs (Small Medium Enterprises) for genome-based technologies. Importantly, the LAL model has
been implemented in the EU flagship pilot project ICT Future of Medicine (www.itfom.eu). Furthermore,
apart from being referred to in literature [1, 3, 20-27] and conferences [28-31], mostly self-cited (refer to
Google Scholar2 for further citations of reference 2) the model has been referred to in European high
level reports [32-35]. As a result we like to consider the model an overarching framework, which defines
how effectively and efficiently the real-time uptake of relevant technologies by the healthcare can be
realized. This can help investors and industry alike to come to an early on decision on whether or not to
further their technology, modify or end it, thus saving on resources. It is also important for patients in
need for relevant GBTs possibly decreasing the burden of disease [3].
The article aims to build a case for the LAL model as an overarching framework as earlier stated. This can
then help users (academics, industry, doctors, patient groups, clinicians, insurance, HTA professionals,
etc.) to address all issues of translation and implementation to increase the likelihood of real-time
integration of relevant personalized medicine related technologies (GBTs). The reason behind such an
endeavor is that in the original article [2] we developed the conceptual model and detailed the
development of its creation and the reasoning behind it. In our next article, we then elaborated on the
detailed steps involved in the application of the model [3]. Given the model’s expansion and usage as
1 EU Framework Program 7 (FP7) --> COST - European Cooperation in the field of Scientific and Technical Research,
Title: An integrated European Platform for Pancreas Cancer Research: From Basic Science to Clinical and Public
Health Interventions for a rare disease; FP7-Health-2012-Innovation - Title: RARE Best Practices – Best Practice and
knowledge sharing in the clinical management of rare-diseases. EU  DG  SANCO  European  Agency  for  Health
Consumers --> Public Health Genomics European Network, Title: Best Practice Guidelines on Quality Assurance
Provision and Use of Genome-based Information and Technologies. Canadian -->  APOGEE  Net  CanGeneTest  –  A
Research and Knowledge Network on Genetic Health Services and Policy, Pilot Project Title: Efficient integration of
genome-based technologies into the healthcare system. Note: other grants in application.
2 http://scholar.google.com/scholar?hl=en&lr=&safe=off&c2coff=1&q=link%3Ahttp://www.translational-
medicine.com/content/9/1/207&btnG=Search
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stated  above  in  this  paragraph,  we  now  wish  to  elaborate  why  the  model  can  be  considered  an
overreaching concept for translation and integration into healthcare systems. Also these three topics are
evident in their details, therefore had to be treated separately and each compliments and adds/builds on
the other. Before we go into the methodology of the approach, we will first briefly describe generally
accepted and used concepts in translation and implementation in this field.
Translational Research and its coverage
Commercialization or transfer of the technology from the lab to the market for us applies to the concept
of TT whereas implementation applies to PHAT. Translational research covers the whole pipeline, i.e., TT
and PHAT.
The term ‘translational research’ is generally considered from ‘bench to bedside’ [36], which
encompasses the whole arena of translation from the lab (bench) to healthcare going beyond clinical
applications (bedside).
Encompassing properties of Technology Transfer
For the academic-industrial complex, to our knowledge, transfer or commercialization of their concepts
(in  the  lab)  to  technologies  (on  the  market)  is  generally  done  through  knowledge  valorization.  The
complete concepts of knowledge valorization and spin-offs fall under the activity of TT (see bottom part
of  figure  2).  By  definition,  TT  is  as  ‘an  activity  of  the  migration  of  academic  discoveries  to  useful
application in the development of marketable products or processes’ [37]. Such ‘academic discoveries’
are a product of ‘translational research’, which in turn is defined as the ‘effective translation of new
knowledge, mechanisms and techniques generated by advances in basic science research into new
approaches  for  prevention,  diagnosis  and  treatment  of  disease  essential  for  improving  health’  [38].  It
should be noted here that these are ‘new approaches’ and not the ‘migration’ itself of ‘academic
discoveries’ to ‘useful application’ rather just ‘new approaches’. TT migrates these ‘new approaches’ to
‘useful application’ (see figure 2). This ‘migration’ within TT is done through the concept of ‘valorization’,
which is defined as already mentioned earlier in the introduction as the ‘transformation of knowledge
into concrete new products, services and processes’ [10]. These products can be developed by regional
valorization systems.
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Regional valorization systems can be defined as valorization systems from a ‘regional perspective with an
ecosystem of firms in the region, including customers, contractors, competitors and collaborators
providing supporting services, potentials for subcontracting, knowledge collaborations and collective
learning, aside from access to knowledge sources in the country and abroad’ [39]. This can possibly be
achieved through the concept of open innovations, which can be defined as ‘any form of cooperation
with third parties that can contribute to improve the long-term performance of a company’ [40]. This
may or may not result in spin-offs dependent on the origin of that knowledge; for example,
establishment of an SME from the academic setting and/or through an established enterprise
respectively. It can be said that spin-offs can be considered a possible product of knowledge valorization.
However, these ‘concrete new products, services and processes’ need to be further developed to the
form of ‘marketable products or processes’, which is within the definition of TT. TT therefore moves from
basic research to the exit strategy of the product in question or to the market. Consequently, a spin-off is
considered as one of several outcomes of TT.
TT is the most widely used and accepted activity [103] when it comes to the translation of technologies
to the market and business plans and may have several variations from actor to actor. It should be noted
here  that  as  the  definition  of  translational  research  contains  the  term ‘effective  translation’  as  well  as
‘bench to bedside’, therefore it aims for the translation of evidence-based knowledge. In other words, it
goes beyond the translation from lab (bench) to the market (using TT) and includes translation all the
way to clinical practice and beyond, i.e. into healthcare (bedside), as can be seen in figure 2, the latter of
which we will come back eventually in the text. The definitions above are subjective, can overlap and
open  to  interpretation.  However,  we  take  the  above  concepts  as  they  are  mentioned  when  we  talk
about the encompassing properties of TT for the academic-industrial complex to use for transferring
concepts into technologies on the market.
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Public Health Genomics
After market introduction (through TT) and before these technologies are taken up or implemented by
healthcare systems and hospitals in daily practice they generally go through various assessments for
their approval by decision makers generally unaware to basic scientists and industry (academic-industrial
complex). There exist various assessment tools and frameworks in the Public Health Genomics field,
which are considered important prior to uptake. Public Health Genomics is defined as ‘the responsible
and effective translation of genome-based knowledge and technologies into public policy and health
services  for  the  benefit  of  population  health’  [41].  Major  tools  used  by  decision  makers  directly  or
indirectly include Health Needs Assessment (HNA), Health Technology Assessment (HTA) and Health
Impact Assessment (HIA) [2].
Health Needs Assessment
HNA is ‘a systematic method of reviewing the health issues facing a population, leading to agreed
priorities and resource allocation based on the needs of the population that will improve health and
reduce inequalities’ [42].  HNA can use epidemiological, qualitative and comparative methods to this end
to address the above definition [43]. HNA works towards influencing policy through logical decision
making, promoting interagency collaboration and advance prioritized R&D [44]. The methodology of
HNA involves first estimating the frequency of health issues in a given population and then evaluating
the proof for the positive and negative effects of the technologies per health issue [45]. In the process,
HNA addresses the impact, changeability, acceptability and resource feasibility with respect to maximum
positive impact the technology can have on the health of a population, i.e. targeting whole populations,
subpopulations as well as individuals [42].
Health Technology Assessment
HTA can be defined as a ‘multidisciplinary process that summarizes information about the medical,
social, economic, legal and ethical issues related to the use of a health technology in a systematic,
transparent, unbiased, robust manner’ [104]. HTA strives for the best possible value and also works on
informing in the development of effective and safe (health) policies that are focused on the
patient/citizen [104]. As this applies HTA’s involvement in interventions and appraisals it is considered as
an important information tool for decision-making [2]. According to Battista [46] HTA could be perceived
to bridge the gap between decision-making and research, however, it is perceived to be based in
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scientific method [104]. Policy analysis, (health) economic evaluation and evidence-based medicine play
a pivotal role in HTA. This is also extended to humanities/social sciences as well [47].
HTA is complimented by horizon scanning (HS - identifying emerging and new technologies) [48] and
Constructive Technology Assessment (CTA). The latter addresses the issue of technologies being highly
dynamic [49]. Historically HTA was developed from the need of healthcare systems and/or decision
makers to identify economically relevant technologies for their usage [50, 51]. However there does not
exist a bridge between HTA professionals and the academic-industrial complex. Recently, an EU tender
to address the issue was proposed [105]. On the other hand the American system has a chaotic
documented history on HTA [52, 53].
Health Impact Assessment
HIA is ‘a combination of procedures, methods and tools by which a policy, program, or project may be
judged as to its potential effects on the health of a population, and the distribution of those effects
within the population’ [54]. In other words, HIA gives decision makers insights of the full spectrum of
consequences of GBTs or policies as a result, as well as informs about unpredictability [55]. HIA, as a tool
first investigates and determines various polices which can positively or negatively impact health. This is
followed by considering both, direct as well as indirect health effects, thereby determining, which
populations are affected as a result and on what basis. This is followed by reporting the findings to
decision makers and finally evaluating the result of actual implementation [43].  HIA originated partly
from environmental policy development, health equity and a social view of health [56].
In conclusion, HNA identifies ‘health priorities for a given population’, HTA evaluates the ‘performance of
health care technologies’ and HIA assesses the ‘effects of policies, programs or projects on the
population’s health’ [43]. There are professionals and organizations, some designated by policy makers
working on these separate 3 yet overlapping tools to develop recommendations for decision makers.
The ACCE model
On the other hand, the ACCE (Analytical Validity, Clinical Validity, Clinical Utility, Ethical, Legal, and Social
Implications) is considered a benchmark framework to evaluate emerging genetic tests [57]. Supported
and developed by CDC, it aims to inform decision makers by presenting data on genetic tests in an
updated readable format for them to make decisions [106].  From ACCE, Analytical Validity defines ‘how
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accurately and reliably the genetic test measures the genotype of interest’ [106]. Clinical Validity defines
‘how consistently and accurately the test detects or predicts the intermediate or final outcomes of
interest’ [106]. On the other hand, Clinical Utility defines ‘how likely the test is to significantly improve
patient outcomes’ [106]. The last ‘E’ in the ACCE stands for ELSI (Ethical, Legal, and Social Implications)
form an important part of the ACCE framework as implications may arise in context of using the genetic
test [106].
The ACCE methodology includes gathering data, assessing it and interpreting the results followed by
reporting that data to decision makers in an understandable updated read for them to come to a
decision. This data is generally about DNA-related testing or genetic disorders [106]. A standard set of 44
specific questions comprises the model. These 44 questions are divided into 5 sections namely,
disorder/setting (7 questions), analytical validity (10 questions), clinical validity (8 questions), clinical
utility (16 questions) and ELSI (3 questions). Some of these 5 sections are also further divided into
subsections [106]. The model has been both praised as well criticized (for it limitations) [57] for its
different sections of ACCE. However, recommendations have also been given this is regard [57].
The EGAPP Initiative
EGAPP (Evaluation of Genomics Applications in Practice and Prevention) established in 2004 [107], can
be in a way considered as the successor to the ACCE model as it builds upon ACCE and was also
developed by CDC, USA. The EGAPP working group aims at the development of a ‘systematic, evidence-
based process for assessing genetics tests and other applications of genomic technology in transition
from research to clinical and public health practice’ [107]. The methodology constitutes existing
recommendations based on epidemiological studies as well as knowledge from prior initiatives [107].
EGAPP consists of independent multidisciplinary panel of 15 experts sanctioned through CDC.
The general methodology involves selecting potential topics for review through horizon scanning and
feedback, and then defining disorders of interest, specific tests and clinical scenario. This is followed by
brief summaries of identified tests and a preliminary review and prioritization of topics using specific
criteria ending in voting. The next step involves the EGAPP evidence review process. This starts with
formulation of key questions and analytical framework for evidence review followed by a systematic
evidence review either in the direction of comprehensive EPC (Enhanced Primary Care) reports or
Rapid/Targeted reviews. After this, the EGAPP reviews the evidence reports, considers contextual issues
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and may consider other sources of evidence, and as a result a draft recommendation peer-reviewed
statement is developed and published. This ends with the dissemination to stakeholders. Detailed step
by step can be found in the document [58] CDC published.
The T1 to T4 phases in translational research
Khoury et al. [59] propose a framework for the continuum of multidisciplinary translation research.
Although not part of the assessment used by decision makers, this framework has received attention
[43]. The authors divide their framework into 4 phases. Phase 1 translation research (T1) aims to move a
‘basic genomic discovery into a candidate health application’. This is followed by phase 2 (T2), which
‘assesses the value of a genomic application for health practice leading to the development of evidence-
based guidelines’. Phase 3 (T3) moves from ‘evidence-based guidelines to health practice’. The final
phase 4 (T4) evaluates in practice the health outcomes the genomic application. T1 to T4 can have
feedback loops [59].
The Public Health Genomics Enterprise
The Public Health Genomics (PHG) Enterprise (see figure 3 below) is a composite ‘for effective translation
of genome-based knowledge and technologies into improved population health’ [41]. The consensus was
developed by an international expert workshop held in Bellagio, Italy in 2005 with 18 experts from US,
Canada, Germany, UK and France. Although not part of the assessment process by policy makers, it
nonetheless contains important components and overlaps with tools previously mentioned. The PHG
Enterprise’s knowledge integration is considered pivotal [41]. It can be defined as ‘the process of
selecting, storing, collating, analyzing, integrating and disseminating genome-based information both
within and across disciplines for the benefit of population health’. This can also constitute
methodological progression as well [41]. Further information can be seen from figure 3 below.
The Public Health Wheel
The Public Health Wheel adopted for Public Health Genomics (PHG) [19] can be seen from figure 4. This
methodology has been widely used by the Public Health Genomics European Network (PHGEN I and II)
[20] to develop European best practice guidelines for quality assurance, provision and use of genome-
based information and technologies by different stakeholders at EU level. PHGEN II is a DG SANCO issued
project with over 25 member institutions throughout Europe. The PHG Wheel demonstrates the
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integration of genome-based information and technologies into Public Health by addressing the 10
essential tasks of public health in the translation of the technology in question.
Figure 3: The PHG Enterprise - Blue represents the scope of the enterprise, which is the definition of PHG stated
earlier in the manuscript. Yellow indicates creation of knowledge through research and red indicates genome-
based science and technology playing a pivotal role. Green indicates society in its widest sense including
stakeholders, activities, etc. Two sided arrows indicate dynamic and interactive nature of the enterprise. As can be
seen the PHG enterprise has four main activities, viz. communication and stakeholder engagement, informing
public policy, developing and evaluating preventive and clinical health services as well as education and training.
Research identifies gaps with differentiation between basic and applied research being blurred. Also the generated
knowledge  is  modulated  by  the  results  of  its  own  output.  This  includes  a  cycle  of  analysis,  strategy,  action,
evaluation, which is widely regarded in public health practice. Taken from [41] and adapted for resolution/color.
Further detailed definitions of these 10 essential tasks of Public Health within the 3 domains of
assessment, policy development and assurance have been adopted and defined for the field of Public
Health Genomics by Beskow et al. in tabular form [19],  of which they can be found in table 1.
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Figure  4: The  PHG  Wheel  - The PHG Wheel
demonstrating the 10 essential tasks of Public
Health with the task research at its center.
The 10 essential tasks can be distributed over
the 3 domains of Public Health namely
assessment, policy development and
assurance with systems management at its
center. Taken from [19] and adapted for
resolution/color.
This summarizes the current and relevant tools, frameworks or models present for the market
introduction and uptake of technologies in healthcare systems and hospitals with emphasis to the
decision maker. We will now proceed to associate these different tools and frameworks through a
common domain/framework and draw results and justification of an overarching existing framework.
This can then help users to address all issues of translation before implementation to increase the
likelihood of real-time uptake of relevant technologies in healthcare systems worldwide.
Table 1: Definitions of the task of the PHG Wheel. Taken directly from [19]
Assessment Core function
The regular systematic collection, assembly, analysis and dissemination of information
including human genome epidemiologic information, on the health of the community
Related essential services
· Epidemiologic and laboratory research: quantifying the impact of gene variants on
human health and identifying and quantifying the impact on human health of
environmental risk factors that interact with gene variants.
· Monitoring health: monitoring health status, including genetic factors, to identify
health problems within the community.
· Diagnosing and investigating: investigating the distribution of genetic and
modifiable risk factors within the community to determine their contribution to
identified health problems and to improve health outcomes.
Policy Development Core function
The formulation of standards and guidelines, in collaboration with stakeholders, which
promote the appropriate use of genetic information and the effectiveness, accessibility
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and quality of genetic tests and services.
Related essential services
· Policy and communications research: identifying and analyzing the economic,
social, ethical and political implications of advances in human genetics, including
the information and communications needs of stakeholders.
· Informing, educating, empowering: facilitating communications and education
about the integration of genomics into health promotion and disease prevention
programs.
· Mobilizing partnerships: fostering collaboration between public and private
agencies and constituent groups to promote effective and efficient
communication and policy making about genomics.
· Developing policies: establishing standards and guidelines for when and how
genetic information should be applied to promote health  and prevent disease.
Assurance Core function
Assuring constituents that genetic information is used appropriately and that genetic tests
and services meet agreed-upon goals for effectiveness, accessibility and quality.
Related essential services
· Health services research: identifying and analyzing the factors that influence the
impact of genetic information and the delivery, utilization and quality of genetic
tests and services.
· Enforcing laws: promoting the enforcement of policies and standards enacted to
ensure the appropriate use of genetic information and the effectiveness,
accessibility and quality of genetic tests and services.
· Linking to/providing care: ensuring the availability and accessibility of genetic
tests and services and associated interventions to improve health and prevent
disease.
· Assuring a competent workforce: ensuring that present and future health
professionals have training and skills in the appropriate use of genetic information
to promote health and prevent disease.
· Evaluating: evaluating the impact of genetic information and the effectiveness,
accessibility and quality of genetic tests and services.
System
Management
Building and maintaining the capacity of the public health infrastructure to integrate
genomics into public health research and practice.
| CHAPTER II
92
Methods	
The methodology used in the article to build a case for the overarching framework of the LAL model
(figure 1) will be using the LAL model itself as a reference point [2]. The methodology will use a
qualitative approach. Qualitative (logical) reasoning will deduct the priorities of inclusion or exclusion of
various tools, frameworks/models or methods mentioned in the background section to the LAL model.
Also, components included in the LAL model will be addressed to justify the model’s overarching reach.
The tools selected for description in the background and results section were based on our experience
with working with such tools and our broader network of peers working in this field through our close
work with academics, industry, governments as well as European networks or organizations like PHGEN II
(www.phgen.eu), EUNetHTA (www.eunethta.eu), Euroscan (www.euroscan.org.uk), HTAi
(www.htai.org), EAPM (www.euapm.eu), ESF (www.esf.org), EPIRARE (www.epirare.eu), PerMed among
others and including information from CDC, USA. In addition, we also searched on PubMed for related
terms. The PubMed search initiated with the terms based on our experience and networks above, and
then expanded to terms based in those literature to include additional tools to ensure coverage of tools.
As a result all tools are currently relevant and updated. The focus was to mostly include popular practical
tools, which were previously used and exclude tools, which closely overlapped with selected ones or
were adaptions.
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Results		
Included Concepts (TT, HNA, HTA & HIA)
TT, given its place in literature and extensive usage [60-62] by the academic-industrial complex can be
considered the most widely used and accepted activity [103] in translation from academic knowledge to
products on the market. Being the benchmark in valorization and essential part of translational research
(see background) in variety of forms, TT tends to become an undisputed fact. Therefore it is logically a
representation of translation of the academic-industrial complex and covers all aspects of translation. As
a result it is considered one of the two pillars in the LAL model [2] speaking for the academic-industrial
complex.
Same could be said for HNA, HTA and HIA, which we here refer to as PHAT [2],  being the most widely
used assessment tools [43] including its outreach through international organizations like the European
Public Health Association’s (EUPHA) ‘Health Impact Assessment’ section and HTAi and EUNetHTA among
others. These tools (HNA, HTA and HIA) are mainly used at the local/national level (with some
exceptions) for assessing technologies to be implemented in healthcare by decision makers (DM) and are
well institutionalized [43], and therefore are the other pillar (PHAT) of the LAL model. As earlier stated
the core of the model revolves around the pseudo-parallel initiation of TT and PHAT resulting in cross-
talk, consultation and public-private partnership (PPP). The LAL model brings two important
components, in fact in our view the most important components for translation (TT) and implementation
(PHAT) respectively and encourages interactions between these two pillars.
Excluded Concepts (ACCE, EGAPP, T1-T4, PHG Enterprise)
The ACCE model and EGAPP Initiative
ACCE historically was developed from a human geneticists’ perspective to evaluate specifically genetic
tests as evident from use of the framework. It  is  based on a deterministic and linear understanding of
genetics and genetic diseases. It is mostly limited to within the Unites States although there are
indications of being used in other places [57]. On the other hand HTA is recognized worldwide1 and
actively used for assessment of not only genetic tests, but in principle for all technologies in healthcare
[108]. Furthermore, it is known that HTA also incorporates elements of ACCE when evaluating genome-
1 www.htai.org and www.eunethta.eu
| CHAPTER II
94
based information and technologies [43]. Importantly, ACCE has been in a way considered to be
expanded to EGAPP (as it builds on ACCE), although ACCE is still utilized. Apart from being criticized [57],
ACCE is limited in its approach that it is from the perspective of human geneticists focusing on genetic
testing assessment only, and only in the clinical setting as well.
The LAL model already having TT is from the perspective of the academic-industrial complex, which
includes basic scientists including human geneticists, but also all omics’ sciences, using translational
research to develop new approaches to healthcare. A valid point in addition to this is that HTA, already
included in the LAL model, is from the perspective of the requirements of the healthcare system and not
what the human geneticists perceive as required. Aspects of ACCE have been covered in the LAL model
under the concept of the reference frame of the Public Health Genomics (PHG) Wheel [19], which we will
come back later in this text. Therefore, ACCE did not seem appropriate to include in the LAL model.
The same is the case for EGAPP, although incorporating parts of ACCE and encompassing the term
genomic, is mostly limited within the boundaries of America however been documented elsewhere [63],
is from the perspective of human geneticists and genetic epidemiology. Certain aspects are already
covered  as  part  of  the  reference  frame of  PHG.  In  summary,  ACCE  and  EGAPP are  limited  in  scope  of
geography, narrowed focus of the technology (genetic tests), and genetic epidemiology approach.
Furthermore, it is already covered within the PHG wheel, parts of HTA already included in the LAL model.
As a result ACCE and EGAPP were not considered at par with HTA therefore not included in the LAL
model as such.
The T1 to T4 phases in translational research
T1-T4 phases as mentioned by Khoury et al. [59] like other similar models have been criticized by some
[17]. It divides translation and implementation in 4 phases. In our previous article [2], in which the LAL
model first appeared, we have defined our own phases. This includes translation from lab to industrial
application as the first phase (T1 for Khoury et al.). The transition from industrial application to market
penetration being the second phase and the move from market to integration and implementation in
policy is seen as the third phase [2]. Out of our own three phases, the first two can find home in TT of
our model with the third allocated to the PHAT. Our last phase can be said as related to the T2, T3 and T4
of Khoury et al. is partly included in the LAL model, although from a different format. So the T1 of Khoury
et al. falls within TT while T2, T3 and T4 fall under PHAT of our model. This also changes the timeline
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initially drawn by Khoury et al. as TT and PHAT run simultaneously. It is important to state that the idea
of our own translational phases is not to add to the already existing models, which have been criticized
for adding to the complexity like T1-T4 among others [17]. Rather taking T1-T4, which has been prevalent
in literature (cited by 88 PubMed central articles and from CDC) and demonstrating it falls within our 3
phases.
The  purpose  of  our  own  phases  is  to  illustrate  the  steps  of  the  LAL  model.  In  other  words,  the  term
bench to bedside involves basic research possibly leading to applied research for an industrial application
(our T1). The next step is to develop the technology for this industrial application and enter the market
(our  T2).  Once  in  the  market  the  aims  should  be  to  integrate  or  implement  it  in  healthcare  systems
through best practice guidelines and health policy (our T3). We wanted to simplify multiple steps
involved into 3 categories, which the LAL model addresses and is easier to focus with fewer phases
involved.
Public Health Genomics Enterprise and its relation to the Public Health Wheel
Based on our own participation and discussions in the Bellagio meeting in 2005, and after reading both
articles [19, 41], we consider the PHG Enterprise [41] and the PHG Wheel [19] as one and the same thing
seen from a different perspective. Members of the Bellagio group [64] are authors on both papers with
the PHG Wheel clearly defining all 10 essential Public Health tasks applicable to GBTs. This PHG
Enterprise framework can be considered as rupturing up the pie chart of the PHG Wheel of figure 4 and
converting it into a spread sheet. A lot of aspects overlap with the PHG Wheel, and as a result the PHG
Enterprise covers all aspects within the assessment, policy development and assurance phase of the PHG
Wheel (figure 4).
For the assessment phase (see table 1), just by looking at the PHG Enterprise aspects in figure 3,
‘epidemiological’ (population sciences, humanities and social sciences) and research data are covered on
the research aspects of the enterprise (red color figure 3). ‘Monitor health’ spreads across the enterprise
with the focal point being ‘knowledge integration’ (through developing and evaluating health services)
towards improvement in ‘population health’ (see figure 3). Similarly, ‘diagnosing and investigating’
moves from research (keyword distribution) towards also in the improvement in ‘population health’ of
the enterprise. Within ‘policy development’ all the tasks mentioned in the PHG Wheel (and table 1) can
be clearly seen in the PHG Enterprise (see blue figure 3). In addition, ‘health services research’, ‘linking
| CHAPTER II
96
to/providing care’, ‘assuring competent workforce’ and ‘evaluating’ of the assurance phase of PHG wheel
(figure 4 and table 1) are clearly seen within figure 3 (blue). These tasks of the PHG Wheel are however,
in some cases merged or separated in the PHG Enterprise itself.
In addition, the ‘System Management’ of the PHG Wheel (figure 4, table 1) is covered in PHG Enterprise
as a spread-out version of research (see the term ‘research’ in figure 3) with ‘society’ of figure 3 spread
through the 10 tasks of the PHG Wheel (figure 4). However, the PHG Enterprise is not definitive in its
steps rather a layout as such. On the other hand, the PHG Wheel is in a form of a pseudo-pie chart with
the 10 essential public health tasks clearly defined, described and well distributed over Assessment,
Policy Development and Assurance as can be seen from figure 4. Furthermore, the PHG Enterprise will be
hard to use to as a reference frame as tasks are not defined rather distributed in terms sometimes
vague. Therefore we decided to use the PHG Wheel instead of the PHG Enterprise for the LAL model’s
reference frame as the concrete tasks of PHG Wheel can easily be used to identify gaps besides the fact
that these 10 essential tasks for our reference frame have been used to develop the best practice
guidelines [20] at the EU level.
PHG Wheel
As stated above, given the clear and detailed tasks’ distribution of the PHG Wheel, we have included it in
the LAL model as a reference frame, which the LAL model consults through the pipeline of the parallel
initiation of TT and PHAT. The concept of the reference frame is  used as such that while going through
HNA, HTA and HIA in the TT pipeline, common traits of HNA, HTA and HIA within the PHG Wheel are
cross checked for coverage and expanded to other tasks of the PHG Wheel, thereby covering all aspects
of public health.
Based  on  the  definitions  given  in  table  1  of  the  PHG  Wheel  (figure  4),  and  with  reference  to  the
definitions and aspects covered per tool or framework, we have assigned these tools or framework to
sections of the PHG Wheel, which can be found in table 2 below. It should be noted that research is
common to all tools/frameworks and corresponds to the research component of the PHG Wheel. Also
the allocation of tasks per tool should not be considered absolute rather, as an indication. Please refer to
table 2 throughout the text below.
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Table 2: Results of qualitative association of tools/frameworks to the PHG Wheel. Refer to table 1 and see text
below for details. HNA is health needs assessment, HTA is health technology assessment, HIA is health impact
assessment, ACCE is analytical validity, clinical validity, clinical utility and ELSI (ethical, legal and social implications),
EGAPP is evaluation of genomic applications in practice and prevention, T1-T4 is translation phase 1 to translation
phase 4 and PHG enterprise is the public health genomics enterprise.
Tools (see
background)
Common denominators to the PHG Wheel (see table 1 and figure 4)
HNA Assessment: Epidemiological research, monitoring health, diagnosing and investigating
Policy Development: Policy and communications research, mobilizing partnerships, developing
policies
Assurance: Health services research, linking to/providing care, evaluating
HTA Assessment: All aspects
Policy Development: Policy and communications research, mobilize partnerships,  developing
polices
Assurance: All aspects
HIA Assessment: Epidemiologic and laboratory research, diagnosing and investigating
Policy Development: Policy and communications research
Assurance: Health services research, evaluating
ACCE Assessment: All aspects
Policy Development: Policy and communications research, informing, educating, empowering
Assurance:  Health services research, evaluating
EGAPP Assessment: All aspects
Policy Development: Policy and communications research
Assurance: None
T1-T4 Assessment:  All aspects
Policy Development: Policy and communications research, mobilizing partnerships, developing
policies
Assurance: Health services research, evaluating
PHG Enterprise Assessment: All aspects
Policy Development: All aspects
Assurance: Health services research, linking to/providing care, evaluating
Health Needs Assessment and the PHG wheel
HNA in its aspects as stated (see background section), can use epidemiological data, and the definition of
‘epidemiological data’ within the PHG wheel in table 2 corresponds to identifying the health needs,
therefore justifies its’ presence in the same context within the PHG wheel. Similarly HNA covers
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‘monitoring health’ as the latter’s definition key lies in it mentioning of identifying health problems
within the healthcare systems. ‘Diagnosing and investigating’ also falls within the scope of HNA as it
includes contribution (or impact) to identify health problems (needs) and relates to HNA’s objective to
improve health outcomes (PHG wheel). Within the policy development spectrum of the PHG wheel, HNA
covers ‘policy and communications research’ as it relates to the identification of information and
communication needs of stakeholders (can include the general population). ‘Mobilizing partnerships’
computes with HNA as both sections involve fostering (interagency) collaboration and promotion of
policy through decision-making. ‘Developing policy’ is a key factor in the HNA process through both,
allocation of priorities/resources and its support in decision-making.
In the assurance phase of the PHG wheel, HNA can be allocated to three tasks. ‘Health services research’,
being the first, as it is a measure of the impact of genome-based information, quality, services, etc. can
have, which can pave the way for the identification of the current health needs. The second task
encompassing HNA is the ‘linking to/providing care’ aspect as the resource allocation and prioritizing of
policy with aims to improve health of HNA is compatible to the definition. The last task being evaluating
is quite obvious.
Health Technology Assessment and the PHG Wheel
HTA covers all tasks of the assessment sections (table 2) of the PHG wheel based on its definition.
‘Epidemiological data’ and basic research results are required for its assessment the latter of which form
a rooted part of HTA. ‘Monitoring health’ and ‘diagnosing/investigating’ can fall under HTA’s initial need
assessment similar to HNA’s above apart from covering aspects of the HTA’s definition (safe, effective
health polices, etc.). Also these two are required to complete the HTA analysis. Within policy
development HTA can allocate to ‘policy and communications research’, ‘mobilize partnerships’ and
‘developing polices’. For the first, the definition of HTA justifies its allocation as ELSI and economic
aspects in the public health context are present. In ‘mobilize partnerships’; policy-making plays a large
role  in  HTA as  well  as  consultation  with  external  experts  in  order  to  get  the  best  value  (HTA).  This  is
achieved through partnerships to sketch such policies. Developing polices through recommendations
and formulation of health polices as per HTA form a key role in the assessment process. HTA is heavily
dependent on policy analysis. Finally, HTA’s role related to the tasks of the assurance phase of the PHG
wheel, comprises the assessment of each stakeholder’s contribution in fulfilling the tasks in
complementary way (‘who is doing what?’).
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Health Impact Assessment and the PHG Wheel
HIA  can  fall  in  all  the  three  phases  on  the  PHG  wheel  as  well.  Within  assessment,  it  covers
‘epidemiologic’ and basic research as well as ‘diagnosing and investigating’. The common denominator of
these tasks with HIA is the keyword ‘impact’ (contribution in the latter). In other words, to study or
measure the ‘impact’ of a technology epidemiological studies have to be done or are required. Similarly,
one has to ‘diagnose and investigate’ to ascertain the possible impact of that technology. These are in
context of societal, financial as well as organizational aspects. Within the ‘policy and communication’
task the definition aspects covered contribute to assessing the impact of a health technology or policy on
healthcare. In the assurance phase, HIA can be associated with ‘health services research’ and ‘evaluating’
tasks of the PHG wheel. Again, the keyword for definitions on both sides is in analyzing the ‘impact’ of all
kind of interventions.
Going through PHAT (HNA, HTA and HIA) as mentioned just above, in the TT pipeline for the LAL model
[2], as can be seen, sections of the PHG wheel (table 1 and figure 4) are covered. Here we tally or cross-
check the PHAT to corresponding sections of the PHG wheel to fill in any gaps in the process addressing
public health conformity of the technology required for PHAT. From here the expansion to unaddressed
sections of the PHG Wheel including in non-traditional sense can be done to ensure all aspects of
conformity are covered in the reference frame building a stronger case for decision-makers (including
but not limited to reimbursement) and industry alike. We will now show that the left out components to
the LAL model are still in a way covered through the PHG wheel known as the reference frame. This also
justifies apart from previous reasoning, their exclusion.
The ACCE model and the PHG Wheel
The ACCE framework covers all aspects within the assessment phase (table 2) of the PHG wheel (table 1)
from the perspective of the clinical setting and related to genetic tests. This is justified just by the
abbreviation of ACCE compounding into the definitions, which make an obvious connection (see
background section of ACCE). However, in the policy development phase, ACCE falls under the two tasks,
namely ‘policy and communications research’ and ‘informing, educating and empowering’. For the prior,
ACCE by definition covers the ELSI aspects in the clinical context. Similarly, ACCE covers ‘informing,
educating and empowering’ (see figure 5 below and definitions of ACCE) related to genetic counseling.
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For the assurance phase, ACCE associates with ‘health services research’ and ‘evaluating’ related to
genetic services. In the case of the prior, quality assurance, effectiveness, economics and ELSI of genetic
tests (see figure 5) within ACCE compute to the task’s definition. The task of ‘evaluating’ genetic tests is
as obvious as its name and definition, with some keywords from ACCE here being quality assurance,
effectiveness, facilities, evaluation, etc.
Figure 5: The ACCE - Sketch of the ACCE framework. Taken from [106]. Adapted for resolution.
EGAPP Initiative and the PHG Wheel
The EGAPP framework covers all aspects within the assessment phase of the PHG wheel (table 1 and 2)
similar to the ACCE framework above and can be considered an upgrade of the ACCE with a more
systematic  approach,  and  from  the  perspective  of  (genetic)  epidemiology.  By  definition  it  is  an
assessment tool for genetic tests, which implies its association within the assessment phase. The
justification here can be similar in nature to the ACCE case for spectrum covered in the assessment
phase including by just looking at the methodology of EGAPP. EGAPP covers the task ‘policy and
communication research’ but does not have involvement in the assurance phase of the PHG wheel. In
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‘policy and communications research’, similar to ACCE, EGAPP covers ELSI aspects in the clinical context
as well.
T1 to T4 Translational phases and the PHG Wheel
T1-T4 covers all aspects in the assessment phase (table 2) with T1 covering ‘epidemiological data’ as the
starting point. T2 finds its way in ‘monitoring health’ as well as ‘diagnosing and investigating’ with the
latter partly covered by T3 including T4. In policy development T1-T4 can be allocated ‘policy and
communications research’ (T3-T4), ‘mobilizing partnerships’ (T1) and ‘developing policies’ (T2). In the
assurance phase the framework can be placed with ‘health services research’ (T2) and ‘evaluating’ (T4).
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Discussion		
As earlier stated the methodology approached the issue with a qualitative rather than a quantitative
technique. Although this approach makes it more subjective and indicative, nonetheless, quantitative
analysis cannot be practically measured within an association study for this aspect. We have justified
well-known and applied tools to be included in the LAL model, which mainly constitutes TT and PHAT
(HNA, HTA and HIA) and kept out others (ACCE, EGAPP, T1-T4 and PHG enterprise) due to their
weaknesses and overlaps with existing tools (like PHAT and the PHG wheel). We have demonstrated that
both included and excluded tools show relation with the PHG wheel as well. This demonstrates the
importance of the PHG wheel as a reference in integration of genome-based information and
technologies into public health and healthcare as a whole as it covers excluded tools which may have
sections not covered otherwise.
Another perspective on table 2
Coming  back  to  the  subjectivity  of  the  coverage  parameters  of  these  different  tools  in  table  2  with
respective to the PHG Wheel; it is an inclination towards a more indicative rather than an absolute
description. Although our analysis was related more strictly to description of each tool then compared to
the 10 essential tasks of the PHG wheel, it is nonetheless subjective. For example, a different view can be
seen from table 3 below. Here some aspects covered are completely different from table 2 above unlike
in table 2 some aspects of a domain were covered or not. Given the definition of HTA, and based on this
table it seems that ACCE and EGAPP apparently do not perceive give way towards development of
(health) policy. As a result these can be considered as non-HTA configurations. This is based on the usage
of these different tools by different peers. This again is still subjective as other peers may see the
coverage completely different. However, the important point stands that the PHG wheel has been
demonstrated in the results section to be considered the most comprehensive of all these tools or the
common denominator among these tools and serves as a reference frame for the tools incorporated in
the LAL model.
Placement of the PHG Wheel in the model
The PHG wheel therefore extensively defines and covers all tasks in PHG. One can argue that why not
then the PHG wheel is the second pillar along with TT in the LAL model instead of PHAT. The reason
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being that the PHG wheel only describes various public health tasks to be covered and not the methods
how to do such tasks.  On the other hand PHAT in the format of HNA, HTA and HIA are proven methods
of assessment for healthcare interventions and their implementation thereby integration and widely
used. Furthermore in a way HNA, HTA and HIA combined (PHAT) are methods that are applied to and
cover the 10 essential task of the PHG wheel.
Table 3: Another perspective of the subjectivity coverage to the PHG Wheel. Comparable to table 2
Tools (see
background)
Common denominators to the PHG Wheel (see table 1 and figure 4)
HNA Assessment: All aspects
Policy Development: All aspects
Assurance: All aspects
HTA Assessment: All aspects
Policy Development: All aspects
Assurance: All aspects
HIA Assessment: All aspects
Policy Development: All aspects
Assurance: All aspects
ACCE Assessment: All aspects
Policy Development: None
Assurance:  None
EGAPP Assessment: All aspects
Policy Development: None
Assurance: None
T1-T4 Assessment:  All aspects
Policy Development: Policy and communications research, mobilizing partnerships, developing
policies
Assurance: None
PHG Enterprise Assessment: All aspects
Policy Development: All aspects
Assurance: All aspects
Relevance to Horizon Scanning and Constructive Technology Assessment
There have been other initiatives like ‘early HTA’ [65] with the idea to promote pre-market evaluation for
new upcoming technologies. Nonetheless, such initiatives lack the academic-industrial aspect (TT, see
introduction section and figure 1). HTA now includes horizon scanning (HS) and Constructive Health
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Technology (CTA) as stated in the introduction section above. However the concept alone is more
pseudo-real in nature. Reason being that there is no real-time communication between the academic-
industrial complex and policy, therefore HS and CTA become limited to the knowledge they know or are
provided  with  from the  market.  Recently,  an  EU tender  call  has  been proposed  to  bring  together  HTA
and technology developers (TT) to cross-talk [105] to answer aspects of this non-communication.
Through our model by real-time cross-talk, true HS and CTA can be realized as policy is no longer limited
to publicly known knowledge of upcoming technologies [3]. Through lobbying within the LAL model
framework by TT, currently confidential or non-public emerging information can be tested for HS and
CTA bringing into action the intended true nature of HS and CTA for assessing upcoming technologies
within the HTA framework. As a consequence, HS and CTA hunting within HTA is made easy ensuring
possibly missed technologies for assessment are covered as these innovators themselves approach HTA.
Of course this does not replace the traditional HS and CTA approach rather supplements them and in the
process defining their intended output.
The overarching concept
Furthermore, PHAT implementation process corresponds well with TT belonging to the academic-
industrial complex, although not yet interactive. The LAL model addresses the issue of effective and
efficient real-time integration of GBTs in healthcare by bringing together existing frameworks for the first
time.  Given  the  PHG wheel  touching  all  assessment  tools,  makes  it  an  excellent  reference  frame to  go
through all public health tasks to see if they are addressed or not in order for the final product to
conform to public health needs as required by these assessment agencies (HNA, HTA and HIA).
Although the PHAT are extensive in approach and put together in the PHG wheel make quite a powerful
approach in combination with the other tools, it not sufficient as the alienation to academics and
industry makes this combination incomplete. The LAL model has this unique advantage bringing together
TT and PHAT as well as the PHG wheel in the picture making it quite an extensive model. Moreover the
LAL model takes into consideration the VoI in detail and develops the innovation network (see figure 1)
through cross-talk, PPPs and consultation between TT and PHAT. The VoI runs in a same pattern as the
PHG wheel (running in parallel to PHAT as a reference frame). VoI is important from two perspectives,
namely from a business point of view and the traditional VoI of HTA [3] as approaches are different from
these perspectives. This ensures that business aspects are covered and HTA’s interest of the VoI is
checked in advance before the HTA process. Based on these two aspects and VoI’s well-known
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importance in decision making for both fields of work, namely business and healthcare decision making
(HTA) it was decided to include VoI as the other important reference frame. The VoI through the steps of
TT and PHAT always takes into consideration the processing ability of the users of the upcoming
technology, relevance to the target group and restrictions of use due to Intellectual Property Rights (IPR).
Hence, VoI recommends through the process to make sure the technology addresses these three areas.
On how to use the VoI reference frame in parallel to the PHG wheel has been explained in our recent
article [3].
It has been stated [66] that although several tools or concepts exist, their cross-integration is important
in order to speed up the translation and currently no framework exists to do so. This article
demonstrates the depth at which the LAL model can go when it comes to healthcare implementation as
a  result  of  the  interactions  between  TT  and  PHAT  with  PHG  wheel  and  VoI  as  the  reference  frames
encompassing several tools resulting in cross integration. The PHG wheel in the LAL model guarantees a
check list of aspects (tasks) and techniques or tools to be looked at through the pipeline of the
innovation being developed making sure that all issues are covered apart from PHAT on a case by case
basis. Also aspects not generally addressed in traditional PHAT (subjectively speaking like ACCE, EGAPP,
etc.)  can be addressed through the tasks of the PHG wheel.  Thus they all  go parallel  in the LAL model
(including ACCE, EGAPP which also overlap with HTA, etc. for example, but in the case of ACCE from the
perspective of the evaluation of genetic tests in the clinical  setting,  and in the case of EGAPP from the
perspective of genetic epidemiology). As result, the LAL model covers the whole wheel including gaps in
the  PHG wheel  (in  terms  of  TT),  as  well  as  concepts  like  the  value  of  information  among others,  thus
making it the best possible framework for healthcare integration.
Pending issues
It should be noted that TT in itself is very subjective and depending upon the actors’ problems within TT
can occur. However recommendations in literature has been given to this end [62]. This model is on the
assumption that TT (academic-industrial complex) internally works out their issues possibly using our
business VoI [3]. Nonetheless, TT is very active in transferring technology even if issues occur and the
authors think it is not such problem to resolve any perceived differences and that interaction with PHAT
is the bigger issue given the tools’ independence from each other.
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Also with regard to PHAT, the protocols of the three components namely, HNA, HTA and HIA may vary
from region to region and TT will have to adapt accordingly, if they wish to conform the technology for
that region and in some instances (like the US) the protocols may be carried out by a differently labeled
agency [52]. Given these differences, a certain perspective and lobbying with organizations, networks,
industry and decision makers including these three components (HNA, HTA and HIA) will be required to
implement the LAL model. In this regard, we have already been active for some time now since the
original article’s publication in 2011 [2], which we briefly described in the background section stating
where the LAL model has been published, integrated, lobbied and being currently implemented. Of
course, organizational issues in some instances will have to be addressed and we still have a long way to
go for it to be generally accepted. We have recently submitted an article defining the detailed steps
involved to use the LAL model with respect to GBTs [3].
Diffusion of Innovations
We believe that the concept of ‘diffusions of innovations’ [67] is incorporated within the LAL model,
although the idea of the model is not to study the concept rather to utilize and incorporate it through
the LAL model’s extensive interactions within the innovation network [2, 3] (see figure 1). Reason being
that through these interactions in the innovation network of the LAL model between TT and PHAT as
well as early on involvement of all stakeholders, the four main components that impact a concept
according to Rogers [67] namely, innovation, communication channels, time and the social system are
addressed. The ‘innovation’ is addressed through TT and its interactions with PHAT regarding its spread.
‘Communication channels’ are addressed and established through the interactions within the LAL model
through the innovation network by the development of broadly defined public-private partnerships both
formal  and  informal  [2].  ‘Time’  in  the  form  of  the  bottleneck  of  effective  and  efficient  real-time
integration is the basis from which the LAL model was developed. ‘Social system’ is incorporated through
these interactions in the innovation network with TT conforming to the requirements of public health
and health care systems via these assessments. Also the involvement of all stakeholders including
patient groups, insurance companies, doctors, academicians, decision makers, HTA professionals,
industry among others throughout the process of the LAL model ensures that the ‘social system’ the LAL
model works within is addressed. Furthermore, the ethical, legal, social and economic implications are
addressed through tools in PHAT. In addition human capital is an important aspect of the LAL model as it
is according to Rogers.
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Also, the categories of adopters according to Rogers [67], namely innovators, early adopters, early
majority, late majority and laggards are encompassed within the LAL model. The motive in the LAL model
is to shift towards early adopters through the conformity requirements and stakeholder involvement
during the implementation phase of an innovation early on. In addition, the concept of ‘critical mass’ in
‘diffusions of innovations’ can draw parallel with the ‘absorption capacity’ [2] of the LAL model (see
figure 1). Using the concept of ‘diffusion of innovations’, the LAL model can develop the required
interactions for effective and efficient real-time uptake of GBTs within its innovation network. In other
words, even if the actors utilizing the LAL model are not familiar with ‘diffusion of innovations’ they are
bound to use those concepts knowingly or unknowingly as a result of the complex interactions of
stakeholders within the LAL model as concepts like social, change, mentality and organizational issues
will be addressed in the LAL model.
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Conclusions		
This article demonstrates the added value and comprehensibility of the LAL model as a result of inclusion
of  the  PHG  wheel  in  parallel  and  overlapping  to  the  PHAT.   We  found  that  the  PHG  wheel  to  be  a
powerful instrument for reference of the different PHG tools in the form of the 10 essential public health
tasks.  However,  we  find  that  the  PHG wheel  is  not  sufficient  for  the  integration  process  as  it  lacks  the
academic-industrial concepts like TT and VoI besides not having defined methods as well as not being
directly involved with implementation unlike PHAT. The pseudo-parallel initiation of TT and PHAT are
two sides of the coin of market introduction from lab to industrial product (TT) and implementation
through PHAT (HNA, HTA, HIA), thereby integration. Using the PHG wheel as the reference frame in
parallel to PHAT makes it a powerful combination and checklist to ensure the upcoming technology
conforms to public health issues required by assessment agencies (PHAT). This reference frame includes
possible overlooked sections and/or (of) excluded tools as well as limited perspectives (like ACCE, EGAPP,
etc. due to previously mentioned reasons). The reference frame expands from PHAT to other sections of
the PHG wheel. Similarly, VoI ensures the developing technology conforms to its accessibility in terms of
its friendly platform, relevance to consumers and any IPR issues. The cross-talk critical for successful
integration exists through the innovation network (figure 1) of the LAL model. Therefore the LAL model
covers all aspects and components from the first idea in the lab to the product on the market (TT) to
healthcare implementation (PHAT and PHG wheel) resulting in real time integration of personalized
healthcare applications (GBTs) in healthcare systems. In conclusion, the LAL model should be used as the
standard for healthcare integration as it covers extensively all important components for translation and
implementation.
The LAL model identified 3 phases of translation [2] as earlier stated. As described in the article [2] the
entities (academic-industrial complex and decision makers), which govern these phases through various
tools  (TT  and  PHAT  respectively)  have  lack  of  communication,  hence  the  bottleneck  of  real-time
integration. The unique nature of the LAL model is that it brings together these two entities and their
respective tools to cross-talk, PPPs and consultation, thereby developing the innovation network striving
to  an  optimal  (absorption)  capacity  to  operate  within  (figure  1).  The  current  article  demonstrates,  the
LAL model incorporates relevant widely used tools for these entities, moreover, includes reference
frames (PHG wheel in particular and VoI) to cover all possible gaps with feedback loops. Therefore, the
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LAL model should be the sought answer to the question of cross integration [66] of different concepts of
public health and even beyond (through TT). In a nutshell the LAL model can be an overarching
framework covering critical translation and implementation activities for personalized healthcare
applications into the healthcare systems in a well described method [3].
Future Perspective
As given in the background section, the LAL model has been written into both accepted and ongoing
grants and ongoing collaboration with SMEs. Also this model is being used in the EU flagship project
ITFoM (www.itfom.eu) and other EU projects. The model has been lobbied for in the EU member states
as well as integrated in the EU best practice guidelines for quality assurance, provision and use of
genome-based information and technology for use by different stakeholders as well as high level reports.
As a result of these best practice guidelines it has been presented at the EU parliament. Recently the EC
has come up with a very specific tender, which completely fits to the model showing the direction the EU
is interested. Furthermore, the model transcends various disciplines in its creation spanning from basic
sciences, technology to translational research by technology transfer, public health and health sciences
including HTA among others. We therefore see the sustainability of the model in the near future. Given
all these activities we believe the model has a chance of being widely used in the next 5-10 years and can
be eventually considered an overarching authoritative framework for translational research in
personalized medicine and beyond to ensure GBTs reach in an effective and efficient manner the
healthcare systems in real-time. However, in these next years the aim of the model would be towards
demonstrating the results of the proof of concept of the model, which will feed into is spread.
Executive Summary
Proposal of framework of translation into personalized healthcare
· Through genome-based technologies we see a huge market development for personalized
medicine.
· However, the time from market to healthcare integration is quite delayed.
· This results in disadvantage to both industry and healthcare.
· Previously we developed the Learning-Adapting-Leveling model to resolve this issue.
· We aim to demonstrate the overarching framework of this model in personalized healthcare.
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Conceptual Demonstration
· We see that technology transfer (TT), health technology assessment (HTA), health needs
assessment (HNA) and health impact assessment (HIA) is quite useful for their inclusion in the
model.
· Furthermore, the public health genomics wheel and value of information included in the model
ensure that all aspects of public health tasks and business aspects are covered respectively.
· Additionally, the public health genomics wheel ensures the activities of all tools rejected in the
model are addressed ensuring coverage.
Conclusion
· The LAL model can be considered as an overarching framework for translation from the lab to
the market into the healthcare systems.
· In the next few years, the proof of concept will be tested.
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Abstract	
We see a backlog in the effective and efficient integration of personalized medicine applications such as
genome-based information and technologies into healthcare systems. This article aims to expand on the
steps of a published innovative model, which addresses the bottleneck of real-time integration into
healthcare. We present a deconstruction of the Learning-Adapting-Leveling model to simplify the steps.
We found out that throughout the technology transfer pipeline, contacts, assessments and adaptations/
feedback loops are made with health needs assessment, health technology assessment and health
impact assessment professionals in the same order by the academic–industrial complex, resulting in
early-on involvement of all stakeholders. We conclude that the model steps can be used to resolve the
bottleneck of implementation of personalized medicine application into healthcare systems.
Keywords
Health Impact Assessment, Health Needs Assessment, Health Technology Assessment, LAL Model, Life
Cycle, Personalized Healthcare, Personalized Medicine, Public Health Genomics, Technology Transfer,
Translational Research.
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Introduction	
Through  scientific  and  technological  advancement,  we  have  come  to  know  the  dynamically  complex
nature of human molecular biology [1–8]. Furthermore, epigenomics [9] and pharmacogenomics [10]
have demonstrated that individuals are unique and may respond differentially to a lifestyle change,
treatment or disease. The interactome, which is the complete repertoire of interactions potentially
encoded by the genome [11], indicates a more unique or personalized reaction to the exposome, which
is the combined exposures from all sources that reach the internal chemical environment [12]. Since the
post-genomics era and the inception of systems biology and systems biomedicine [13], we have seen a
shift towards the concept of ‘one shoe does not fit all’ [14] as every individual is unique. This has made
us reconsider our approaches to health. With the advent of social media and access to the internet, a
trend is being seen by patients not wanting to be treated collectively, but in a more personalized or
individualized manner [15]. As a result, technological innovation in the form of computational power,
including systems biology coupled with wet laboratories, has driven genome-based information and
technologies (GBITs) to push the agenda of healthcare systems to personalized medicine. Consequently,
personalized medicine refers to the use of genome-based information and technologies for providing
more stratified and precise (and possibly truly personalized) interventions [16] to individuals. ‘Genome-
based’ encompasses all omics deriving from the human genome. Technologies include technologies in
the general sense, as well as techniques, processes, methodology, diagnostic kits, applications,
interventions (including drugs) and activities [17]. Genome-based information also constitutes omics
interactions with the environment [18]. The environment not only embraces the location and exposures
to known and unknown toxic agents, and climate, but also lifestyle and socioeconomic factors. These
GBITs give true meaning to personalized medicine, as omics and other unique data retrieved from an
individual combined with computational modeling bring a sense of individualized medicine [16]. In other
words, GBITs have helped propel, as well as clear, the information cloud mentioned above. As a result,
GBITs have brought discovered treatment options to a more personalized level. Therefore, in this article,
the focus is not just on translating genome-based technologies [17] into personalized medicine, but also
on the translation of GBITs.
As promising and exciting as personalized medicine may be, we see a lack of, or delay in translation of
these GBITs into healthcare [17]. This is due to the lack of a cross-cutting integration of different and
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related concepts/tools [19] for translation and implementation. These different and yet related tools
address different and/or similar or overlapping aspects of the various stages of translation and
implementation but have not been used with an integrative approach. This issue also occurs in many
other types of health technologies. As a result, manufacturers of technologies and systems are pushing
for an early dialog among the different parties involved in translation and implementation [101].
Therefore, a need exists for innovative translational models to bring personalized medicine research into
healthcare systems through relevant GBITs. This article aims to demonstrate the steps of such a model.
In 2011, we published the Learning-Adapting-Leveling (LAL) model [17], in which we addressed the
bottleneck of effective and efficient real-time uptake of relevant GBITs by healthcare systems. We
identified the non-synergy or non-alignment between the academic–industrial complex [20] and policy-
makers that mostly run in parallel (at different timeframes of GBIT development) with no interaction
among them. Consequently, we stated that technology transfer (TT) and the public health assessment
tools (PHAT) are the authoritative tools or activities used by the academic–industrial complex and
policy/decision-makers, respectively [17,18]. TT is the translation of research ideas from the laboratory
through the industrial application onto the market. TT can be defined as the migration of academic
discoveries to useful applications in the development of marketable products or processes [21]; in this
case,  GBITs.  On  the  other  hand,  PHAT  correspond  to  implementing  GBITs  from  the  market  into
healthcare, hence its integration. This includes aspects of reimbursement, quality assurance, policy,
recommendations and best practice guidelines as well as decision-making. PHAT include health needs
assessment (HNA), health technology assessment (HTA) and health impact assessment (HIA). In simplistic
terms, HNA identifies the needs of the population and takes into account the characteristics of the
systems in order to allocate resources accordingly. HTA assesses the performance of healthcare
technologies including their ethical, legal, organizational, economic and social implications. HIA on the
other hand, assesses the effects of policies, programs or projects (including technologies) on the
population’s health [22]. The collective PHAT (HNA, HTA and HIA) are used by decision-makers (policy)
based on reports from these three different assessment domains and working organizations. These
recommendations, among others (opportunity is also part of the game), enable policy development,
which in turn affects the wide usage and acceptance of GBITs in hospitals, healthcare systems and public
health in general. These political decisions will determine the final outcome of treatment in patients and
citizens, as well as the burden of disease; for example, reimbursement and insurance premium will be
determined through these decisions, guideline and protocol development, release of government
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funding and restructuring of systems to accommodate these technologies, among others. On the other
hand, if a relevant technology that can reduce the time to diagnosis and prognosis is rejected, it could
possibly lead to higher costs as late diagnosis and prognosis will require more expensive treatments
compared with early diagnosis and prognosis leading to prevention. This affects the profit margin of
industry, as well as patients willing to receive relevant GBITs for treatment, in a timely manner. Similarly,
from a different perspective, if rejection of the GBITs is not done, its inadequate inclusion itself can result
in incorrect wide and early adoption yielding similar results as mentioned above.
The LAL model is hypothesized to be a possible solution to this bottleneck as at its base lies the pseudo-
parallel initiation of previously non-communicative TT and PHAT giving rise to cross-talk, public–private
partnerships (PPP) and consultation in order to create a networking and crossing exercise [17]. As a
result, participation of all stakeholders in the value chain of the technology early on in its development
brings in a so-called win–win process [17,18]. Stakeholders include, but are not limited to, HTA
professionals, insurance companies, healthcare providers, health professionals, patient groups, citizens,
venture capitalists, decision-makers, industry and academics, among others. TT and PHAT through the
process use the Public Health Genomics (PHG) wheel [23] as a reference to ensure that any possible
overlooked gaps are addressed [17] through the ten essential public health tasks, which integrate GBITs
in healthcare at its different levels. This affirms that by the time the technology is developed, it conforms
to the standards required by decision-makers, possibly preventing an eventual lag in uptake. The LAL
model includes feedback loops and is dependent on the value of information (VoI) or quality of evidence
(QoE). The VoI determines the understandability of the technology to the end-user, and its relevance and
limitations in terms of patents, among others, for wide usage. The LAL model works around this issue,
thereby giving recommendations. In summary, the LAL model can be seen as a framework to assess the
feasibility of the developing technology from the start to near-end of the technology maturation process
for real-time uptake by healthcare systems and policy guidelines. Consequently, the model develops
real-time recommendations to compensate for any gaps in the process prior to the launch of the product
through contact with policy [17] by building a network. This ascertains that by the time the technology is
ready, it can be immediately taken up by healthcare. Recently, we have argued the case for the LAL
model as the required cross cutting [19] overarching framework for the effective and efficient
integration of relevant genome-based technologies into healthcare systems [18] and also given its
integration in best practice guidelines [24] and other running EU grants, small medium enterprises
(SMEs) and consortia [102,103]. In addition, it is much more structured compared with other existing
| CHAPTER III
122
initiatives of early dialog; for example, the Green Park Collaborative [104], which defined just outcomes
of interest that will be used in future steps of the life cycle of a technology. As a result, we believe that a
higher order structured model, such as the LAL model, can offer an advantage over simpler models.
The  unique  case  of  the  LAL  model  brings  together,  for  the  first  time  on  the  same  platform,  the
academic–industrial complex (through TT) and decision-makers (through PHAT) [14,17,18,25]. Platform,
in this case, is the common grounds or table on which these stakeholders are brought to cross-talk; in
other words, providing a stage for cross-talk and bilateral communication. In this article, we aim to
develop an adapted yet flexible step-by-step methodology (toolkit) for the framework regarding how to
use the LAL model. This, we believe, can eventually help in providing valuable information and to pilot in
a concrete subset of health technologies that are GBITs. These developed steps can be useful for
academics, industrial partners and decision-makers alike, as well as patient groups, in order to advance
timely uptake of relevant GBITs benefiting all. It could also be a useful framework for other types of
health technologies that experiment with a stop in their development and subsequent uptake by
healthcare systems, but fine tunings may be needed to adapt it to these specific technologies.
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Methodology	
The method used to describe the step-by-step guide of the LAL model will be the deconstruction of the
LAL model itself [17] as can be seen in Figure 1. We will start with the elaboration of the reference
frames (the VoI and PHG wheel). VoI will be touched upon from two perspectives; business and the HTA
point of view. We will then go through the pseudo-parallel initiation of TT and the PHAT in the
innovation network. Pseudo-parallel indicates a sense of parallel flow, however may not be absolute.
Furthermore, TT initiates a bit earlier than PHAT (Figure 1). The deconstruction of the steps of the
pseudo-parallel initiation of TT and PHAT will be based on the development of the innovation network
(Figure 1) through the steps below [17]:
· Identification of the health need (market pull/push) by industry and subsequent research and
development. We mark this as 0% innovation network;
· After initial research and development, contact should be made with the relevant authorities in
HNA/HTA and policy. We consider this 10% development of the innovation network, which starts
from 0%;
· A proposal is developed either jointly (PHAT and industry) or individually (e.g., academia-
industry) and it should be advocated. Networking is the key here. We consider this 20%
development of the innovation network;
· Initiation of PPP of the industry with policy through the PHAT authorities. Partnership can be in
terms of collaborations, knowledge sharing and joint investigations, among others. This is a
major milestone; therefore, we consider this 40% capacity of the innovation network;
· Over time, the innovation network will be developed and expanded as the industry collaborates
with decision-makers through the process of the PHAT and TT activity pipelines, which can look
like a pseudo-merger. We consider this 60% network capacity;
· Finally, the innovation network should have matured enough to integrate relevant technologies
into healthcare systems and policy in real time as a consequence and evaluate the impact using
HIA. We believe the innovation network is at 80% functionality and is considered the threshold
of the absorption capacity of this apparatus.
| CHAPTER III
124
Figure 1: The Learning-Adapting-Leveling model. The distinct feature of the model is at its very heart: it brings
together for the first time TT (used by the academic–industrial complex) and PHAT (accessed by DMs) to bilateral
communication, resulting in an (innovation) crossing. The idea is, that through this two-way communication (ad hoc
crossings), professionals on both sides can cooperate and participate in the development of a new genome-based
information and technology for the academic–industrial complex, resulting in conformity to previously unmet
healthcare needs and also discern the relevant technology based on the needs of the population identified by DMs
(via PHAT). In other words, early involvement of all stakeholders ensures, through interaction and participation,
that the emerging technology answers all questions required, and if not, it is adapted accordingly or dropped,
thereby restarting (or continuing in parallel) on an alternate. This is an iterative activity involving pushing the
agenda of relevant technologies (lobbying), resulting in possible broadly defined PPP [17] (see pages 11–13 in this
reference). The preferred sequence of events in the PHAT are in the order stated viz. health needs assessment,
health technology assessment and health impact assessment, respectively, although this is not absolute. Through
the flow of work between PHAT and TT, the PHG wheel, via its ten essential public health tasks [23] distributed over
the domains of assessment, policy development and assurance, is used as a reference frame to ensure all possible
gaps in healthcare integration are addressed. In parallel, the value of information or quality of evidence with
respect to the technology’s ‘relevance’ (added value) to the population or end-user (e.g., health professionals,
managers and patients, among others) including its affordability (economic, ethical, legal, social and organizational)
by the systems, its ‘processing ability’ in terms of understandability or ease of use to the handler/user, and
‘exclusivity’ resulting in restriction of usage due to patent issues, among others, are addressed, thereby solutions
can be developed from them. The value of information and public health genomics wheel ensure that all gaps and
issues are dealt with at an early stage of technology development. TT is symbolically an inverse triangle as there is a
large amount of data generated initially in research and development and, from that data, it narrows down to a
few options through the TT pipeline to innovate or valorize. During this initial stage it is hard to compute with
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PHAT, hence TT’s first research and development starts slightly earlier than PHAT (see inverse triangle to PHAT
block). The (market or population) need is the driving force behind both TT and PHAT. These bring in the concepts
of market push and pull of a relevant technology as TT uses both in its strategy and PHAT evaluate the market pull
and investigate a technology to (market) push, based on population needs. The absorption capacity is the optimal
threshold of the innovation network achieved over several iterations of this PPP.
DM: Decision-maker; PHAT: Public Health Assessment Tool; PPP: public–private partnership; TT: Technology
transfer. Reproduced with permisson from [17].
Where required, further description of a concept will be emphasized, provided it has not been
mentioned in the introduction section above or is new.
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Results	
The LAL model is named as such because within the model, the stakeholders learn (from each other),
adapt (to each other’s requirements and conform within their organization) and level (or even the
modes of communication for understanding and adapting through these widely defined PPPs).
Therefore, iterations and feedback loops are primarily involved in this model through the innovation
network.
As stated in the LAL model, there are two reference points; one being the VoI and the other being the
PHG wheel. When talking in terms of VoI, it can be seen from two different perspectives with both
simultaneously applied within the LAL model as reference frames. The first being the VoI from a business
perspective and the other being VoI from an HTA perspective. When speaking in terms of business, VoI
with its three pillars (Figure 1) of relevance, processing ability and exclusivity tends to incline towards a
more customer-centric model or end-user-centric model. This end-user-centric model is in the form of
customer  value  management  (CVM)  or  end-user  value  management.  Adapted  [26],  CVM  is  managing
each end-user relationship with the goal of achieving maximum lifetime profit from the entire user base.
When using VoI in the form of CVM, we believe the following questions need to be taken into
consideration [26] while developing the technology and if possible even before:
· Question 1: Is CVM being used to improve business performance?
· Question 2: Is the current model of CVM more end-user driven rather than IT driven?
· Question 3: Is customer lifetime value (CLV) being used as an important core measuring tool? ƒƒ
· Question 4: Are competing technologies and context-dependent organizational frameworks
considered when analyzing the CVM?
· Question 5: How strong are our analytical capabilities?
· Question 6: Are the drivers of customer acquisition, retention and expansion recognized?
· Question 7: Are we creating customer value in the currently managed communication channels?
The seven questions above are the guiding tools for the business side of the VoI with question 1 within
the ‘exclusivity’ pillar and 2–5 within the ‘relevance’ pillar. Questions 6 and 7 are part of the ‘processing
ability’ pillar. According to Verhoef and Lemon [26], if the above questions are answered in the positive
or adapted to answer in the positive, it can help in giving an advantage over the competition. This is due
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to the fact that these questions develop the business plan towards an end-user-centric concept. These
plans can be provided through a concrete analytical capability. This capability is defined as the process of
extensively employing data, quantitative analysis, statistical models and fact-based management
techniques to drive firm decisions and actions [26]. Furthermore, these plans can be evaluated through
CLV. CLV is defined as the net present value of all future profits derived from a customer over his/her
lifetime with the business [26]. When businesses or SMEs have a more end-user-centric model resulting
in investment in customer (end-user in our case) intelligence (CI), it has been demonstrated to give an
advantage in the market [26]. CI is the process of gathering and analyzing information regarding
customers, their details and their activities, in order to build deeper and more effective customer
relationships and improve strategic decision-making [105]. Answering the above seven questions
positively has been demonstrated to give better outcomes in profit and success. Verhoef and Lemon [26]
provide an excellent (review/research) article demonstrating this aspect. The article mentioned
demonstrates that these questions should not be answered simply in the ‘yes or no’ format, but rather in
more detail describing what steps have been taken to adapt the answers to yes.
Therefore, the seven questions are one aspect of the reference frame of the LAL model’s (business) VoI,
answered simultaneously with HTA’s VoI. In this sense, we have taken the liberty of deriving a table
summary from Verhoef and Lemon [26] per derived question above and its approaches in the format of
adapted sub-questions as given in Box 1. If TT goes through these questions and acts upon them, it can
ensure that their product is well received by the end-user.
On the other hand, we have VoI from the perspective of HTA. It is to be noted here that within the core
of the LAL model, VoI is assessed during the HTA step (described in the subsequent paragraphs).
However, we believe a shorter version of this HTA’s VoI should be kept as a reference frame prior to the
start, as well as in the process itself, to prepare oneself for adaptations or loose ends. HTA-based
decisions to adopt a technology always pose the question of whether the evidence base to support this
decision is sufficient. VoI analysis provides an analytical framework to determine the value of expanding
the evidence base to inform a decision problem by performing additional research. VoI from the HTA
perspective involves decision analysis regarding the commitment of resources for future research in
order to minimize uncertainty surrounding the expected benefit from a new technology and to maximize
the health gain. A framework has been published by Claxton et al. to compare the potential benefits of
further research with the costs of further investigation, a comparison and prioritization of alternative
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research recommendations, as well as an assessment of the value of investing resources in research or
other activities, such as the provision of health service [27]. The expected VoI for a technology is simply
the difference between the expected value of the decision made with perfect information about the
uncertain parameters and the decision made on the basis of existing evidence. VoI is further described
later in this article under the heading of ‘innovation network’. This perspective should be looked upon by
both TT and PHAT prior to and during the process of the LAL model to meet head-on on issues coming up
as a consequence.
Box 1: Summary of approaches per question with respect to customer value management. CLV: Customer lifetime
value, CVM: Customer value management, ICT: Information and communication technology. Data taken from [25]
with exception of question 4.
Question
No.
Approach
1 · Does it give an improved competitive advantage?
· Does it increase the company’s end-user centric model?
· Does it increase marketing accountability?
2 · Is the focus more internal than external?
· Does the current ICT facilitate the management of end-user relationship?
· Is the focus on the underlying value of the enhancement rather than the enhancement
itself?
· Is the technology investment benefiting the end user and their management?
· Is there an end-user strategy before implementation?
· Can your organization infrastructure translate CVM information into decision making?
· Is your organization counter-productive to customer (end-user) orientation by being
excessively product-oriented?
· How much employee level involvement exists with end users?
· Do all departments have defined responsibilities within the customer centric model?
· Are customer profitability and customer satisfaction taken into account?
3 · Are sales promotions decreasing customers by increasing consumer price sensitivity?
· Is the interdependency of purchase behavior within product categories defined?
· Is the focus too much on a single product option?
· Are there strategies focused on maximizing CLV?
· Can you evaluate or interpret investments and marketing strategies using CLV thus increase
marketing accountability?
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· Can you determine the value of your user base?
· If so, can you link their equity to shareholder value?
· Is segmentation and resource allocation with end users plausible as a result?
· Is the end-user portfolio dependent on CLVs?
· Are bonuses and incentives based on evaluation of CLVs?
4 · Do you have knowledge of the organizational and structural conditions of the end user?
· Have you taken into account the influence of competing technologies in the end user
perception of the value of the technology?
· How could competing technologies and the perceptions of managers’ influence future
pricing and reimbursement?
5 · Do you have an end-user oriented analytical based selection strategy?
· Do you use fact based management techniques?
· Do you heavily rely on customer intelligence?
· If so do you use cross-tabulation, tree-based methods, logistic regression and/or boosting
techniques?
· Does your company also have a customer intelligence marketing interface to translate the
data?
· Does your customer intelligence have interdisciplinary functions?
6 · Are you aware that the perception of value influences the behavior of the end-user?
· If yes, do you assess value equity, brand equity and relationship equity in your business
model as these influence end user acquisition and retention?
· Are you aware of the distinction between acquisition drivers and retention drivers based on
end-user behavior?
· Why are potential end-users drawn to your competitor?
· Do you survey both current end-users and potential users?
· Do you employ customer (end-user) equity analysis?
· Can you distribute end-users according to their motivation or interest in your product?
· If so, do you use customer (end-user) valuation? Do you have an active end-user portfolio?
· If so, is this portfolio a function of time?
· With this function of time, are you able to mix these portfolios to optimize return on
investments?
· Do you have a diverse end-user portfolio?
· Are you able to link your strategies to end-user responses?
7 · Is customer value maintained as well as created in the diverse communication channels you
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use?
· Having multiple channels make things more complex or valuable?
· Are your end-users lost in translation by these multiple channels?
· Are you forcing end-users to a specific channel?
· Do you have a feedback process on multichannel usage?
· Are you able to allocate resources efficiently over these channels?
· Is there consistency between your different channels?
The other reference frame is the PHG wheel [23] with its domains of policy development, assurance,
assessment and reassessment (possible disinvestment or deprescription) defining the ten essential tasks
as given in Table 1. These tasks fulfill the public health integration. The idea behind this reference frame
of the PHG wheel is to cross-check these tasks for possible issues within each domain, which may need
to be taken into consideration for the specific technology in development for acceptance in public health
and healthcare. Although these topics are touched upon in the PHAT [18], like VoI, these are good
reference points to be taken into consideration based on the relevance of the reference point to the
applicability of the technology. Noticeable is that the application of the reference points of VoI and the
PHG wheel have direct implications on the development of the innovation network (Figure 1). If one goes
through the processes involved in either reference frame, it inevitably gives rise to the innovation
network. The reference frames therefore are a prelude to the actual development of the innovation
network through broadly defined PPPs [17] materialized through the core interactions between TT and
PHAT. Importantly, the reference frames are to be kept in parallel as a checklist prior to starting the LAL
model and during the LAL model (when TT and PHAT have been initiated). This way, overlooked issues,
both from business development and healthcare integration, as well as public health perspectives, are
brought up and addressed. The PHG wheel does not have a defined methodology, but rather defines the
tasks to be addressed. The PHAT resolve or define this in its own methodology [18]. On the other hand,
in the case of VoI, it is possibly addressed before or during the development of the technology. It is
essential to state here that the reference frames are not themselves the core steps within the LAL model
but can be considered a pre-step or a continued step, or as a checklist for which to prepare.
We have defined and described how to use the reference frames prior to and while embarking on the
core of the LAL model.  As stated in the LAL model article [17,18],  and based on Figure 1,  we will  now
present our step-by-step method on how to use the framework. Some assumptions have to be stated.
The ideal standard for an idea to develop and reach the market is 5–10 years (innovation pipeline) on
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average. This ideal standard is based on the time to market, given a reasonable return on investment
[28], as well as being based on our own experience. So we will keep the timeframe of the usage of the
LAL model for 5 years in the current example, although this may vary depending on when the technology
reaches the market and can give some room for the analysis. Our steps are summarized in Figure 2.
Table 1: Details of the (ten) essential tasks of the domains of assessment, policy development and assurance of
public health. GBIT: Genome-based information and technology. Adapted with permission from [22] with findings
taken from [23].
Assessment (2)
- Monitor Health
- Diagnose &
investigate
Core function
The regular systematic collection, assembly, analysis and dissemination of personal
health information including GBITs
Related essential services
· Basic research: quantifying the impact of GBITs and their interaction with
environmental factors including knowledge from epigenomics, microbiome
etc.
· Monitoring health: monitoring health status, including genome-based
factors, to identify health problems within the healthcare system.
· Diagnosing and investigating: investigating the distribution of genome-based
and modifiable risk factors to determine their contribution to identified
health problems and to improve health outcomes.
Policy Development (3)
- Inform,
educate,
empower
- Mobilize
community
partnerships
- Develop
policies
Core function
The formulation of standards and guidelines, in collaboration with stakeholders,
which promote the appropriate use of GBITs and the effectiveness, accessibility and
quality of their tests and services.
Related essential services
· Policy and communications research: identifying and analyzing the economic,
social, ethical and political implications of advances in GBITs, including the
information and communications needs of stakeholders.
· Informing, educating, empowering: facilitating communications and
education about the integration of GBITs into health promotion and disease
prevention programs.
· Mobilizing partnerships: fostering collaboration between public and private
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agencies and constituent groups to promote effective and efficient
communication and policy making about GBITs.
· Developing policies: establishing standards and guidelines for when and how
genetic information should be applied to promote health and prevent
disease.
Assurance (4)
- Enforce laws
- Link to/ provide
care
- Assure
competent
workforce
- Evaluate
Core function
Assuring constituents that GBITs are used appropriately and that tests and services
meet agreed-upon goals for effectiveness, accessibility and quality.
Related essential services
· Health services research: identifying and analyzing the factors that influence
the impact of GBITs and the delivery, utilization and quality of health
information and services.
· Enforcing laws: promoting the enforcement of policies and standards
enacted to ensure the appropriate use of GBITs and the effectiveness,
accessibility and quality of genome-based (health) information and services.
· Linking to/providing care: ensuring the availability and accessibility of GBITs
and services and associated interventions to improve health and prevent
disease.
· Assuring a competent workforce: ensuring that present and future health
professionals have training and skills in the appropriate use of GBITs to
promote health and prevent disease.
· Evaluating: evaluating the impact of GBITs and the effectiveness, accessibility
and quality of this information and related services.
System Management (1) Building and maintaining the capacity of the public health infrastructure to integrate
GBITs into public health policy, research and practice.
As can be seen from Figure 2, TT starts a bit earlier than PHAT (Figure 1) as the latter’s HNA cannot
identify with the early stages of the current research [17]. Initial work starts with basic research (and
preclinical research and development) which can be motivated by the need (market pull/push) in the
market (Figure 1). The pseudo-parallel initiation is from the concept of broadly defined PPPs [17], which
bring  in  the  early-on  involvement  of  all  relevant  stakeholders.  From  our  previous  article  [17],  we
hypothetically demonstrated the steps involved in the development of the innovation network given in
the methodology section above. In the subsequent paragraphs, we will expand on these steps. It is to be
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noted that feedback loops and iterations are commonly based on the response of either party.
Furthermore, the reference points (VoI and PHAT) are cross-checked for applicable areas possibly
overlooked throughout the whole innovation pipeline (0–80% innovation network). These two important
points may or may not be mentioned again for the sake of simplicity, however, should be kept in mind at
all times. Please refer to Figures 1 & 2 through the steps below.
Figure 2: Summary and breakdown of the pseudo-parallel initiation of technology transfer and the public health
assessment  tools.  The  first  two  rows  belong  to  TT  and  the  third  row  belongs  to  PHAT.  The  fourth  row  gives  an
estimation of the duration of the parallel initiation (TT and PHAT). The first row subjectively indicates the complete
TT activity [107]; the second row indicates the US FDA’s view on drug development, which is within the boundaries
of TT, of which the parallel is shown [108]. TT starts with basic R&D in the laboratory which leads to an idea of an
application, which develops into an invention or conceptual illustration. This invention is assessed for its feasibility
for market introduction including strength, weaknesses, opportunities and threats and qualitative research
analysis. If the assessment proves worthwhile to pursue, prior to market introduction, the invention or product’s
intellectual property is protected giving it IPR and market approval is sought during or after the assessment.
Depending on whether the invention is a small medium enterprises product and/or from a larger established
organization the product can be licensed for mass production or sales, which results in new products and services.
Consequently, the licensed products generate possible profits which give return on investment by the stakeholders
and payments on royalties. In the FDA’s view, Phase I concerns testing the drug for safety, administered amount
and side effects in a volunteered small healthy group of subjects [108]. Phase II is concerned with effectiveness, as
well as safety, in a small healthy group of volunteer subjects. Phase III involves testing the drug on a large group of
volunteer subjects. This is to establish the effectiveness, as well as to observe side effects and compare with
currently used treatments. Phase IV is carried out when the drug is approved and is being used. The concept is to
gather and analyze data on risks, benefits and best usage. HNA (1 year) identifies the required needs of the
population and allocates resources accordingly. HTA (3 years) assesses the performance of healthcare technologies,
including ethical, legal, economic, organizational and social implications. HIA (2 years), on the other hand, assesses
the effects of policies, programs or projects on the population’s health [22].
HIA: Health impact assessment; HNA: Health needs assessment; HTA: Health technology assessment; IPR:
Intellectual property right; PHAT: Public health assessment tool; PPP: Public–private partnership; R&D: Research
and development; ROI: Return on investment; TT: Technology transfer.
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Part 1: 0% innovation network
Market dynamics are driven by the need in the market. This (health) need can either be created (market
push) or can capitalize on existing demands (market pull). The academic–industrial complex [20] is at the
forefront in identifying or developing the need; however, the healthcare system itself can sometimes
identify the need, depending upon patient/healthcare need. These healthcare system-identified needs
are selected through early awareness and alert systems including strengths, weaknesses, opportunities
and threats, and qualitative research analysis [29,30]; however, we believe true early awareness and
alert systems are not fully realized [18] as healthcare is in reach with only upcoming technologies in the
public domain to assess. Coming back to the academic–industrial complex, the market health need is the
driving force behind research (including preclinical research). The academic–industrial complex keeps in
mind the VoI and PHG wheel and tries to conform to the developmental process of their research to the
references while in these stages. As can be seen from Figure 2, during the initial research, HNA cannot
identify with the preliminary ongoing research as it is in its initial stages and promising applicability
cannot be determined. This is considered as 0% of the innovation network as no communication has
been made with healthcare policy.
Part 2: 10% innovation network
During the different phases of research and development (Figures 1 & 2) and in the case of drug
development, the latter phases of preclinical research and the different stages of preclinical
development including initial stages of Phase I, initial contact followed by multiple contacts, will be made
with HNA. This is the start of the broadly defined PPPs [17] of the innovation network. Based on the
requirements of the reference frames and the current identified need, feedback is sought based on the
relevance of the solution. A preliminary HNA assessment will be carried out, which will bring the TT
people back and forth to the drawing board to conform to the identified health need. TT will  conform
according to the given information, as conformity will ensure acceptance of their technology to
healthcare systems, thus possibly generating profit.
The need from this perspective can be defined as ‘the ability to benefit from the intervention’ [31]. The
availability of an intervention may not necessarily indicate a need; similarly a demand for an intervention
may not indicate a need. The need for healthcare must be distinguished from the need for health. The
need for healthcare is much more specific than the need for health and is now widely accepted to mean
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the population’s ability to benefit from healthcare. It depends on the potential of preventive or
treatment services to remedy health problems.
HNA, therefore, is a systematic method of identifying unmet health and healthcare needs of a population
and making changes to meet those unmet needs. It provides information for:
· Improving health;
· Service planning;
· Priority setting;
· Policy development.
HNA is thus not a health status of population assessment. It aims to improve health and it incorporates
the  concept  of  a  capacity  to  benefit  from  an  intervention.  HNA  usually  aims  to  make  incremental
changes to existing services [106].
HNA is performed by combining epidemiological approaches with patient’s perspectives, assessment of
the effectiveness and possible cost–effectiveness of interventions. The principal activities involved in
healthcare needs assessment are therefore:
· The assessment of incidence and prevalence (how many people need the service/intervention);
· The effectiveness and cost–effectiveness of their services (do they confer any benefit, and if so,
at what cost, i.e., what is the relative benefit?) and the baseline services.
During the process of HNA, the following questions are answered;
· What is the problem?
· What is the size and nature of the problem?
· What are the current services?
· Identify interventions by asking patients what they want;
· Identify interventions by reviewing scientific knowledge;
· Consult professionals and other stakeholders;
· What are the most cost effective solutions?
· What are the resource implications?
· What are the recommendations and plan for implementation?
· What are the outcomes to evaluate change?
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Subsequently, initial contact is made with HTA professionals during or after adaptation has been
performed based on the HNA assessment. The idea is to get them in touch with a prospective upcoming
technology which is not currently in the public domain for the HTA’s early awareness and alert systems
bringing the concept of true alert systems and constructive technology assessment (CTA) [18,32,33]. This
is during the near-end of the invention phase (Figure 2) and also includes Phase I of drug development.
This is considered 10% of the innovation network.
Part 3: 20% innovation network
This involves the near-end of the invention development including the assessment for feasibility in the TT
pipeline (Figure 2) and the start of patenting (intellectual property rights). This also includes Phase I
through Phase III of drug development. The HTA professionals assess (possibly via horizon scanning or
CTA) [34] this prospective technology for its relevance to a society’s need. This involves feedback loops
and communication both ways and possibly going back to the drawing board for the TT professionals,
adapting to conform to HTA requirements based on its horizon scanning and CTA, including HTA’s VoI.
HTA is a way of assessing the ways science and technology are used in healthcare and disease
prevention. It covers medical, social, economic legal, organizational and ethical issues. It provides policy-
makers with objective information, so they can formulate health policies that are safe, effective, patient-
focused, context tailored and cost-effective. Five distinctive activities have been described by Sullivan et
al. to define the HTA process [35]:
· Horizon scanning or early awareness alert systems;
· Topic determination and queuing;
· Collection and quality assessment of evidence;
· Appraisal;
· Assessment.
Early awareness and alert (e.g., horizon scanning) involves the early examination and active monitoring
of emerging technology to determine, in part, potential evidence requirements, and budgetary
implications [32,33]. CTA is a form of early HTA to minimize social conflicts, inadequate diffusion and
unwise investments. CTA assesses the exact impact of a new technology to a broader approach,
including the analysis of design, development and implementation of that new technology [36]. CTA can
be done in parallel with the early awareness and alert system.
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Economic evaluation is a dimension of the HTA tool to determine the value of a new medical technology
and is defined as ‘the comparative analysis of alternative courses of action in terms of both their costs
and their benefit’ [37]. Decision-making between alternative courses of action in healthcare is based on
evidence regarding clinical and cost–effectiveness and aims to maximize net health benefit. At the time
of decision, clinical and cost–effectiveness evidence regarding the medical technology in question, may
not be sufficient enough. This may result in a potentially wrong decision. Therefore, decision-makers
would face the dilemma of taking an uncertain decision or expanding the evidence base to increase the
net benefit of healthcare to society.
VoI analysis may answer this question by providing a framework for HTA, thus falling between questions
4 and 5 above. VoI estimates the potential benefits of gathering further information before making a
decision [27]. VoI is a systematic decision-analytic approach to determine whether there is enough
evidence to support new technologies, optimally designing research studies and setting research
priorities for HTA [38]. VoI analysis helps decision-makers to allocate resources to further research
regarding any chosen intervention in order to achieve the greatest return in terms of outcomes, for
example, health gain from the resources available.
Using currently available information, it is possible to calculate the expected added value of the new
technology against the existing practice, if any. Uncertainty in one or more parameters of current data
(imperfect information) may adversely affect the precision of added value of the new technology. Thus,
the uncertainty in the available data raises the possibility of a wrong decision. VoI analysis calculates the
expected value of perfect information using methods such as the Bayesian method. The essence of the
Bayesian approach is to provide a mathematical rule explaining how one should change one’s existing
beliefs in the light of new evidence. The difference between the expected value of the technology with
current information and the expected value of the technology with perfect information is ‘VoI’. This
helps the decision-maker in research prioritization, as the cost of the new research for evidence base
expansion should be lower than VoI. We believe that VoI could be used as a tool for research and
research funding or investment prioritization and it has significant potential to assist in the decision-
making process regarding the adoption of a technology into the practice [39].
It should be noted here that lobbying through advocating and reasoning, in a way that defends the
conformity and relevance of the upcoming technology should be done by the TT professionals
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(academic–industrial complex) and communicated with HTA in a polite manner before and/or
throughout the process, or possibly at the end of a short initial assessment. This defense of conformity
and relevance of the upcoming technology will be based on the VoI and PHG wheel reference frame
questions answered, including HNA’s assessment conformity. Of course it can be unavoidable that the TT
professionals will have to go back to the drawing board to adapt to the HTA’s assessment. Multiple
contacts are made between the two parties. Early on involvement with all stakeholders is established
here throughout the process and possibly earlier (10% innovation network). These stakeholders, apart
from the academic–industrial complex and HTA professionals, involve medical doctors, insurance
companies and patient groups, among others. Feedback will be sought from these stakeholders to build
a good case for the HTA assessment or post-assessment. Based on HTA’s feedback and assessment, TT
should adapt the emerging technology accordingly so that it conforms to the need as perceived by
policy. This is how the proposal will be developed. This will complete 20% of the innovation network.
Part 4: 40% innovation network
These potential interactions between TT and PHAT could possibly lead to fully fledged, broadly defined
PPPs [17]. According to our original article [17], these PPPs are collaborative and involve bilateral
communication, cross-talk and consultation, among others. The prelude to these fully fledged PPPs can
be seen until 20% of the innovation network. The theory here is that, throughout this interaction, by the
time it reaches 20% development of the innovation network, a sense of reliability and trust can develop
and both parties will see the benefit of this PPP. For the academic–industrial complex, this will be from
the perspective of saving resources and profit. The benefit of PPPs for policy-making can be seen as the
realization of true horizon scanning [18] and timely interventions removing the issue of the circle of
destination [18] (which is the cycle of late introduction of a then relevant technology, but now less
relevant due to the functions of time and emerging technologies). Saving resources occurs not only from
the perspective of time, but also from the fact that realizing early on that the technology development
needs adaptations and, if not possible, can dictate whether or not to stop the project before its success
or failure, respectively. Through these PPPs, the true sense of the impact of the technology can be
investigated via HIA, as not only HIA data but company statistics are shared. HIA investigation starts in
the TT pipeline from the early stages of intellectual policy rights through market introduction and its
dynamics. For drug discovery, it starts at Phase IV. The HIA can significantly boost the case for TT towards
the policy-makers by combining HTA recommendations, as well as the HNA.
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HIA, including post-introduction observation [40] is the process of identifying the future health
consequences of a proposed action. It has been defined in the Gothenburg Consensus Paper that the HIA
is a combination of procedures, methods and tools by which a policy, program or project may be judged
by its potential effects on the health of a population, and the distribution of those effects within the
population [41]. HIA is one way in which policy proposals, which affect determinants of health, can be
assessed for both their potential intended and unintended consequences on the health of the population
and the distribution of impacts within specific subgroups [42].
HIA includes the following elements:
Consideration of evidence about the anticipated relationships between a policy, program or project, and
the health of a population;
· Consideration of the opinions, experience and expectations of those who may be affected by the
proposed policy, program or project;
· Provision of more informed understanding by decision-makers and the public regarding the
effects of the policy, program or project on health;
· Proposals for adjustments/options to maximize the positive and minimize the negative health
impacts.
HIA offers a systematic five-step process for structuring actions aimed at identifying which health
determinants will be affected by planning and conducting a study of the potential repercussions on a
given population’s health, and interacting with policy developers on the basis of the results.
The steps of HIA are as follows:
· Screening – to determine whether or not there exists the potential for significant health impacts
as a result of a policy, program or project;
· Scoping – establishes the study area boundaries, identifies possible consequences, and
determines a management approach for the HIA;
· Appraisal – considers the nature and magnitude of health impacts and the affected populations;
· Reporting – develops practical recommendations as to whether the decision-makers will
consider the results of the HIA in their decisions;
· Monitoring – reviews the effectiveness of the HIA process and evaluates the actual health
outcomes as a result of the project or policy.
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In addition to drawing on public health information produced through research, the HIA process is
designed to accompany the process of public policy development, encouraging decision-makers and
groups within the population to take part in identifying potential health effects. Therefore, HIA is an
interaction between the public health sector, those responsible for the proposed policy and the
population, whenever possible. This relates to our concept of PPPs.
Part 5: 60% innovation network
Given that the above conditions are fulfilled through these now established PPPs, the LAL model will be
reused in the development of other upcoming technologies. As a result, it is perceived that confident and
streamlined processes will be developed over the second and third runs of the LAL model with the same
policy agencies. Over several iterations or runs of the LAL model, the PPPs will recognize room for
improvement in the innovation network in order to efficiently execute the model. As a result the
innovation network matures enough to further shorten the time frame of this process. This is considered
60% coverage of the innovation network.
Part 6: 80% innovation network
Over time, the innovation network should develop into a system through repeated TT and PHAT
interactions to involve decision-makers early on, along with the PHAT (of course these decision-makers
heavily rely on PHAT). By this stage, it is perceived that the network of interactions will become stable
and near perfected (not perfect, hence 20% always remains as room for improvement). So in a way,
efficient assessments and adaptations have been implemented to bridge the gap between TT and PHAT
and the timeframe has been standardized ending with HIA followed by the decision by policy-makers.
This is the threshold we call the absorption capacity.
The steps are designed to show that, through the process of feedback loops, conformity requirements
and reference frames, by the time the technology is ready for launch or launched, it can be readily taken
up by healthcare systems in real-time as all assessments would have been met head on, which would
have traditionally been taken after the technology information was in the public domain. In addition, the
technology was adapted to the perceived requirements for policy guidelines. As a result, market
penetration and reimbursement issues, among others, are resolved as guideline development is
addressed by early dialog through the PPPs. In addition, timely intervention is a possibility, as is reducing
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the redundancy of a technology by its timely uptake [17,18]. A summary of our innovation network
development and its steps are shown in Figure 3.
Figure 3: Summary of steps 1–6
for the execution of the
Learning-Adapting-Leveling
model. The whole process in the
left column involves feedback
loops  and  iterations.  The
slashed circle indicates possible
discontinuation if the
adaptations are not feasible for
TT.  Early  involvement  of
stakeholders  can  also  start
during the HNA contact level.
The  right  column  shows  the  TT
phases and drug discovery
phases (within TT). Throughout
the whole process, VoI and the
PHG wheel are used as
reference frames to ensure that
the technology conforms with
business and public health
requirements. This eventually
leads  to  PPPs  in  the  innovation
network.
CTA: Constructive technology
assessment; HIA: Health impact
assessment; HNA: Health needs
assessment; HTA: Health
technology assessment; PHG:
Public health genomics; PPP:
Public–private partnership; TT:
Technology transfer; VoI: Value
of information.
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Discussion	
We aimed to develop concrete steps from the LAL model framework. Keeping the VoI and PHG wheel as
the reference frame, we started off with defined steps initiated by research and development. After
basic research and development, initial contact was made with HNA professionals by TT professionals or
technology developers. After the HNA and subsequent feedback loops and adaptations, contact was
made with HTA professionals and stakeholders. These stakeholders were given active involvement in the
process, followed by HTA assessment in the form of CTA. After feedback loops and adaptations, contact
was made with HIA professionals for the final round of assessments and feedback loops to be done by
HIA. As a result the technology is then conformed to PHAT and ready to be forwarded to decision-makers
for final decision and guideline development.
However, there are issues which need to be addressed. The VoI and PHG wheel reference frames are
more  of  an  indicative  reference  than  a  fully-fledged  litmus  test.  Certain  questions  in  the  case  of  VoI
(business) and steps in the case of VoI (HTA), as well as statements in the PHG wheel can be skipped
based  on  the  applicability  of  the  technology  or  relevance  of  the  reference  frames’  components  to  the
technology’s objective. This also applies to the stakeholder using it (TT for business VoI and TT/PHAT in
the case of the PHG wheel). This is why piloting should be performed as it is required to demonstrate the
applicability of the model itself and the modifications or tunings that may be required.
The steps involved for migrating the answering of the reference frames from negative to positive are not
described as this will greatly vary from stakeholder to stakeholder depending upon their interest,
capability and applicability, and are therefore of a subjective nature. This is outside the scope of the core
steps themselves. The reference frames themselves are a prelude to the actual development of the
innovation network.
HNA, HTA and HIA are sequential approaches with significant overlap in their aims, procedures and
methodologies. All three deliver facilitating components for various phases of translational research, as
described by Khoury et al. [43]. Furthermore, they go beyond these four phases. HNA, HTA and HIA have
their own timeframes and independence from each other and TT. Also, a personalized healthcare
intervention has been proposed with decision-making on a ‘case by case’ basis [44]. This will redefine the
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roles of HNA, HTA and HIA in translational research and its implementation. As a consequence, they do
not currently compute with the LAL model, therefore an adapted version of each is necessary. This can
also apply for TT to conform to the sequence of events. However, this still does not guarantee that PHAT
professionals will be on board. As a result, it can be an absolute that TT professionals will always have to
contact PHAT to execute the LAL model. Furthermore, its tailored tuning to different technologies and
their characteristics (which is also the proposal of Figure 1) will still have to be done. It can be possible,
that over time, the model becomes a standard in some places, whereas elsewhere, it may not be that
soon. In any case, the current economic landscape could encourage an enabler to a broader expansion of
the model. Still, the model steps can be applied internally by TT professionals, including the PHAT
assessments, the reason for which is elaborated on in the text. The distinct advantage of doing so is that,
even if PHAT are not on board, TT is still able to conform their technologies to healthcare and public
health requirements, possibly reaping a similar benefit. This should not be considered a replacement of
contact, as networking in the innovation network is required for real-time acceptance into healthcare
and the development of PPP can be beneficial in the long term. The non-synergy between TT and PHAT is
the inherent problem, and to resolve this, their bilateral communication is required. Therefore, it is not
recommended to just stick to internal assessments.
In relation to the above paragraph, timelines of assessments in the LAL model (Figure 3) cannot be
defined at this stage. The timeframe we suggest is ideal (5-10 years; this is quicker than normal, but can
perhaps be still too long for the integration of a new molecular diagnostic assay), with HNA, HTA and HIA
being 1, 3 and 2 years, respectively (Figure 2), for the 5-year period. However, when previous work has
been performed, especially in the case of HNA, it can be shortened. On the other hand, however, to
address this issue, current systems in place have evolved over time to a more structured, transparent
and informative way of execution. Nonetheless, currently existing technologies are required in many
senses to enable and optimize this structuring and potential restructuring possibly through the LAL
model. This also includes feedback loops (Figure 1). However, even if we were able to adapt HNA, HTA
and HIA within the timeframes, adaptations on the feedback would require additional time. Initially,
when the model is applied, time can increase due to the added steps outside of TT’s domain.
Nonetheless, it is advantageous compared with the time lost from market to healthcare systems (circle
of destination) [18]. In the long run, the timeframe can be reduced and eventually adapted to be
sustainable for the PPPs. These PPPs can take more time to come into form and a few iterations may be
required before the PPPs are formalized. However, according to our broadly defined PPPs, this also
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involves consultation and two-way communication. The decision-makers in Figure 1 are indirectly
present through their domains of HNA, HTA and HIA (these give recommendations to decision-makers).
Here, over time, decision-makers can also be more directly involved through these PPPs in the
innovation network. Lobbying can bring ethical, legal, societal and organizational issues of misled or
hidden agendas, which we proposed in our original article [17]. As well as their own source, HTA should
have, apart from their own source and the TT data, a third opinion, for example, the patient groups
when these PPPs are formalized.
The quantification of TT products to a single qualitative product (see Figure 1 inverse triangle) [17], does
not hinder its process when getting feedback from PHAT, as through feedback, options can be added or
reduced, eventually choosing one with which to go forward. Of course, this does not imply that TT
should show several options to PHAT as they will outright reject it, unless some of them are worth
investigating (in their opinion). TT can identify which of their products through the reference frames are
worth forwarding to PHAT for investigation, or if the current one needs to be replaced with a new one
halfway through, possibly bringing it back to square one.
Irrespective of the issues stated above, the problem of this non-synergy and inexistence of crossings are
the main issues [17,18] and the LAL model, through its steps, ensures all aspects of business and public
health, as well as healthcare issues, are covered [18]. This non-communication causes a delay in the
uptake of relevant GBITs in healthcare, therefore bilateral communication is necessary to ensure real-
time interventions. In other words, as we elaborated, the LAL model covers all possible areas of business,
public health and healthcare requirements which can be neglected. Being the overarching framework
[18] through its extensive coverage of these neglected areas, the LAL model should be implemented.
Other issues in the delay to healthcare integration can include lack of funding to research institutes and
limited return on investments for some diagnostics as compared with pharmaceuticals and biologics.
However, for the limited return on investments, this can also be an issue of not implementing the LAL
model, as conformity issues being resolved can open currently inaccessible markets and/or healthcare
systems more quickly for better returns in real-time. Coming back to lack of funding, it  can be seen as
another issue, in itself detached from the major issue of cross-cutting communication. Even if the
funding issue is resolved, communication barriers, which we have elaborated on in this article, will still
remain,  which  can  be  resolved  through the  LAL  model.  Apart  from this,  clinical  utility  of  current  GBITs
limit their usage in healthcare systems. However, this again is an issue related to the LAL model as the
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oversight of the clinical utility is a product of this lack of stakeholder engagement between healthcare
systems and industry, which our model resolves from the perspective of conformity. A game theory
approach to these situations as well as the LAL model interactions in general can be an interesting
endeavor.
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Conclusions	
The documented backlog of relevant GBITs inhibits the deployment of personalized medicine
applications in healthcare. This is evident by the promises of the post-genomic era through systems
biology regarding a truly personalized treatment, compared with its actual execution in healthcare
systems. We believe that the LAL model, through its steps, can resolve this issue of backlog of relevant
GBITs, and thereby release the GBITs in an effective and efficient manner in real-time for personalized
applications in healthcare.
We have described the LAL model step-by-step as to how it should be used. The VoI and PHG wheel
should go throughout the LAL model processes of execution to ensure that all business, as well public
health, issues are covered. Iterations are important as adaptations and conformity issues are resolved
through the process, ensuring that by the time the technology is rolled out, it conforms to decision-
makers for real-time uptake and policy guidelines. TT starts slightly earlier than HNA and, later on, moves
in parallel with HNA, HTA and HIA in the same order as assessment feedback. A case is built for the
decision-makers of the technology being developed through feedback, reference frames and approval
from each domain (HNA, HTA and HIA). The innovation network develops accordingly, with early
involvement of all stakeholders. PPPs are developed within the innovation network over some iterations.
Timeline issues of the steps involved still need to be defined as this may vary from type of technology to
assessment timeframe, as well as TT and PHAT tools adaptability to each other. Over time, however, this
can be reduced and become sustainable. During this time, internal assessment of PHAT by TT can be
performed; however,  this is  not recommended in the long term, as it  will  not resolve the issue of non-
synergy, possible stagnating profits. Through these steps, real-time uptake of GBITs by healthcare in an
effective and efficient manner becomes plausible. Apart from decreasing the timeframe to healthcare in
the long run, not only can TT come to an early decision to continue or kill the technology through PHAT
feedback, thus saving on resources, but it can also tap into a previously unexplored market due to
timeframe constraints. In other words, although businesses make profits on who they sell their
technologies to, if the whole healthcare system accepts their product, that is a larger market than
traditionally sold to for example, a few hospitals, research centers or other companies, among others. In
time, however, there may be a chance that eventually the healthcare systems accept (or reject) the
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technology, which gives more reason to execute the LAL model to ensure acceptance. Also,  healthcare
systems can benefit from timely interventions and technologies reaching the patient in an effective and
efficient manner. As a result, this could positively impact on health outcomes. Previous ways of doing
this, although they, in some cases, provided benefits to manufacturers and systems, are not possible
under the current economic landscape and, thus, this approach is more likely to be successful because it
provides a rational, structured and logical process to introduce added value technologies in healthcare
systems. The described methodology of the LAL model framework can benefit all stakeholders who use
it. Although the model is being implemented in some contexts as this article goes into publication, its
proof of concept still remains to be seen at the end of the technology maturation process. Nonetheless,
the LAL model framework, given its overarching frame [18], can be the answer to cross-integration [19]
and a  focus  on  GBITs  might  eventually  make  it  a  possible  tool  for  the  implementation  of  personalized
medicine.
Future Prospects
We believe that if the model is properly lobbied, although it is currently being advocated including
through grants, high level policy reports and industry support, it can become the de facto model for the
evaluation of GBITs for effective and efficient integration of personalized medicine applications in
healthcare in a timely manner. As our current work is inclined to pilot studies to test the robustness of
the  LAL  model,  we  aim  to  tweak  and  refine  TT,  HNA,  HTA  and  HIA  to  each  other  for  streamline  a
performance. Over time, this will be achieved and the general acceptance will grow as we work closely
with several agencies and industries. Furthermore, elsewhere we have demonstrated why the LAL model
is an overarching framework covering all aspects of healthcare integration, building its case. In addition,
we see growing evidence of demand for early dialog and early involvement of all stakeholders with
programs and initiatives towards this end. The LAL model addresses this early dialog and stakeholder
involvement. Given the fact that the framework constitutes all of the necessary tools and early dialog
demanded for healthcare integration, it may eventually be used in different adapted forms by relevant
stakeholders. As a result, it may be an essential tool used in personalized medicine for healthcare
implementation.
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Executive Summary
Delayed personalized medicine application
· Personalized medicine has become the central focus of the concept ‘one shoe does not fit all’,
resulting in a more personalized approach towards healthcare.
· However, the implementation of personalized medicine applications such as genome-based
information and technologies is not completely seen.
Bottleneck and solution
· This bottleneck is due to the fact that there is lack of communication between the academic-
industrial complex and healthcare assessment professionals.
· We expand upon the innovative Learning-Adapting-Leveling model framework as this framework
addresses the bottleneck.
Developed concrete steps
· We  develop  in  chronological  order  the  steps  of  this  model  to  resolve  the  issue  of  delayed
implementation
· The value of information from the business perspective and health technology assessment
perspective as well as the ten essential public health tasks are used as reference frames for early
detection of issues throughout the process.
· Throughout the technology transfer activity, the academic-industrial complex makes contacts
with the health needs assessment, health technology assessment and health impact assessment
professionals in the same order.
· These contact lead to assessments, adaptations and feedback loops.
· As a consequence, early involvement of all stakeholders is guaranteed.
Key issues
· This model addresses the effective and efficient implementation of personalized medicine
applications to healthcare in a timely manner.
· However, the model still needs to be tweaked for compatibility between technology transfer,
health needs assessment, health technology assessment and health impact assessment,
including timelines of parallel work.
· We believe the model can become the overarching framework in personalized medicine for
healthcare integration of genome-based information and technologies.
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Conclusions	
With  regard  to  specific  objectives  of  Part  A,  with  respect  to
chapter  I, the thesis completed and answered the objectives
pertaining namely:
· Presenting the problem statement of the bottleneck of
integration of genome-based technologies into
healthcare
Based on the exponential increase in genome-based
technologies (including personalized healthcare
applications) onto the market, patents and scientific
literature, there seems to be a backlog of integration
of these technologies into healthcare. Although there
are tools and systems in place for move from bench
to healthcare, still the backlog remains regarding the
real-time effective and efficient real-time integration
of genome-based technologies. The chapter
identified the reason for the bottleneck mainly being
the non-synergy or lack of communication between
the academic-industrial complex and the decision
makers of healthcare integration. Furthermore, these
two entities use different tools for translational
research
· Identifying the rationale behind the problem statement
The rationale behind the problem of the real-
time effective and efficient integration of
genome-based technologies is the different tools
used by the non-synergistic academic-industrial
complex and the decision makers for healthcare
Take	Home	Message	
Although	 there	 is	 an	 exponential	
growth	 of	 genome-based	
technologies	its	real	time	effective	
and	 efficient	 integration	 in	
healthcare	is	not	realized.		
The	bottleneck	is	identified	as	the	
non-synergy	 between	 the	
academic-industrial	 complex	 and	
health	policy	decision	making.	
These	 two	 entities	 namely	 use	
different	 tools	 for	 translation	
(Technology	 Transfer)	 and	
implementation	 (Public	 Health	
Assessment	 Tools)	 respectively	
used	in	different	timeframes.	
By	 the	 time	 a	 new	 technology	
enters	 healthcare	 it	 becomes	
outdated	 as	 a	 newer	 technology	
presents	itself	on	the	market.	
The	 Learning-Adapting-Leveling	
model	 resolves	 this	 bottleneck	 by	
bringing	Technology	Transfer	and	
the	 Public	 Health	 Assessment	
Tools	together	for	the	first	time	on	
a	 common	 platform	 in	 parallel	
along	with	other	concepts.	
The	 protocol	 developed	 on	 this	
framework	 can	 help	 industry	 to	
come	 to	 an	 early	 on	 decision	
saving	 on	 resource	 as	 well	 as	
possibly	 help	 decision	 maker	
diffuse	 relevant	 technologies	 and	
develop	policies.	
The	model	has	been	argued	as	an	
overarching	 framework	 and	 has	
been	 demonstrated	 accordingly.	
Conceptual	 issues	 of	 tools	 used	
have	 been	 cleared.	 Issues	
regarding	 compatibility	 of	 the	
tools	 in	 the	model	still	need	 to	be	
resolved.		
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integration. As a consequence, by the time a technology reaches the healthcare, it can be
considered less relevant compared to a new emerging technology on the market. This is a
continued cycle. As a result, both industry and healthcare systems including individuals
(both patients and healthy people) are at a disadvantage. For the industry, they are
unable to tap into a much larger market than currently perceived. For example the
industry sells their technology or product to a few research hospitals, labs and partners
making millions in the process. However, if healthcare accepts the technology and its
widespread usage becomes a reality, it becomes a much larger market, generating larger
sums of profit. Furthermore, several technologies perceived by the academic-industrial
complex are answering the need generally get rejected or delayed by the healthcare. If
the academic-industrial complex can come to an early-on decision to the developing and
emerging technology regarding its acceptance and conformity to healthcare
requirements, it can save a lot on resources like time and money. In addition the
academic-industrial complex based on the new information, make the decision to either
adapt the technology before market introduction or kill it entirely or continue with it for
the traditional perceived market. On the other hand, both citizens and healthcare are at
a disadvantage due to the delay of relevant genome-based technologies. Reason being
this relevantly blocked technology may be more effective and efficient than the currently
utilized one. As a possible consequence, for example the emerging diagnostic technology
can predict susceptibility or onset to a disease better than the currently utilized one, if
integrated timely. It can possibly reduce the burden of disease through the concept of
early prevention better than only by cure. Similarly, patients can benefit from other
genome-based technologies if integrated on time.
· Introducing  tools to resolve the problem statement
In this chapter it was concluded that technology transfer is the most widely used tool for
commercialization of technologies from bench (the lab) to the market and return on
investments. This is mainly used by the academic-industrial complex for valorization and
commercialization. On the other hand, HNA, HTA and HIA are the most widely used tools
referred to by decision makers to come to a decision on healthcare integration and
allocation of resources. Furthermore the value of information is considered pivotal for
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decision making. Also the PHG wheel seems relevant for its inclusion as a good reference
point for integration into public health.
· Defining valorization in public health genomics
Valorization in public health genomics is defined as the process of realization of added
value bioproducts in the domain of public health for benefit of the population and
healthcare systems. Here realization is considered in terms of understanding the
importance, impact or potential benefit and implementing the bioproduct. Bioproducts
are defined as sustainable novel products or products satisfying novel health applications
derived or inspired from genome-based information or technologies. Genome-based
means everything deriving from the human genome, for example all ‘omics’, like
genomics, proteomics, metabolomics, etc. Genome-based information implies ‘omics’
interactions with environmental factors like lifestyle, location, climate, etc. Technologies
can be a technique, process, clinical application, diagnostic kit, methodology, activity or
technology in the general sense.
· Developing the framework to close the gap – the LAL model
The Learning-Adapting-Leveling model was developed using the methodology of an
integrated approach of the basic design cycle and the fish trap model. Based on the
reasoning in the methodology, tools were selected or discarded for their relevance to the
problem. The Learning-Adapting-Leveling model for the first time brings together the two
major activities used by the academic-industrial complex and the decision makers,
namely technology transfer and the public health assessment tools (HNA, HTA, HIA)
respectively in a pseudo-parallel initiation. The proposal is, that through this parallel
initiation, there will be interactions and feedback loops to conform the technology to the
healthcare requirements. These interactions will be on a platform defined as the
innovation network, possibly leading to broadly defined public-private partnerships.
During the whole process, the model takes into consideration the value of information
and the public health genomics wheel as reference points to ensure that all business
aspects and as well as healthcare aspects are addressed by the time the technology is
rolled out into the market. As a result, it can be readily taken up by healthcare system as
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the technology would now conform to its requirements. This over time will be optimized
with an operational threshold which is defined as the absorption capacity.
With  regard  to  specific  objectives  of  Part  A,  with  respect  to chapter II, the thesis completed and
answered the objectives pertaining namely:
· Elaborating on various concepts used in the field and arguing the exclusion/inclusion of them
with respect to the developed framework
In this chapter, all relevant concepts were described and defined which are used for
translational research. The tools or activities defined and described were valorization,
spin-offs, regional valorization systems, open innovations, drug discovery, HNA, HTA, HIA,
ACCE, EGAPP, T1-T4, PHG Enterprise, and PHG Wheel. Based on the definition of
technology transfer, and in parallel to definitions of valorization, regional valorization
systems, spin-offs, open innovations and drug discovery were placed within the
overarching framework of technology transfer. Technology transfer was described to be
the most popular tool or activity used for commercialization of technologies onto the
market and return on investments so it was considered one of the two core components
of the Learning-Adapting-Leveling model. Similarly, HNA, HTA and HIA in the form of the
public health assessment tools are widely used assessment tools referred to by decision
makers in healthcare systems with defined methodology. Therefore it was the other core
component of the Learning-Adapting-Leveling model. On the other hand ACCE, EGAPP,
T1-T4 and the PHG Enterprise although having valid points in their own application were
left out due to their assorted weaknesses or ill-defined methodologies and/or overlaps
with existing tools in the Learning-Adapting-Leveling model like the PHG wheel. The PHG
wheel was demonstrated to show its overarching framework over the rejected tools and
overlaps to HNA, HTA and HIA, therefore was considered an important part of the model.
Reason for it being not considered at par with HNA, HTA and HIA was that unlike them
the PHG wheel does not have a defined methodology rather just mentions the 10
essential public health tasks, which address public health integration and the way of
doing it (e.g. using HTA). Nonetheless, the PHG wheel is a good reference point to ensure
that aspects of even rejected tools are covered and possible overseen gaps can be
addressed.
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· Resolving the issue of overlapping tools and defining them with relation to each other.
Through the definitions in this chapter, the tools with a commercialization aspect seem to
greatly overlap with each other. It was cleared that translational research covers the
whole aspect from bench (lab) through the market to healthcare. For the first half, i.e.
from lab to market, technology transfer is considered the overarching framework.
Technology transfer was defined to demonstrate its encompassing various tools or
concepts (valorization, regional valorization system, open innovation and drug discovery
and spin-offs) within commercialization and defined their slots in time through the
process.
· Argumentation why the solution framework is the answer
The Learning-Adapting-Leveling model brings for the first time the two widely used and
popular activities for translational research namely, technology transfer and the public
health assessment tools (HNA, HTA and HIA) onto a common platform (innovation
network) and aims for broadly defined public-private partnerships through these
interactions. Technology transfer addresses the move from lab onto the market and the
public health assessment tools define the move from the market to healthcare
integration through recommendation given to decision makers. This chapter defined the
comprehensibility of the PHG wheel (part of the model) as an overarching reference
frame to ensure that all aspects are covered including rejected tools. Similarly the value
of information ensures that the relevance, processing ability in terms of understandability
of the technology to the end user and exclusivity in terms of patents which restrict the
wide usage are addressed. The value of information is dealt from both a business aspect
and HTA aspect for early on assessment. In addition, the model encourages early-on
involvement of all stakeholders. The model is quite comprehensive in its reach of issues to
be addressed from both a business as well as from the healthcare perspectives due to its
extensively defined tools. Also the model has been heavily cited, presented, published in
high level reports and is being implemented in pilot studies. Moreover, the model has
been developed specifically for the bottleneck defined. Therefore, it should be considered
an overarching framework and the solution to the defined bottleneck.
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With  regard  to  specific  objectives  of  Part  A,  with  respect  to chapter III, the thesis completed and
answered the objectives pertaining namely:
· Elaboration on the defined steps of the solution framework
The defined steps start off with basic research and development in the lab. After some
initial feasibility tests and the development of the idea which would answer the need or
create one, the technology transfer professionals make contract with the HNA
professionals. The HNA professional do an initial assessment and this leads the
technology transfer professionals back to the drawing board and adapt. Thereafter, the
technology professionals contact the HTA professionals with their conformed technology,
keeping in mind the HTA’s value of information. The HTA professionals assess the
technology and give feedback based on that assessment. The technology professionals go
back to the lab and conform the technology further. The same step is repeated with the
HIA professionals. This can involve several feedback loops per agency. Also the PHG
wheel and the value of information are taken as a reference point throughout the
process to ensure that all aspects are addressed. As a consequence, by the time the
technology is rolled out onto the market, through relevant lobbying based on the
conformity issues addressed, the technology can be readily taken up by decision makers
who assess it based on the original assessment requirements addressed. The aim is that
overtime of these interactions public-private partnerships will be developed and will be
optimized.
· Addressing issues still to be resolved
Initially through this process, the timeframe will be increases as additional steps will be
added in the technology transfer pipeline, however in the long run this will be optimized
and compared to the delayed uptake, it is a good tradeoff. Also HNA, HTA and HIA have
to be compatible to each other as well as technology transfer which are believed to be
resolved through the development of public-private partnerships. Furthermore, not all
aspects of value of information and the public health genomics wheel need to be
addressed depending on the type of the technology or the user of the Learning-Adapting-
Leveling model. However, addressing these reference points from negative to positive will
enhance the possibility of healthcare integration. Another point to be noted is that how
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to bring these reference points from negative to positive is not answered here as this is
entirely subjective depending upon the user of the reference points. Even after the
model’s wide attention, it does not guarantee that it will be widely used. As an initial
solution the technology transfer professionals should do these assessments internally
however this should not replace the actual networking, which is the problem to begin
with. The internal assessment will only prepare for perceived assessments in a non-
cooperative manner. Another point is that ethical issues can develop as a result of
lobbying which should be addressed using the public health assessment tools
recommendations, the technology transfer proposal and a third opinion from patient
groups and external ethical committees.
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POTENTIAL IMPLEMENTATION OF LAL MODEL
IN PRACTICE
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Specific	Aims	
After the development of the Learning-Adapting-Leveling model as the theoretical solution framework to
the bottleneck of effective and efficient real-time integration of genome-based technologies and laying
the foundation of theoretical concepts and argumentation of the model as the overarching framework
this section of the thesis aims to document potential scenarios where the model could be implemented
given its protocol has been defined.  The use of the model and its potential scenarios has already been
mentioned in various relevant national as well as European policy reports and other key documents. Also
this part aims to contribute to the development of European best practice guidelines for genome-based
knowledge and technologies including personalized healthcare applications as current guidelines do not
compute with emerging genome-based information and technologies for personalized medicine
applications. The aims of Part B relate to the following general objectives mentioned in the introduction
chapter:
· Giving examples where the new framework can be implemented
· Contribution to the development of the European best practice guidelines on genome-based
information and technologies
The specific aims of this section derived from the general objectives above are as follows:
· Chapter V
o Demonstrate the complexity of biology reasoning for the move in the post-genomics era
to systems biology and systems medicine for personalized health applications and
beyond
o Signifying the issue of taking into account environmental factors interacting with ‘omics’
factors as well as health systems when developing such applications
o Using  the  EU  flagship  pilot  project  ICT  Future  of  Medicine  (ITFoM)  as  example  of
European research project where the Learning-Adapting-Leveling model is being
implemented
· Chapter VI
o Applying it to Chlamydia trachomatis as the leading cause in tubal pathology and
infertility
o Demonstrating the implementation of the Learning-Adapting-Leveling model to potential
SMEs
· Chapter VII
o Contributing to the development of the European best practice guidelines for genome-
based information and technologies (PHGEN II)
o Integration of the Learning-Adapting-Leveling model into these guidelines
· Chapter VIII
o Conclusions based on the specific aims mentioned
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CHAPTER	V	FUNCTIONAL	DYNAMICS:	FROM	BIOLOGICAL	COMPLEXITY	TO	TRANSLATION	AND	IMPACT	IN	HEALTHCARE	SYSTEMS	
Published as:
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Abstract	
Biological complexity at a molecular and physiological level is dynamically translucent and requires a
system-wide computational approach to possibly elucidate underlying mechanisms for medical and
public health applications. Functional dynamics is ideal to study molecular functions given biological
functions are dependent on the dynamic nature of networks it operates within. However, environmental
factors significantly affect the molecular dynamics in biology, which still needs to be incorporated in
study of functions for medical applicability. Through technological innovation medicine is seeing a
potential shift in demand for personalized interventions, which has not been fully realized yet. Also the
applicability of functional dynamics’ utility seems not visible in healthcare systems. This article addresses
the above mentioned issues, challenges in translation/implementation using the example of the “virtual
patient” developed through the pilot EU flagship project ICT Future of Medicine, and provides possible
solutions and insights of new and existing scientific data, infrastructures and frameworks like the
Learning-Adapting-Leveling model to make it feasible including policy-wise by incorporating best practice
guidelines developed through the Public Health Genomics European Network and tries to touch upon its
consequential impact. As a result, we see that real time integration in healthcare requires early-on
involvement of all stakeholders as well as taking into account health policy issues, which is addressed by
the proposed Learning-Adapting-Leveling model and the best practice guidelines. Furthermore,
environmental factors and exposome properties need to be taken into consideration, which the pilot ICT
Future of Medicine has been taken into account. We now possibly see a shift from stratified medicine
through personalized medicine and possibly towards individualized medicine. This coupling of the pilot
project ICT Future of Medicine by integrating the Learning-Adapting-Leveling model to resolve real-time
integration issues and considering policy-wise the best practice guidelines has set the stage for it to
potentially revolutionize the healthcare system as a whole.
Keywords: Computational biology, Functional dynamics, Information and communication technologies,
Public health genomics, Personalized medicine, Systems biology, Genomics, Health technology
assessment, Health needs assessment, Health impact assessment, Technology transfer.
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Introduction	
The Complexity of Biology
Over the progression of scientific knowledge and discovery especially in the field of genome-based
information and technologies (encompassing all–omics, for example genomics, transcriptomics,
proteomics, metabolomics, etc. and their interaction with environmental factors), we come short of
understanding the complexity of the highly dynamic molecular human biology with all permutations and
combinations of interactions and physiology itself; rather we are only able to grasp the complexity of it.
What makes the molecule level biology far complex is that not only does function rely on the molecule
(genes, proteins, transcription factors, metabolites, etc.) itself, but also relies with the combination of
network of interactions (for example gene-gene, gene-protein, protein-protein, 1 protein-12 proteins,
etc.) it is attached. This can constitute feed-back/forward control [1,2], modularity [3], redundancy [4]
and multitasking [5]. The function of operation can also be dependent on the structure of the molecule
and/ or the structural  stability of the network [6] and localization. Certain molecules can act as genetic
switches among others. Inhibiting a molecule (say gene) may not inhibit the function itself, but being
linked to a stable network and/or complimentary genes can compensate. Also networks can be
unaffected to perturbations as complimentary yet unrelated networks can stand in. In addition to that
the combination of the functional molecule and the network itself is required for execution of the
function as separated, may not work. Furthermore, large well connected networks are least affected to
perturbations compared to not so well connected networks, however the prior can be fragile if the most
influential nodes are corrupted. This is all being in a highly dynamic, constantly adapting and changing
environment and at different levels (molecular, cellular and tissues). A very nice review to this end has
been written by Kitano already in 2002 [7]. What adds to the complexity of the network is that previously
unconnected diseases or genes seem related and have not yet been medically classified accordingly [8].
Systems Approach
From the above, what can be understood is that although single gene/protein research is still required to
gather information about function and processes, a more holistic approach is needed to elucidate the
functional complexity of a system, which is the human. This also implies for drug discovery and targeting
as well as therapy. Through –omics based research, we now know that functionality or execution of a
process is dependent upon multiple molecules and networks and no one molecule or network can work
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on its own, therefore can be viewed as a system. Drug targeting now requires consequences to the
network (or so called side-affects). The data generated by this information, especially in biological
systems impracticably large, consequentially make it dependent on computational power to store,
analyze and interpret it unlike what was previously thought to be localized to the wet lab. This has been
evident from the very basic of biological computing in BLAST [9] to data analysis [10,11], among others
[12-14]. This convergence of biology and computation power has been recently discussed [15], stating
the fact that the two fields have been alongside each other for quite some time and rely on each other
for inspiration.
Systems biology is defined as an integrative, interdisciplinary approach to biological science that is built
around the concept of close integration of computational methods, technology development (including -
omics) and global measurement and analysis of biological systems [16], and seem to be the future to this
holistic or system-wide approach. Functional dynamics within systems biology as a field on its own
greatly corresponds to the study of biological systems as the latter being dynamic is a key in its function.
The challenge for functional dynamics and systems biology as a whole is to integrate not just biological
complexity previously mentioned above, but also take into consideration external environmental
interactions with the biological system at different levels which can significantly impact (through
mutations, single nucleotide polymorphisms, change in network behavior, etc.) the biological system.
From epigenomics/ epigenetics, we now know that genome-based information and its’ permutations are
not the only factor detrimental in health outcomes but environmental (including chemical, surroundings,
lifestyle, social and economic) factors influence the interactome (complete repertories of interactions
potentially encoded by the genome) [17], of human molecular physiology through the superimposition
of the exposome (combined exposures from all sources that reach the internal chemical environment)
[18]. With the exposome being in constant contact with the molecular complex system, one cannot
appreciate and predict the functionality of the dynamics involved without taking into account the
exposome.
Personalized and Individualized
With the completion of the human genome project and the post-genomics era, which started off with
transcriptomics, proteomics and metabolomics among others pointed to the direction of a more
individualized or personalized healthcare effort. As the user or patient became aware of knowledge
through the influx of information present on the internet and (social) media and related online tools and
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digital libraries, the user demands personalized or preferentially individualized approaches towards
his/her medical interventions and wants to be more involved in the decision making process [19].
Scientific data through research made it possible to predict at a systems level through simulations and
models as well as through identification of early on biomarkers for diseases. Similarly prevention through
early diagnosis (including family history, risk groups, genetic susceptibility, etc.) and understanding
disease progression in an individual with reference samples as well as involving the person in the
decision making process brought forward the concept of P4 (predictive, preventive, personalized and
participatory) medicine [20]. However, this was not followed through contrary to the fact that there is
now a gradual shift towards personalized interventions in the whole arena of healthcare [21], given the
concept of ‘one shoe does not fit all’. This transition also evolves from genomics focused personalized
medicine to personalized medicine that takes all the relevant factors (including environmental) into
account [21], shifting the paradigm from genomics to a systems approach in medicine and healthcare.
Given the dynamic nature of molecular life sciences as a large system (human) as mentioned above, this
article aims to touch upon the challenge of encompassing environmental factors affecting biological
molecular systems in scientific data and address the issue in personalized medicine of the bottlenecks of
real-time integration of systems biology innovations in healthcare systems.
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The	Pilot	
Computational power in the form of ICT (information and communication technologies) was driven by
large scale physics and commercial applications where medicine played a small role [22]. This is now
changing as more ICT tools are being used and developed towards medicine. A revolution in ICT can
potentially open the door for functional dynamics studies including systems biology applicability in
healthcare like it did for other sectors.
The challenge remains largely for ICT to develop tools in the form of hardware and software to compute
these already existing large data sets and ongoing generation of data taking into account the dynamic
nature of the interactome [17], as well as all factors including socioeconomic, environmental and
molecular determinants of health to implement the P4 medicine [20]. The EU pilot flagship project
ITFoM (ICT Future of Medicine) is one of the six pilot projects in the ‘European Future and Emerging
Technologies flagships’ and does take this into consideration. ITFoM aims to develop the virtual
counterpart of an individual pulling the healthcare towards not just personalized medicine but
individualized medicine, given the fact as described before that ‘one shoe does not fit all’ [21]. The idea
is to first simulate and test drugs/medicines on the virtual patient (ICT-based replicas of molecular
organization of individual humans) and/or gets advice from this developed ITFoM system and then
executing the advice on the actual patient/individual. This can be accessed by both the individual and
doctor for solutions. ITFoM and related projects of the “virtual patient” will develop an entirely new ICT
that will enable real-time dynamic models of biochemical pathways, cells, tissues, diseases and
ultimately, the entire human [22]. The strategy will be based on a common denominator replica [22]. Not
only molecular data but all types of medical dataflow will be integrated in the system as well as
environmental and lifestyle factors and will be a self-learning, follow-up system with reference datasets.
Implementation
However, like genome-based technologies and system biology, studies of functions of molecules or
networks in dynamic environments although partly successful, do not see the implementations or direct
use of these generated computational data applications in healthcare systems. Even if ICT does give a
push in the right direction and we are able to develop the virtual patient there still seems to be a
roadblock. This is given the assumption that the logical roadblock itself viz., the complexity of data and
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functionality in a dynamic environment is well understood or statistically significant and the
environmental factors are acceptably taken into account. Furthermore, the ethical, legal, economic as
well as privacy issues are considered. Although ICT and related projects may be the forerunners of taking
into account to some extent ethical, legal, economic as well as privacy and governance issues there are
implications beyond the obvious, which are generally an oversight and a common mistake of the
academic-industrial complex [23].
ICT tools have been developed for medicine but its practical usage for most parts is far away. It can be
also said that ICT tools developed for medicine, were limited to just molecular interactions and not
taking into account general medical, environmental and lifestyle factors which greatly influence the
outcome. ITFoM addresses these issues among others, however, from patterns [24,25], in technological
integration in healthcare systems [26], it seems evident technological diffusion is a long process [24].
ITFoM and related projects will set the stage for an ICT revolution in medicine. Learning from history, ICT
innovations like health technologies, in general lack to capitalize on the issues of healthcare integration
or translation, in a timely as well as effective and efficient manner [24,27,28].
Public health and healthcare systems are a different system compared to tools (including technologies)
developed for  them.  Coming  back  to  the  oversight  or  common mistake  and  the  reason  for  the  above
mentioned pattern of delayed implementation, is that when developing technologies or knowledge
discovery for transferring to healthcare systems, one generally neglects the health policy aspects of the
healthcare system [29]. The commonly used activity for such translation [30,31], is technology transfer
(TT), which is seen as the activity of the migration of academic discoveries to useful application in the
development of marketable products or processes [32]. When valorizing new technologies focus is
generally to the market itself and stays there. The push for healthcare implementation stagnates as a
result  and  can  be  very  long  say  20  years  [24].  Scientific  merit  or  just  evidence  is  not  sufficient  for  real
time uptake by healthcare. For example, the technology’s clinical utility, which is a measure of the health
care  value  provided  by  the  technology  [33],  is  of  relevance,  as  well  as  the  market  authorization,
reimbursement and insurance. Unheard terms like Health Needs Assessment (HNA), Health Technology
Assessment (HTA) and Health Impact Assessment (HIA), collectively known as the Public Health
Assessment Tools (PHAT) [29,34,35], play an important role in healthcare implementation and are used
by health professionals, doctors, decision makers or policy makers and are detrimental to insurance and
reimbursement policies regarding a technology.
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HNA is a systematic method of reviewing the health issues facing a population, leading to agreed
priorities and resource allocation that will improve health and reduce inequalities [34]. HTA is a
multidisciplinary process that summarizes information about the medical, social, economic and ethical
issues related to the use of a health technology in a systematic, transparent, unbiased, robust manner.
Its aim is to inform the formulation of safe, effective, health policies that are patient focused and seek to
achieve best value [36]. This corresponds to interventions and involvement in appraisals making HTA an
influential tool to inform decision-making [29]. HIA is a combination of procedures, methods and tools by
which a policy, program, or project may be judged as to its potential effects on the health of a
population, and the distribution of those effects within the population [37]. In summary, HNA identifies
health priorities for a given population, HTA evaluates the performance of health care technologies and
HIA assesses the effects of policies, programs or projects on the population’s health [34]. The above
mentioned terms are generally neglected during technology transfer resulting in healthcare
implementation delay [29].
Recently to resolve the bottleneck or roadblock a new framework called the LAL (Learning-Adapting-
Leveling) model has been developed addressing healthcare implementation through and to the end of
the technology transfer activity [29]. The LAL model’s core (Figure 1) lies at the pseudo-parallel initiation
of TT and PHAT through bilateral communication, feedback, public-private partnerships, and
consultation between the two enterprises to adapt, stop or further the developing relevant technology
based on its value to healthcare. Thus saving time and resources and accomplishes in real time by
minimizing the delay of non or mis-communication between the different fields i.e. technology transfer
and PHAT. Also, early on involvement of all stakeholders including the academic-industrial complex [23],
health professionals, doctors, insurance companies, policy makers, patient groups, investors, etc. is
within the framework of the model. In addition the 10 essential tasks of the Public Health wheel [38],
which will ensure genome-based information and technologies, can be integrated into public health are
covered. The LAL model brings two different fields of work for the first time together, i.e. technology
transfer (TT) and the public health assessment tools (PHAT) and early on involvement of all stakeholders,
public health integration and the value of information generated [29]. Ethical legal, social, economic
aspects and clinical as well as personal utility [39-41], among others are covered in the model [29]. The
model operates as a feedback mechanism to adapt and integrate new information and compensate
through its collaborative communication network. It works as an overarching framework among
frameworks within and between different enterprises.
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Figure 1: The Learning-Adapting-Leveling (LAL) model – The LAL model is a framework, which addresses the issue
of real-time integration in healthcare systems. The added value of the model is that for the first time it brings
together technology transfer and the public health assessment tools in parallel working together by crosstalk (via
public-private partnerships or PPPs), giving rise to the innovation network, and in the process adapting the
technology to public health and society needs. By the time the technology roles out of the TT pipeline, it is well
suited to the conformity of PHAT, and to be taken up by decision makers (DM). This model takes into consideration,
the 10 essential tasks of the public health wheel in the form of its 3 domains, namely policy development,
assessment and assurance. The model also takes into account the Value of Information from the perspective of the
developing technology’s relevance to the end consumer, its processing ability or understandability to the user, and
exclusivity like intellectual property rights, which may restrict its wide usage. This (innovation) network through
PPPs has an optimal working function called the absorption capacity [29].
ITFoM also takes into consideration healthcare integration issues by following the LAL model in its
implementation  plan.  Although  the  LAL  model  sets  the  stage  for  real-time  uptake  of  relevant
technologies and information data for healthcare implementation and the primordial soup for new
policies in that direction, the development of policies favoring relevant uptake is an important aspect.
Based on these polices which in part are contributed through recommendations of HTA reports, actual
implementation and acceptance of health technologies or health information in healthcare settings are
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executed and for the technologies, reimbursement and market authorization is released. Policy tools in
the form of guidelines have been developed by the Public Health Genomics European Network [42],
(www.phgen.eu ) complimenting ITFoM and the LAL model.
The Public Health Genomics European Network (PHGEN II) is a European Commission DG SANCO
(Directorate General for Health and Consumer Affairs) supported project and constitutes partners from
all European Member States and observers. The aim of PHGEN II is to develop European best practice
guidelines for quality assurance, provision and use of genome-based information and technologies by
different stakeholders at an EU level [42]. The scope of PHGEN II is to assist EU Member States among
others to develop relevant policies for –omics integration in healthcare. These guidelines [42] are a meta
level guidance tool to further develop guidelines and are based around the 10 essential task of the Public
Health Wheel [38], as can be seen from figure 2, which strives to integrate genome-based information
and technologies into public health. This brings in the field of Public Health Genomics, which is the
responsible and effective translation of genome-based knowledge and technologies into public policy
and health services for the benefit of population health [43]. With final dissemination of these guidelines
to all Member States and advocacy for policy implementation as well as set up of PHGEN National Task
Forces will help towards healthcare implementation of ITFoM and the LAL model.
Figure 2: The 10 essential Public Health tasks
– The 10 mentioned tasks are given in the
pie chart divided over the 3 public health
domains of assessment, policy development
and assurance, with research being the core
in all tasks. The European best practice
guidelines developed by PHGEN were based
around these 10 essential tasks [38].
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Discussion	and	Conclusions	
Although functional dynamics as just a field of study can exist as a research theme within systems
biology, however for it to be useful to medicine, personalized medicine, personalized healthcare and
healthcare as a whole, knowledge generated and subsequent relevant technologies developed need to
be readily absorbed by healthcare systems in real-time. In order for that to happen the field while
embarking on such an endeavor should not neglect health policy aspects and all stakeholders involved
from an early on stage. The platform is set through ITFoM, the LAL model and PHGEN II for scientific,
implementation and policy-wise respectively for healthcare uptake. However, these levels or steps can
be achieved only once stability has been achieved with regard to the challenges functional dynamics face
with biological complexity as previously stated. Moreover, environmental interactions add on to this
seemingly chaotic, but actually synergistic complexity. ITFoM and related projects aim to address these
two supposedly loose ends.
Another aspect of this implementation is the fact that there is a shift from the ‘one shoe fits all’ concept
of medical classification and from stratified medicine to personalized and possibly individualized
medicine given the uniqueness and similarities of individuals; and need to be taken into consideration
when  advocating  for  new  policies.  The  LAL  model  and  PHGEN  II  supports  this  shift  in  priorities  and  is
already pre-existent within the core concept of ITFoM and related projects of the “virtual patient”.
Systems biology coupled through the power of ICT seems to be the future of medical research and
beyond given its systemic complexity and likely will benefit research and application of functional
dynamics through magnifying its computational power and inclusion of environmental factors as a
standard. Studying functions of molecules and networks without the exposome is indeed incomplete.
This research will eventually push for personalized/individualized medical as well as health interventions
in the future.
Future Prospects
Functional dynamics has a bright future given the incremental potential of ITFoM through systems
biology. This is just not from a scientific point of view but given the framework of the LAL model and the
policy in place through PHGEN II, active uptake by healthcare is a possibility. What remains to be seen is
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how the ITFoM pilot project develops its models further and integrates data both scientific and
environmental to its new ICT as well as developed infrastructure in hardware and software. The impact
of the translation of this research and development into healthcare systems is hard to accurately predict
given the semi-theoretical nature of what is currently implied, but what can be said is once accomplished
it will greatly impact and revolutionize healthcare as a whole. It will change for sure the doctor-patient
relationship. ITFoM tools can be used by both patients and doctors among others to be decided,
however this will change the role each stakeholder plays and will bring it a new set of ethical, legal and
socio-economic implications and organizational changes currently immeasurable.
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Abstract	
Chlamydia trachomatis (CT) infections in women can result in tubal pathology (TP). Worldwide 10–15%
of all couples are subfertile, meaning they did not get pregnant after 1 year. Part of the routine
subfertility diagnostics is the Chlamydia Antibody Test (CAT) to decide for laparoscopy or not in order to
diagnose TP. The CAT positive and negative predictive value is such that many unneeded laparoscopies
are  done  and  many  TP  cases  are  missed.  Addition  of  host  genetic  markers  related  to  infection
susceptibility and severity could potentially improve the clinical management of couples who suffer from
subfertility. In the present study, the potential translational and clinical value of adding diagnostic host
genetic marker profiles on the basis of infection and inflammation to the current clinical management of
subfertility  was  investigated.  This  review  provides  an  overview  of  the  current  state  of  the  art  of  host
genetic markers in relation to CT infection, proposes a new clinical diagnostic approach, and investigates
how the Learning-Adapting-Leveling model {LAL, a public health genomic (PHG) model} can be of value
and provide insight to see whether these host genetic markers can be translated into public health. This
review shows that the preliminary basis of adding host genetic marker profiles to the current diagnostic
procedures of subfertility is present but has to be further developed before implementation into health
care can be achieved. CT infection is an example in the field of PHG with potential diagnostic to be taken
up in the future in the field of subfertility diagnosis with a time line for integration to be dependent on
enhanced participation of many stakeholders in the field of PHG which could be advanced through the
LAL model.
Keywords: Chlamydia trachomatis, Genomics, Host genetic markers, Learning-Adapting-Leveling model,
Molecular diagnostics, Public health genomics, Stakeholders, Subfertility, Translation.
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Introduction	
Chlamydia trachomatis Infection
Chlamydia trachomatis is the most common bacterial sexually transmitted infection throughout the
world.  An  estimated  89  million  cases  per  year  worldwide  are  reported.  The  infection  is  often
asymptomatic resulting in patients not seeking treatment. Untreated urogenital C. trachomatis may give
rise to late complications, including pelvic inflammatory disease, ectopic pregnancy and tubal pathology
[1–4]. The clinical course of chlamydial infections is heterogeneous i.e. transmission, symptoms,
clearance, and development of late complications differ per patient [5–7].
Sexually acquired C. trachomatis is an important public health concern for its effects on reproduction.
Women who develop late complications, such as pelvic inflammatory disease or tubal pathology, suffer
considerable morbidity and emotional distress, and are a socio-economic burden [8].
To prevent such outcomes, early diagnosis is important. Currently, screening for tubal pathology is
performed via laparoscopy, a procedure, which is invasive and expensive, labor intensive and has a risk
for surgical complications. This has resulted in extensive efforts to improve noninvasive diagnostic tests
to decrease the risks of current screening methods.
Much research on bacterial components, clinical and environmental factors [9, 10] has been done, but
no definitive correlates of late complications have been identified [11]. For a variety of infectious
diseases (e.g. malaria, hepatitis and meningococcal infections), it has been shown that host genetics play
a crucial role in susceptibility to and severity of disease [12–14]. To estimate the role of genetics in
course of infection, twin studies are a powerful tool, and Bailey et al. [15] have shown that host genetic
factors contribute almost 40% to the variation in clinical course of Chlamydia infection. These results
establish the potential importance of genetic studies. Den Hartog et al. [16] showed, in a cohort of
subfertile women, that single nucleotide polymorphisms (SNPs) in several pattern recognition receptors
(PRRs) increase the risk of developing tubal pathology following a C. trachomatis infection.
The innate immune response is the first line of defense against a C. trachomatis infection. PRRs recognize
components of the bacterium, and SNPs in these genes may affect the functionality of these PRRs and
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may, therefore, increase the risk for development of late complications. In addition, SNPs in genes
coding for cytokines involved in immune responses may also be influential. Recently, our group [17]
reviewed the role of SNPs in PRRs and cytokines in relation to susceptibility to a C. trachomatis infection.
It is important that these scientific findings are utilized in the clinic and incorporated in public health
policy. The Learning-Adapting-Leveling (LAL) model [18] is a model of translating scientific data from the
lab through the market and implementing it into public health policy; it will be discussed later in this
review as a possible way to assimilate new findings in clinical settings.
Outline of the Article
The  overarching  aim  of  the  current  review  is  to  determine  if  C.  trachomatis  is  one  of  the  proof  of
principles in the field of public health genomics (PHG) with the potential to be taken up in the future in
the field of subfertility diagnosis. Therefore, we provide an overview of the current state of the art on
host genetic markers in relation to infection, propose a new clinical diagnostic approach in subfertility
diagnostics based on this overview and describe how the LAL model (an integrated PHG model) can be of
value to see if these host genetic markers can be translated from the lab to the market and implemented
into public health.
Overview of CT Host Genetic Determinants of Infection
Several studies have shown the importance of host genetic variation on the clinical course of Chlamydia
infections. This section will highlight recent findings, similar to a recent review [17], divided into
detection of the pathogen Chlamydia by PRRs and the subsequent intercellular signaling by cytokines,
with a focus on the innate immune system. Combined carriage of SNPs in so-called traits may exhibit a
stronger influence on the course of Chlamydia infections, e.g. a reduced pathogen recognition capacity in
multiple PRRs may result in higher susceptibility compared to the susceptibility when only one PRR has a
reduced recognition capacity. Results for trait analyses are highlighted at the end of this section.
Pattern Recognition Receptors
Toll-Like Receptors (TLR)
TLRs are a much investigated group of receptors. Studies have shown that TLRs are essential in the host
immune system by recognizing pathogenic components (pathogen associated molecular patterns
(PAMPs) and danger associated molecular patterns (DAMPs) and inducing an immune response. These
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receptors are present on antigen presenting cells (APC) and epithelial cells; they reside both on the cell
membrane and within cells. The TLR family has been studied in relation to various infectious and
autoimmune diseases with varying associations [17, 19, 20]. TLRs 2, 4 and 9 are well-researched TLR
family members. TLR2 and TLR4, both trans-membrane pathogen receptors, recognize chlamydial
peptidoglycan (PGN) and lipopolysaccharide (LPS), respectively. TLR9 is an intracellular receptor,
recognizing CpG islands in bacteria.
Karimi et al. [19] investigated the role of 2 SNPs in TLR2 in C. trachomatis infected women and control
groups: TLR2 –16934T>A (rs4696480) and TLR2 +2477G>A (rs5743708). They did not find any association
in TLR2 genotype distribution for both susceptibility to and severity of the infection. However, in
haplotype analysis, they showed that haplotype TG was protective for developing tubal pathology. Laisk
et al. [21] also evaluated the role of TLR2 +2477G>A (rs5743708) in developing tubal pathology and
found no association, confirming the results of the single SNP analyses of Karimi et al. [19].
Den Hartog et al. [22] studied TLR4 +896A>G (rs4986790). The genotype distribution of this SNP in
subfertile women with or without C. trachomatis infection did not differ. However, women with this SNP
and who were positive for C. trachomatis IgG and cHSP60 IgG had tubal pathology. Results of this study
are highly specific, but have low sensitivity, since not all women with tubal pathology had this
combination of C. trachomatis and cHSP60 serology, and TLR4 +896 mutation carriage. Laisk et al. [21]
also investigated the role of this SNP in developing tubal pathology; they did not find any association.
Taylor et al. [23] studied a different TLR4 polymorphism, rs1927911, and found that the mutant
genotype increases the susceptibility to C. trachomatis infections. Similarly, they found that the TLR1
rs5743618 TT genotype increased susceptibility to Chlamydia infections [23].
Ouburg et al. [24] studied TLR9 SNPs in a murine model, in a cohort of Dutch Caucasian women visiting a
STD outpatient clinic and a cohort of subfertile Dutch Caucasian women. The overall genotype
distribution did not differ between groups. However, haplotype analyses showed, though not statistically
significant, that distribution of TLR9 haplotype –1486 T (rs187084), –1237 C (rs5743836), +1174 G
(rs352139), and +2848 A (rs352140) was more frequently found in women who developed tubal
pathology.
| CHAPTER VI
186
C-C Chemokine Receptor Type 5 (CCR5)
CCR5 is a chemokine receptor present on several immune cells, including monocytes, dendritic cells,
microglial cells, T helper 1 cells, and macrophages. A 32-bp deletion within the CCR5 gene, CCR5 Δ32,
results in premature termination of the protein, altering its function [25]. Barr et al. [26] demonstrated
that this mutation has a protective effect against developing tubal pathology when both alleles are
mutated. However, these results were not confirmed in a recent study [21] . For this inconsistency, the
authors suggest that the ligand of CCR5, RANTES (CCL5), binds the CCR1 chemokine receptor as well,
therefore inducing a normal response. Since they also used a different study population, they addressed
the importance of group selection, and as a result this may be a reason for finding different outcomes
[21].
Mannose-Binding Lectin (MBL)
MBL is important in the innate immune response. It binds to various carbohydrate structures of a.o.
bacteria and either directly kills the pathogen or promotes phagocytosis [27]. Studies have shown that
MBL inhibits a C. trachomatis infection [28]. Laisk et al. [21] investigated the role of 6 polymorphisms in
the MBL2 gene, coding for MBL. They found that a hyperproduction haplotype of MBL2, HYA/HYA, was a
risk factor for tubal pathology independent of a C. trachomatis infection. They also found this
association, only smaller, in C. trachomatis infected patients with tubal pathology. They suggest that
hyperproduction of MBL may affect epithelial cells within the genitourinary tract, inducing tubal
pathology [21]. The low-producing MBL2 genotypes are associated with tubal pathology and adverse
outcome of in vitro fertilization (IVF) treatment [29].
Human Leukocyte Antigen (HLA)
HLA codes for the major histocompatibility complex and thus, has an important function in the immune
system. The HLA system has been linked to a variety of infectious diseases and disease outcomes. In the
literature, a link between HLA -DQA1 * 0102 and HLA -DQB1 * 0602 alleles, and Chlamydia induced tubal
pathology has been described [30].
Another studied receptor is the major histocompatibility complex class I chain-related A (MICA), present
on a.o. natural killer cells. When its ligand binds, activating signals for natural killer cells increase. Allele
MICA * 008 had a high negative correlation with C. trachomatis IgG antibodies. In this study, IgG
antibodies were associated with tubal pathology. This group hypothesized that MICA alleles might play
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an important role in the development of tubal pathology. However, in the infertile women of their study,
they could not establish an association between MICA alleles and tubal pathology with or without C.
trachomatis IgG antibodies [31].
Cytokines
A variety of cytokines have been associated with disease and disease outcomes. These cytokines have
important immunoregulatory functions, and alterations in function may, therefore, influence immune
responses. Several cytokines have been studied in women who developed tubal pathology. Some
associations were found: IL10 -1082 A allele together with HLA -DQA1 * 0102 and HLA -DQB1 * 0602
alleles; these were associated with severe tubal pathology [30, 32]. Both the TNF-α -308 A allele and the
IL6 CC genotypes were found to be associated with tubal pathology: the former as a risk factor and the
latter as a protective factor for tubal pathology [32].
A statistically significant association between the IFNg +874 polymorphism and chlamydial tubal
pathology  was  not  found  [32]  ,  nor  for  IL1B  +3954,  IL1B  –511,  and  IL1RN  gene  polymorphisms  [33]  .
However, a study performed in an ex vivo model showed that IL1, in the absence of its antagonist IL1RA,
causes destruction of the ciliated cells in the Fallopian tubes [34]. In addition, SNPs in NLRP3 , associated
with hypoproduction of IL1β, is involved in tubal pathology [35] . Due to these findings, one may
hypothesize that SNPs influencing IL1 functionality may affect the development of tubal pathology and
the rate of severity.
The mutant allele of the IL12B rs3212227 SNP is associated with increased susceptibility to tubal factor
infertility and with a more severe progression of disease [36]. The same group also demonstrated that
IL10 and IFNG genotypes affect the lympho-proliferative responses in Chlamydia infections [37].
Trait Analyses
Den Hartog et al. [16] investigated the role of 5 SNPs in 4 genes assumed to play a role in C. trachomatis
infection. The investigated genes were TLR4, TLR9, CD14, and CARD15/NOD2. The risk for development
of tubal pathology doubled if a patient had 2 or more SNPs within the studied genes, compared to 1 SNP.
In addition, when investigating only 1 SNP in TLR4 or CD14 [38], no association with tubal pathology was
found. Due to a small sample size, no statistical significance was observed in the trait analyses; a
statistical trend, however, was observed.
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Ohman et al. [37] found that the combined carriage of specific IL10 and IFNG genotypes has an additive
effect on the risk for Chlamydia infection. Atik et al. [39] demonstrated that combinations of SNPs affect
the adverse that trachomatous trachiasis risk decreased 5 times with the combination of TNFA (–308A),
LTA (252A), VCAM1 (–1594C), and SCYA 11 (23T) minor allele, and the combination of TNFA (–308A), IL9
(113M), IL1B (5 ʹ UTR-T),  and VCAM1 (–1594C).  However,  trachiasis risk increased 13.5 times with the
combination of TNFA (–308G), VDR (intron G), IL4R (50V), and ICAM1 (56M) minor allele. Although these
results are from ocular infections, one might hypothesize that similar effects might be observed in
urogenital infections.
Although compelling, these results have to be confirmed in other studies, and additional SNPs have to be
added in order to define the SNP profiles that are associated with and would help predict a patient’s
predisposition to Chlamydia infections and tubal pathology. This requires large cohorts which can be
obtained via large consortia, in which different disciplines contribute to the overall goal.
Consortium Approaches: EU Framework Program EpiGenChlamydia
To perform large scale typing for the identification of genetic biomarkers, large and clinically well-
defined cohorts are needed. Toward this end, a small consortium was founded in 2005 with Dutch,
Belgian and American partners with expertise on clinical, epidemiological, bacterial, animal,
immunological, and host immunogenetic studies to have an integrated approach to study C. trachomatis
infections, especially the clear inter-individual differences in the clinical course of infection. This
consortium was  named the  ICTI  consortium [40,  41].  Members  of  the  ICTI  consortium applied  for  and
obtained funding from the European Union as a large international consortium consisting of 20 partners,
the EpiGenChlamydia (EGC) consortium [42].
This Chlamydia consortium was funded by the EU Framework Program 6 under the Coordination Actions
in functional genomics research for a period of 2.5 years and provided its closure report in 2010. The aim
of this consortium was to structure transnational research to such a degree that comparative genomics
and genetic epidemiology on large numbers of unrelated individuals could be performed with future
funding. This funding made it possible for 20 groups from Europe, Africa and the USA to participate (see
http://www.EpigenChlamydia.eu  for  details).  The  overall  goal  of  the  EGC  consortium  was  to
accommodate the optimal environment to build and prepare a consortium to reliably determine the
genetic predisposition to infection in both ocular and sexually transmitted C. trachomatis. This will allow
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the development of diagnostic tools that can determine an individual’s predisposition to infection and
the risk to develop late complications. Further, it was hoped that the knowledge generated through this
effort would contribute to the understanding of the Chlamydia – host interaction, in order to allow the
development of novel tools for the detection and treatment of and vaccine development for C.
trachomatis infections.
The EGC consortium has provided the final reports to the EU including state-of-the-art reports on the
epidemiology of both ocular and sexually transmitted C. trachomatis infections [4], bacterial typing [43,
44] , immunogenetics [17] , SNP genotyping strategies, and sample validation. Two deliverables were of
major importance for the future success in translation of immunogenetic markers and for obtaining new
funding for a biobank, consisting of physical and virtual sample collections, and a data warehouse in
which genotyping data together with clinical and demographical data is merged and accessible.
The partners working on ocular Chlamydia diseases coordinated by the London School of Hygiene and
tropical medicine (David Mabey and Robin Bailey together with their Gambian partners) have already
defined and secured 1,500 case-control pairs (total n = 3,000). The scientific coordinator of the EGC
consortium (S. Morré) together with Dutch collaborators have collected more than 7,000 specimens
which are at present in use, while 10,000 specimens are available for further studies.
Currently, part of the consortium has obtained new funding from the EU based on Small-to-Medium-
Enterprise collaborations with universities. This EuroTransBio grant has as main goal to develop a
diagnostic test on the basis of human genetics and C. trachomatis serology to better assess the presence
of C. trachomatis -associated tubal damage in subfertile women. This consortium, ending in the
beginning of 2015, is in progress of performing large scale analyses of human genetic variation to identify
novel genetic markers that are able to stratify patients with tubal pathology. The identified SNPs in the
PRR genes have already shown to be highly predictive for the development of tubal pathology. However,
single SNPs do not provide a high enough predictive value for a diagnostic test. By combining multiple
identified and novel SNPs in the PPR genes and genes in linked pathways, and exploiting them as
susceptibility markers, a highly predictive test for tubal pathology-based subfertility can potentially be
developed. This will be discussed further in the next section.
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Improvement	of	Subfertility	Diagnostics	Based	on	Host	Genetics	
Subfertility poses an enormous burden on healthcare and society throughout the world. Worldwide, 15%
of  couples  trying  to  conceive  suffer  from  subfertility  [45,  46].  In  women,  one  of  the  major  causes  of
female subfertility is tubal pathology [45]. In tubal pathology, C. trachomatis is the single most common
cause for infertility [45].
From all subfertility problems in women, tubal damage is a common cause of infertility. It includes tubal
obstruction and pelvic adhesions resulting from infection, endometriosis and previous surgery. The
current diagnostic procedure for diagnosing this condition can be performed by
sonohysterography/hysterosalpingo contrast sonography, hysterosalpingography (HSG), fertiloscopy,
falloposcopy, or laparoscopy and dye hydrotubation, often using detection of IgG antibodies against C.
trachomatis as first screenings tool.
Despite their effectiveness, the above-mentioned methods are costly and invasive [47] and not suitable
for screening. There are several test methods available to assess the risk of C. trachomatis -associated
tubal pathology in subfertile women. The reference standard for diagnosing tubal pathology in subfertile
women is laparoscopy. However, laparoscopy has several disadvantages. First, it is an invasive, expensive
procedure (on average 3,000 Euros, including additional costs) and requires general anesthesia.
Furthermore, it holds a 1.5% risk of surgical complications (e.g. bleeding, infection).
Since it is widely recognized that a C. trachomatis infection is the single most common cause of tubal
peritoneal damage (WHO task force on the prevention and management of infertility [48]), detecting
evidence of infection using serology is noninvasive, simple and quick to perform [47]. As such, Chlamydia
serology is often used as a first screening test for tubal damage in infertile women but has a limited
sensitivity of 50–60%.
Currently, women with subfertility are screened for a C. trachomatis using serology (see figure 1).
Serologic  testing  (CAT:  Chlamydia  antibody  testing)  for  C.  trachomatis  is  based  on  micro
immunofluorescence assays. Elevated titres of IgG are highly predictive for infection with C. trachomatis.
These serologic assays focus mainly on the major outer membrane protein A, which is an antigen present
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in the outer membrane of a chlamydial particle. When the serology outcome is negative, no further
action is taken, and the couple is asked to try for one more year to get pregnant. Some women undergo
HSG. If the outcome is negative (in most of the cases), they try as well to conceive for one more year. If
positive (in around 5–7% of the cases) a laparoscopy will be performed, and up to 5% will have tubal
pathology and will proceed to IVF procedures. Since HSG does not identify many new cases (5% of HSG
positive cases), its positive predictive value is almost identical to serology. The low specificity of the test
also causes misdiagnosis because women that are negative in the serology test may in fact have tubal
pathology in up to 20% of cases (percentages based on the cohort described in ref [16], personal
communication).
Figure 1: The relation between
serology testing (Chlamydia
antibody testing) and laparoscopy
and the percentages of
misdiagnosis. CT = C. trachomatis;
IVF = in vitro fertilization.
If the serology outcome is
positive, laparoscopy will be
used for further diagnosis.
When tubal damage is detected
using laparoscopy, it is likely
that  an  IVF  procedure  will  be
initiated to get pregnant. One of
the drawbacks of serology is
that it comes with limited
sensitivity: 55–60% of the
Chlamydia serology positive
women actually have tubal
pathology. Subsequently, this
means that 40–45% of the
women are serology positive
and undergo laparoscopy while
there is no tubal disease. In
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conclusion, in the serology negative and positive groups, a significant percentage of the women get
either unneeded laparoscopies or get misdiagnosed.
Given the prevalence of subfertility, each year an estimated number of 300,000 women visit the general
practice with C. trachomatis -associated infertility in Europe. Using the current diagnostic procedures,
there is still a substantial subset of women that are misdiagnosed. This poses an enormous psychological
burden on these women. Additionally, there are tremendous economic costs associated with the
disease.
Despite the rapid development in the field of human reproductive medicine, there is still a medical need
for diagnostic tools that are able to stratify clinically relevant C. trachomatis infections. The diagnostic
test envisioned should be able to predict C. trachomatis -based tubal pathology and subsequent
infertility by complementing serology in such a way that not only the sensitivity, but also the positive and
negative predictive values increase significantly.
Epidemiological studies have demonstrated a 40% inheritable component for Chlamydia infections in
humans [15]. This suggests the need for studies to identify which genes are responsible for this 40%
component of risk. The innate immune system plays a pivotal role in the first recognition of Chlamydia
and the subsequent immune response.
Since a panel of human PRRs are involved in the recognition of Chlamydia, we hypothesized and have
shown that carrier traits (i.e. carrying multiple SNPs in multiple genes) result in a higher aberrant
immune response as compared to single gene association studies. Subsequently, these traits
synergistically increase risk for tubal pathology following C. trachomatis infection. Of 227 subfertile
Dutch women, we performed genotyping of PRR genes TLR9, TLR4, CD14 , and CARD15/NOD2 looking
for common versus rare alleles [16] . Subfertility was defined based on laparoscopic grade of tubal
pathology including extensive peri-adnexal adhesions and/or distal occlusion of at least one tube. Being a
carrier  of  several  rare  alleles  was  more  frequent  in  women  with  tubal  pathology  (who  had  elevated
serum IgG titers against C. trachomatis). We showed that after C. trachomatis infection (these infections
defined as CT IgG titers >32), subfertile women carrying >2 SNPs in PRR genes were at increased risk for
tubal pathology compared to women carrying <2 SNPs (73 vs. 33% risk). This association was not found
among women without IgG antibodies to C. trachomatis. Thus, adequate recognition of C. trachomatis
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by receptors in the genital tract is an important step in the immune response and may play a role in
protecting the host against developing late sequelae following infection.
The single SNP frequencies of TLR2 SNPs did not alter the risk for tubal pathology in subfertile women,
but, combined into specific haplotypes, carriage of haplotype I significantly reduced the risk of
developing tubal pathology after a C. trachomatis infection (p = 0.015, OR = 0.28). This haplotype also
showed a significant trend in an inverse association with disease severity (asymptomatic > symptomatic
> tubal pathology; ptrend = 0.021) [19]. In addition, PRRs, cytokines and chemokines play an essential
role in the immunopathogenesis of C. trachomatis infections. The chemokine receptor, CCR5, is crucial
for T cell activation and function, since its deficiency causes suppression of T cell responses. We showed
that among patients with anti-chlamydial IgG responses, tubal pathology correlated with a low incidence
of the CCR5Δ32 deletion (7%), while women without tubal pathology had a higher incidence of the
CCR5Δ32 deletion (31%), as compared to controls (19%) [26] . Thus, inflammation associated with CCR5
may predispose to development of complications of C. trachomatis infection. Recent findings show a
similar pattern for CXCR5 [49].
Therefore, single SNPs, haplotypes, and eventually larger genetic traits based on genetic variation in
multiple genes can potentially be used as susceptibility or severity markers for tubal pathology as a result
of a C. trachomatis infection. By combining multiple SNPs in one diagnostic test, high predictive values
can be achieved which should be suitable as a future companion diagnostic in the diagnosis and
treatment strategy for subfertility.
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Public	Health	Genomics	Approached	and	Translation	into	Public	Health	
Findings in the field of immunogenetics of C. trachomatis infections are of high relevance for public
health and healthcare in general. Such results contribute to the understanding of infection with this
agent, which is worldwide the leading cause of preventable blindness and the most prevalent sexually
transmitted disease that is strongly associated with ectopic pregnancy, tubal infertility and pelvic
inflammation. Furthermore, our findings provide new insights into the pathways that help explain
individual heterogeneity in the clinical course of C. trachomatis infection and the possible development
of more targeted and personalized approaches in the prevention, diagnosis and treatment of disease.
To improve the health outcomes associated with C. trachomatis infections, there is an urgent need to
timely translate immunogenetic findings into the healthcare system. The specialty having this task is
called PHG, which is defined as ‘the responsible and effective translation of genome-based knowledge
and technologies into public policy and health services for the benefit of population health’ [50] . In the
context of C. trachomatis infections, such a public health initiative has not been advanced, despite
sufficient data and the significant need to do so. However, significant public health strategies need to be
implemented very early after the discovery phase, and proofs of concept need to be obtained to
promote a faster translational process not only from bench to bedside, but also from bedside to
healthcare. Possible bottlenecks for implementation need to be identified.
Developing diagnostic tools based on host genetic predisposition can help determine an individual’s risk
(as well as late complications) of infection. However, moving forward with such a plan has hurdles along
the path. We have seen that C. trachomatis infections, symptoms and complications can differ between
individuals on the basis of host genetic factors, ethnicity and environmental factors. And based on this
review and on the literature, it seems likely that diagnostic assessment will allow for inclusion of a large
number of case-specific variables (i.e. more stratified) that may even become ‘truly’ personalized in the
near future with the incorporation information derived from dynamic fields of investigation such as
systems biomedicine and epigenomics [51] . The major obstacle to implementation is not the CE
(Conformtie Europeene) IVD or FDA approval of diagnostic application, but originates with the
healthcare integration [52] and policy embedment processes. In general, a timely translation with direct
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implementation by the healthcare systems is low [53], which is illustrated by the large amount of data
present in the literature [54] , patents [55, 56] and marketed products [57, 58] compared to technologies
being used in hospitals [53, 59] . In order to minimize failure, it is important that researchers take into
account the policy aspect and the acceptance of diagnostic applications in the healthcare systems [52]
itself, instead of just considering the market.
In order to move into the healthcare systems, it is important to think from the decision-making and
policy implementation perspective. Health policy is generally developed through evidence-based
interventions and around general public health instruments, such as Health Technology Assessment
(HTA)  among  others  [60,  61].  We  use  the  term  Public  Health  Assessment  Tools  (PHAT)  [52]  when  we
refer collectively to Health Needs Assessment, HTA and Health Impact Assessment. Health Needs
Assessment is a systematic method of reviewing the health issues facing a population, leading to agreed
upon priorities and resource allocation that will improve health and reduce inequalities [61]. HTA is a
multi-disciplinary field of assessment that evaluates the medical, economic, social, legal, ethical, and
other implications of the incremental value, diffusion and use of a technology in healthcare [62]. Health
Impact Assessment is a combination of procedures, methods and tools by which a policy, program or
project may be judged as to its potential effects on the health of a population and the distribution of
those effects within the population. For simplicity, we will utilize HTA [63]. This assessment is generally
done by HTA professionals in the form of systematic reviews of an emerging or new technology/tool with
recommendations forwarded to decision-makers. Based on these recommendations, a technique,
technology, tool, or process is implemented in the policy of healthcare, and these policy decisions
determine the acceptability, the applicability in healthcare and the reimbursements. This in our
observations has been generally neglected [52] by the academic-industrial complex [64]. Therefore, it is
of uttermost importance to take into consideration the HTA process while developing a tool, diagnostic
kit or technology, thus, in order to efficiently, effectively and in a timely manner introduce an innovation
into the healthcare system. Although HTA or PHAT themselves are not sufficient when looking at the
whole translational pipeline from bench to healthcare, HTA needs to be streamlined and integrated with
the technology transfer process, which is the process of translating an idea into an innovative product on
the market.
In the case of C. trachomatis, it can be said with some certainty that HLA, specific cytokines including IL-
10 and several TLRs play a role in infection and disease progression. These factors will likely vary
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between ethnical groups. For example, the most important TLR4 SNP, associated with tubal factor
infertility in Caucasians, does not exist in Chinese people at all. Furthermore, the current needs of the
population, relevant technologies on the market and prioritizing technologies based on applicability, the
target audience, and stakeholder involvement including patient groups need to be taken into
consideration. Also, the analytical validity (the ability of a test to accurately and reliably measure the
genotype of interest) [65], clinical validity (the ability of the test to detect or predict the phenotype of
interest) [65] and clinical utility (the likelihood that the test will lead to an improved outcome and
incorporates assessment of the risk and benefits of genetic testing as well as economic evaluation) [65]
of the diagnostic tool will have to be considered. In addition, by performing HTA, the economic, ethical,
legal, and social implications will have to be thoroughly addressed in order to preempt any HTA related
assessments by health policy-makers for technology integration. This collectively covers many aspects of
HTA investigation.
Healthcare aims to improve health of the populations and that the perspective from which the
healthcare decision-maker works is based on HTA recommendations. Therefore, at the end of the day,
the approval of the technology lies in its clinical utility, since the analytical validity and clinical validity
have been more or less addressed. Furthermore, equal weight is given to its ethical, economic, legal, and
social implications (ELSI) in society. Generally, ethical, legal and economic issues are dealt with during
the development of a diagnostic tool or technology; however, the social implications may be overlooked.
This can be the downfall of the tool in healthcare implementation. Also, ELSI can be limited to one
perspective: the industrial and not the population based perspective. Taking into account future
developments such as ‘truly’ personalized medicine moving from clinical utility to personal utility and the
use of ‘personal-genome tests’ [66] , current HTA as a tool for decision-making will be challenged [67] .
Current HTA evaluates a technology on the population or subpopulation, but not on an individual level,
which will be the need in the era of ‘truly’ personalized medicine.
When talking in terms of economics, reimbursement through insurance companies becomes important,
which is sometimes addressed during the development of a technology. Financially stable patients with
no need of reimbursement, early adopters or ‘trendsetters’ do not guarantee acceptance by decision-
makers as this does not represent the majority. HTA analysis is done based on the needs of the
population as a whole and not based on a few elite. Therefore, these ethical questions have to be
addressed here as well. HTA professionals generally prioritize technologies listed by them and investigate
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one or a few of them based on what they deem relevant to the current population need, which also has
to be taken into account during the development of the diagnostic tool. This can be done via comparison
to what already exists on how one can get a competitive advantage based on the current population
need and through consultation with patient groups. This brings in another important aspect: the
involvement of stakeholders. These stakeholders represent the needs of the population and should be
given preference through the development of the diagnostic tool or technology. All these several aspects
should be taken into account while developing a specific diagnostic kit for C. trachomatis subfertility, in
order to decrease the chance of failure, if not guarantee its success in healthcare implementation. As a
result among other factors, there is generally a delay in uptake and wide usage of diagnostic applications
and technologies in healthcare systems and hospitals. Consequentially, by the time the technology or kit
reaches the healthcare system, it becomes inferior in terms of efficiency and effectiveness, given the
exponential growth of newer versions of emerging technologies on the market. The latter again goes
through this delaying process.
Recently, a new framework or model [52] has been developed which addresses all the above mentioned
issues and others not mentioned here with regard to healthcare implementation. The LAL model brings
together for the first time 2 separate entities, namely technology transfer and PHAT in a pseudo-parallel
initiation. Through this, the model promotes early on involvement of all stakeholders (including
academics, industry, patient groups, insurance, policy makers, doctors, HTA professionals, etc.) via
public-private partnership, consultation, bilateral communication, exchange of information, feedback
loops, and relevant lobbying. The model ensures that through the technology transfer pipeline, all PHAT
aspects are addressed, and it also encompasses the Public Health Genomics Wheel [68] as a reference
frame which demonstrates the essential tasks of Public Health for integration of genome-based
technologies ensuring all possible gaps are addressed. This ensures that by the time the technology or
diagnostic application is developed, it conforms to the standards required by decision-makers based on
population needs. This decreases the likelihood of rejection as a relevant tool for healthcare. The model
also puts emphasis on the value of information (how much a decision-maker is willing to pay to come to
a decision) [69]. This is in terms of the end-user clarity, including ease of use, relevance to the patient
and doctors, and any legal issues restricting use of the diagnostic application widely. As a consequence of
the value of information, adaptations in this case to the diagnostic application can be made accordingly.
Through this process, by the time the technology or diagnostic application is developed, it meets all
conditions of healthcare policy, therefore, facilitating timely uptake. We believe this overarching LAL
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model can ease the bottleneck of a real-time uptake by hospitals as well as help industry to come to an
early-on  strategic  decision  on  the  new  technology  and  thus,  save  on  resources  [52].  The  LAL  model
seems an appropriate tool and framework for the development of the Chlamydia diagnostic kit that will
ensure all issues of healthcare, as well as public health conformity and industrial requirements, are met
and addressed. As a result, by the time the diagnostic kit is ready, it can be made immediately available
for widespread use throughout the healthcare system. This can help industry to tap into a generally
wider consumer market than traditionally accessed as well as help decrease the burden of disease that
more would result from delay in the technology. It becomes obvious, that public health approaches need
to adjust to these developments. Thus, PHG in the future will be quite different from PHG in the past
[51].
Rapid scientific advances in genomics and its application to epigenomics, microbiomics and systems
biology not only contribute to the understanding of disease mechanisms, and to the characterization of
each person’s unique clinical, genomic, and environmental information, but also provide the option of
new promising applications in patient and human health management during the whole life-course. In
fact, what was just a decade ago a distant vision for a new era of public health, in which advances from
the -omic sciences would be integrated into strategies aiming at benefiting population health, is now the
soon-to-be realized development of effective personalized healthcare that will be ‘truly’ personalized
medicine. The utility of most genetic tests and biomarkers is still not evidence-based enough. In the
personalized medicine setting, the traditional assessment and evaluation tools are inadequate. We
clearly face the need for a new paradigm because as we start to understand, for example, that what we
call common complex diseases might be a sum of ‘rare diseases’; we move from risk factors to individual
pathways or networks, and from that perspective, we move from clinical utility to personal utility [70] .
However, the real paradigm shift depends on the willingness to restructure policies and on the ability to
train practitioners from various professions. P4 Medicine is a future vision defined by biologist Leroy
Hood, and is short for ‘Predictive, Preventive, Personalized, and Participatory Medicine’ [71]. The
premise of P4 Medicine is that, over the next 20 years, medical practice will be revolutionized by
biotechnology, to manage a person’s health, instead of manage a patient’s disease. Although probably
not around the next corner, there is a clear urgency to prepare healthcare systems and policy-makers in
advance of the inevitable.
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The  implementation  of  PHG  requires  increased  concerted  actions  not  only  on  the  global
(http://www.graphint.org), but also on the European level. The Public Health Genomics European
Network (PHGEN II), which is funded by the General Directorate for Health and Consumer Protection (DG
SANCO) (http://www.phgen.eu), initiated the National Task Forces on PHG in over 15 EU Member States.
Due to these initiatives, the National Institutes of Public Health took a leading role in PHG in Finland,
Belgium, the Netherlands, Croatia, Poland, or Germany. PHGEN II has developed ‘European Best Practice
Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies’
[72], which will assist the European Member States. The LAL model has also been integrated in these
guidelines. A major international research consortium called ‘Information and Communication
Technology for Future Medicine (ITFoM)’ anticipates the medicine of the future, based on molecular,
physiological, anatomical and environmental data from individual patients (http://www.itfom.eu). The
‘ITFoM project’ will create the entirely new ICT that will make it possible to make general models of
human pathways, tissues, diseases, and ultimately of the human as a whole. Patient-individualized
versions of ICT replica (‘virtual patients’) will be used to identify personalized prevention and therapy
schedules and side effects of drugs [73]. The LAL model will play an important role in this project to make
sure that by the time the technology is rolled out, it is adapted and conformed for real-time integration
in healthcare.
Conclusions and Future Prospects
We investigated the potential translational and clinical value of adding diagnostic host genetic marker
profiles relating to infection and inflammation to the current clinical diagnosis and management of
subfertility, which is based on serology and laparoscopy. It is clear from a large body of evidence that
host genetic factors play a role in the susceptibility to and severity of C. trachomatis infection, as shown
by twin studies and many candidate gene studies. To bring this current host genetic work to the next
level, large scale SNP typing and SNP identification in confirmation cohorts is essential and is in progress.
This work will provide insight into what type of host genetic profile can help improve subfertility
diagnoses and whether the added sensitivity, specificity, and positive and negative predictive value will
realize the hope that carrier traits will significantly increase the ability to predict and identify those at
greatest risk of severe complications from C. trachomatis infection. In addition, as shown by the LAL
model, stakeholders have to be informed and participate early-on in the potential implementation of
these findings, a major task and challenge for the field of public health genomics which can be realized
through the LAL model.
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Introduction	
Genomics is a highly dynamic field and, as such, represents a moving target for public health. Public
health is shifting from a focus on the population towards an emphasis of the individual as a means of
supporting the well-being of the population. In particular, we are entering the era of predictive,
personalized, preemptive and participatory (P4) medicine supported by advanced technological
infrastructure. These changes represent a paradigm shift in our approach to healthcare and will go hand-
in-hand with a major reclassification of diseases. The challenge now is to understand how all of these
changes will impact public health and how to ensure that they are translated effectively into benefits for
individual citizens and society as a whole. Thus, there is a need to develop guidelines aiming not to close
doors. Instead, the goal is to create a vision that allows for flexibility and adaptability in their
implementation in order to have a maximum impact on health, the healthcare infrastructure, health
technologies and economic growth in the health sector.
Therefore, the European Commission asked to develop “European Best Practice Guidelines for Quality
Assurance, Provision and Use of Genome-based Information and Technologies” to support the Member
States (and other relevant stakeholders) to more efficiently and effectively work together at a European
level in addressing the challenges deriving from emerging genome-based information and technologies
and to prepare for the paradigm shift of personalized healthcare in time. The implementation of the
concept of public health genomics being the responsible and effective translation of genome-based
knowledge and technologies for the benefit of population health requires modifications of public health
and health governance systems on all levels.
The Public Health Genomics European Network (PHGEN II) fulfills this task. It is an EU DG SANCO
(European Union Directorate-General for Health and Consumers) funded and European Agency for
Health and Consumers (EAHC) issued project (EU Project No. 20081302, 2009 – 2012), which recently
produced the first edition of the “European Best Practice Guidelines for Quality Assurance, Provision and
Use of Genome-based Information and Technologies”. The guidelines will assist all EU Member States,
Applicant and EFTA-European Economic Area (EEA) countries with evidence-based guidance on the
timely and responsible integration of genome-based information and technologies into healthcare
systems for the benefit of population health. They build on the extensive work of the Public Health
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Genomics European Network (PHGEN, www.phgen.eu) being the cornerstone in the development of
public  health  genomics  in  Europe.  Whereas  PHGEN I  (DG SANCO 2006 –  2008)  identified  the  need for
European best practice guidelines (“mapping exercise”), PHGEN II developed the first edition of these
European best practice guidelines using the concept of “genome-based information and technologies”
(Bellagio- Model), which PHGEN I established as a scientific benchmark in Europe. In this concept,
genome-based information is very holistic and includes not only all “omics” data but also environmental,
socioeconomic and lifestyle factors, as well as information on health systems. The process of the
development of guidelines was in line with international standards and acknowledges the diversity and
cultural differences in Europe. Key experts, such as public health experts, EU lawyers, human geneticists,
ethicists, systems biologists, Health Technology Assessment (HTA) experts, representatives from the
private sector and patient groups, as well as policy makers had been involved in PHGEN II.
On 19 and 20 April 2012, experts from across the field of public health genomics representing key
European and national organizations and institutions from policy making, academia and private sector
came  together  at  the  final  PHGEN  II  meeting  in  Rome  –  amongst  them  the  European  Society  for
Pharmacogenomics and Theranostics (ESPT) and the European Medicines Agency (EMA) – to discuss the
future of public health genomics and to endorse the Declaration of Rome on 19 April 2012, a summary of
the “European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based
Information and Technologies”.
Preamble
In the past decade, we have witnessed major changes in our approach to public health, not only in terms
of research and practice but also the policies that support it. New insights into our individual biological
make-up are being obtained from genomics, proteomics, epigenomics, microbiomics and other “omics ”
technologies. As these data are integrated through the use of information and communication
technologies (ICT), we are on the brink of achieving an understanding of the systems biology of human
health and disease that also incorporates environmental contributions. In this way, we can begin to
envisage new approaches to the promotion and management of human health across the entire life
course of an individual. Indeed, we can now consider a future involving truly personalized healthcare in
which technological advances are placed at the service of population health. The evidence we now
require to demonstrate the benefit of new technologies will need to follow a new paradigm, however.
What is required is an assessment of individual benefit rather than overall effects in large populations or
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even subpopulations of patients. Thus, public health assessment and evaluation tools must now address
concepts, such as personal rather than clinical utility.
In light of these changes, PHGEN II recognizes that:
- Common complex diseases can be considered in terms of a constellation of “rare” diseases, each
of which reflects a complex biological system.
- We are moving away from a traditional classification of disease and towards groups of shared
pathology that can be described as “diseasomes” or disease nodes.
- We are moving away from a focus on risk factors within biostatistical models of populations and
towards an emphasis of individual pathways or networks.
- It is time to emphasize personal rather than clinical utility.
The use of genome-based knowledge and technologies will increase the quality of life of European
citizens. Predictive, personalized, preemptive and participatory (P4) medicine serves as a blueprint for
the Public Health Genomics European Network (PHGEN II) to prepare healthcare systems and policy
makers for this paradigm shift in our approach to healthcare. This shift will lead to a fundamental change
not only in knowledge but also in our view of ourselves and the way we are living. As a result, society
must be willing to restructure policies and support knowledge transfer to maximize benefit to public
health.
Information and Communication Technologies
The increasing role of ICT in healthcare is driven by improved technological options. Combined genomic
and phenotypic analysis has become possible owing to advances in technologies to support data analysis
and modeling. The complexity of the task when applied to diagnosis and therapy, however, demands
algorithms and mathematical models to reduce uncertainties. As a result, efforts are now being made to
generate computational models of individual persons (“virtual twins”). Such models can be used to
follow individuals throughout their lifetime and enable health professionals to optimize all types of
health interventions. In this way, it becomes possible to improve the safety, quality, effectiveness and
efficiency of healthcare services. In addition, by following individuals rather than remaining tied to a
given healthcare system, it will enable citizens to handle and access personal health-related data
whenever needed.
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Genome-based information and technologies
PHGEN II builds on the definitions that were developed and agreed in PHGEN I, such as the glossary on
public health genomics and the status of genetic information and genetic testing. The definitions
provided by PHGEN II take into account the most recent developments in the fields of genomics, systems
biology and systems medicine, which provide the evidence base for the “European Best Practice
Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies”
(see Figure 1: Research for new insights and innovative solutions to health problems). The terms
genome-based information (GBI) and genome-based technologies (GBT) are encompassed by the term
genome-based information and technologies (GBIT).
These definitions address the following areas:
- genetics, genomics, functional genomics, systems biology and systems medicine, and the
distinctions between them;
- genetic disease, genomic disease and systems biology disease, and the distinctions between
them;
- the differences between generic, cohort-based, personalized and truly individualized medicine.
Based on these definitions, systems medicine is understood through the integration of genetics,
genomics, functional genomics and systems biology.
Rationale for the European Best Practice Guidelines for Quality Assurance, Provision and Use of
Genome-based Information and Technologies
The ultimate objective of PHGEN II is to enable informed decisions at the macro-, meso- and micro-levels
regarding  quality  assurance,  provision  and  use  of  emerging  GBIT.  The  means  chosen  by  PHGEN  II  to
achieve this is the preparation of European best practice guidelines to support this decision-making
process now and in the future. However, meta-level guidance is also needed. This meta-level guidance
can be achieved by ensuring that the ten essential public health tasks, as described within the public
health wheel or public health trials (assessment, policy development, assurance) can be adequately
fulfilled in each jurisdiction on the basis of a common understanding of best practice guidelines for each
task (see Figure 1). Within these best practice guidelines, translational research considerations are
combined with system management under the concept of public health genomics.
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Figure 1: Public health trias/public health wheel (Institute of Medicine, 1988).
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European	Best	Practice	Guidelines	for	Quality	Assurance,	Provision	and	Use	of	Genome-based	Information	and	Technologies	
1. Research
- Keep up with new insights from the basic sciences.
- Develop trans-disciplinary agendas for translational research.
- Promote sustainable funding for translational research to produce neutral and trustworthy
information.
- Generate evidence to demonstrate when the use of GBIT in public health can improve health
outcomes in a safe, effective and cost-effective manner.
- Engage community members and foster trust by supporting research collaborations and
partnerships between academics and the public.
2. Monitor Health
- Develop prospective surveillance systems for personal health data that facilitate accurate
and ongoing assessment of highly dynamic health information across the life course.
- Promote the use of personal files that contain comprehensive personal health information
including ‘omics’ data and their interaction with all other health determinants.
- Ensure that data obtained from different sources and for different purposes can be securely
linked.
- Maintain the locus of control for health information with the individual citizen.
- Support self-monitoring using ICT tools.
- Develop new strategies for the use of GBIT within the public domain.
- Maintain an infrastructure for the sharing of GBIT data in public health settings.
- Increase the use of Health Needs Assessment (HNA), HTA and Health Impact Assessment
(HIA) tools for the evaluation of GBIT in public health.
3. Diagnose and Investigate
- Move from symptom- and phenotype-based approaches to pathway-based cloud diagnostics
for the early identification of health problems in individual patients.
- Move from clinical utility to personal utility.
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- Identify which information is relevant to an individual, when, and for what purpose across
the life course.
- Use GBIT to identify hazards to population health.
- Identify and assess new GBIT for proactive and timely decision-making.
- Ensure that the assessment of GBIT is comparative, comprehensive and constructive.
4. Inform, Educate, Empower
- Promote health literacy amongst all stakeholders: enable citizens (including health
professionals), individually and cooperatively, to access, understand, appraise and apply
information that will facilitate the application of GBIT for the benefit of individual citizens
and their communities.
- Promote person-centered healthcare.
- Promote  social  media  to  enable  proactive  consumers  (“prosumers”)  to  manage  their  own
health.
- Establish online platforms dedicated to informing users about validated GBIT as well as
available related health services.
- Support participatory and personalized healthcare through the implementation of decision
support tools that link the values and preferences of citizens to the best available evidence
on GBIT.
- Ensure that potential users receive guidance on when and how to use public health
assessment tools (HNA, HTA, HIA) applicable to GBIT.
5. Mobilize Community Partnerships
- Support the establishment and maintenance of national task forces (NTFs) on public health
genomics. NTFs provide a platform for public health practitioners, basic scientists in
genomics, HTA officials and policy makers to listen to, learn from and contribute to public
health genomics, and to define the policy questions regarding GBIT as well as to assess GBIT
at different stages in their life cycle.
- Promote public-private partnerships by establishing mechanisms, tools and models to link
the needs of healthcare systems to those of the private sector and to foster the
development of individualized technologies (e.g., learning adapting leveling model).
- Reinforce the key role of institutes of public health in community engagement.
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- Promote patient- and citizen-oriented social media activities as a new form of community
partnership.
6. Develop Polices
- Reinforce the collaboration between PHGEN NTFs, national HTA agencies and parliamentary
technology  assessment  groups  to  develop  strategies  to  inform  policy  makers  on  the
introduction and iterative assessment of GBIT in an effective, efficient and timely manner.
- Promote policies that cover all phases of the innovation pipeline by combining technology
transfer activities with health policy processes: laboratory–enterprise, enterprise–regulation,
regulation–reimbursement, and reimbursement–disinvestment.
- Improve the implementation of promising GBIT under conditions that safeguard the
wellbeing of citizens.
- Support health policies related to GBIT based on good governance and trust.
- Treat GBIT as the most holistic approach to health information when developing health
policies.
- Ensure that public health genomics works towards health in all policies.
- Support health policy making that takes into account the best available evidence, real-world
context, resources and population characteristics as well as the needs, values and
preferences of stakeholders.
- Translate knowledge in a timely manner from basic sciences into healthcare applications.
7. Enforce Laws
- Use the dynamics of GBIT as a unique opportunity to frame and enforce laws and regulations
proactively.
- Ensure that GBIT and their use in public health meet applicable legal standards. In this
regard, the privacy and security of personal health information should be safeguarded in
accordance with applicable law.
- Work to correct perceptions of genetic exceptionalism and promote laws and regulations
that address personal health information as a whole.
- Use modern ICT to protect personal health data.
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- Assess existing legal frameworks applicable to public health genomics on a regular basis and
adapt them when necessary to ensure the consistency and visibility of enforceable rules on
the use of GBIT in different contexts.
- Support implementation of the EU Data Protection Directive amongst European Member
States to allow the use of personal health data for personal and public health purposes and
to improve the outcome of health interventions.
8. Link to/provide care
- Reduce inequalities in health through sustainable access to and use of GBIT.
- Develop systems that support interoperability between personal and public health
management.
- Support the integration of P4 medicine into healthcare provision.
9. Ensure a Competent Workforce
- Integrate GBIT into the professional training and lifelong learning curricula of health
professionals.
10. Evaluate
- Establish and support a holistic and systems-based evaluation of the impact of GBIT, taking
into account economic issues and the different European health systems.
- Promote a system in which technology transfer activities and policy-based public health
assessment tools (HNA, HTA, HIA) run in parallel for the timely, effective and efficient
evaluation of GBIT.
- Help and support the development of methods, information systems, tools and resources to
adapt assessment tools to changing requirements.
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Concluding	Remarks	
The proposed list of guidelines under the Declaration of Rome is crucial for the implementation of GBIT
amongst European Member States in order to improve public and personal health. Future PHGEN
activities will continue to build on previous work to provide a platform for the developments indicated in
these guidelines. We therefore strongly recommend that PHGEN activities continue to be supported on
European, national and regional levels within the applicable healthcare framework.
The next step: implementation of the 2012 Declaration of Rome in the EU Member States
Because health is not just a value in itself but also a driver for growth, only a healthy population can
achieve its full economic potential. As mentioned in the Europe 2020 agenda ‘promoting good health is
an integral part of the smart and inclusive growth objectives for Europe 2020. Keeping people healthy
and active for longer has a positive impact on productivity and competitiveness. Innovation in healthcare
helps take up the challenge of sustainability in the sector in the context of demographic change’, and
action to reduce inequalities in health is important to achieve ‘inclusive growth’.
Thus, as the next step a Joint Action (JA) “Public Health Genomics and Personalized Healthcare:
Implementing the ‘European Best Practice Guidelines for Quality Assurance, Provision and Use of
Genome-based Information and Technologies’ in rare diseases and cancer” is planned being a joint
financing of a public body or non-governmental organization by the European Community and one or
more Member States. The planned JA fully supports and implements the Innovation Partnership Flagship
Action of Active and Healthy Ageing. It covers not only Innovation/ Genomics and Health in All Policies
(HiAP) in the current program “Together for Health” (2008 – 2013) but it also highly prepares for and
contributes to the new program “Health for Growth ” (2014 – 2020) by applying innovative solutions for
improving the quality, efficiency and sustainability of health systems, putting the emphasis on human
capital and the exchange of European best practices. As such, the planned JA will help Member States,
which are under pressure to strike the right balance between providing universal access to high-quality
health services and respecting budgetary constraints, to reduce healthcare costs and substantially
improve the quality of care to all citizens now and in the future. The European best practice guidelines
developed within PHGEN II and summarized in the Declaration of Rome address many areas of the
Health  for  Growth  Program,  such  as  HTA,  medical  devices,  clinical  trials  and  medicinal  products,  and
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strengthen the link between technological innovation and its effective and responsible uptake and
commercialization.
Therefore, the planned JA will be a very timely and essential next step by:
- Supporting the Member States to prepare in time for the paradigm shift towards personalized
healthcare.
- Bringing together European stakeholders with a common objective and commitment to reduce
the burden of common complex and rare disorders, and providing Member States with a
framework for sharing information, resources, best practices and expertise in monitoring,
surveillance, knowledge integration, prevention and care.
- Helping in the identification of common action at an EU level that can provide added value to
national efforts.
- Helping with the implementation of the HiAP approach and the concepts of HNA, HTA and HIA in
supporting action for active and healthy ageing.
- Serving as an umbrella for researchers from the different stages of translational research in the
life sciences (“from cell to society”) and market authorization, as well as fostering this
translational process to the policy making and public health level.
- Focusing on two key policy areas of application, rare diseases and cancer.
- Using  the  well-established  13  NTFs  of  PHGEN  I  as  the  core  group  and  extending  it  to  the
maximum of Member States.
In conclusion, building on PHGEN I and II the planned JA will help address the transition to personalized
healthcare and personal health from the data integration and modeling perspective points of view in all
EU Member States, Applicant and FTA-EEA countries within the upcoming years.
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CHAPTER	VIII	CONCLUSIONS	PART	B	
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Conclusion	
With regard to specific objectives of Part B, with respect to
chapter  V, the thesis completed and answered the objectives
pertaining namely:
· Demonstrate the complexity of biology reasoning for the
move in the post-genomics era to systems biology and
systems medicine for personalized health applications
and beyond
In this chapter, it was demonstrated that
molecular biology is quite complex and requires
computational power to partially elucidate
answers. However, this has given us more
questions than answers. The chapter shows that
molecular interactions are complex and form
also a hierarchy of thousands of interactions.
These interactions can lead to feed-back/forward
control, modularity, redundancy as well as multi-
tasking. Also structure of a molecule also affects
several functions as well as localization. Further
genetic switches exist in these networks. Several
previous unclassified medical relations have
come up due to the interactome. Several such
complex interactions were described including
interations with environmental factors. This
explosion of data has only been possible with the
explosion of ‘omics’ research through
computational power. However, given this large
amount of data, a more holistic approach is
needed; this can be addressed through systems
biology. With the advent of social media and the
individual/citizen becoming aware of the
uniqueness of individuals, the individual is
demanding for a more personalized approach to
healthcare. Only a systemic approach or holistic
approach can make it possible to understand the
complexity of biological data and address
personalized healthcare applications.
Take	Home	Message	
Complexity	 of	 biology	 has	 been	
partially	 elucidated	 through	
computational	power	 in	 the	 form	
of	genome-based	technologies	and	
systems	 biology.	 This	has	given	 a	
push	 towards	 personalized	
healthcare	 and	 within	 that	
personalized	medicine.		
The	 Learning-Adapting-Leveling	
model	 demonstrates	 its	 potential	
application	 in	 personalized	
healthcare	 through	 the	 EU	
flagship	 project	 ICT	 Future	 of	
Medicine.	 ICT	 Future	 of	 Medicine	
addresses	 the	 environmental	
aspects	 and	 the	 Learning-
Adapting-Leveling	model	 is	being	
implemented	 in	 the	 project	 to	
ensure	by	the	time	the	technology	
is	 rolled	 out	 it	 is	 ready	 for	
healthcare	implementation.	
Chlamydia	 trachomatis	 is	 a	
leading	 cause	 of	 tubal	 pathology	
and	infertility	in	women.	Potential	
SME	 based	 diagnostic	 kit	 for	
genetic	 markers	 in	 tubal	
pathology	 and	 infertility	 to	 be	
used	 in	 conjunction	 with	
Chlamydia	 trachomatis	 serology	
is	proposed	to	avoid	misdiagnosis.	
The	 Learning-Adapting-Leveling	
model	 is	 proposed	 to	 be	
implemented	 to	 this	 potential	
SME	based	diagnostic	kit.	
EU	Guidelines	on	the	QA,	provision	
and	 use	 of	 genome-based	
information	 and	 technologies	
have	 been	 endorsed	 by	 EU	
member	states	 to	compensate	 the	
currently	limited	scope	of	existing	
guidelines	and	the	model	has	been	
incorporated	into	them.		
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· Signifying the issue of taking into account environmental factors interacting with ‘omics’ factors
as well as health systems when developing such applications
This chapter has emphasized that the development of technologies generally do not take
into account the environmental factors, such as lifestyle, climate, social, etc. It is now
known that these do affect the exposome having consequences to ‘omics’. In order to
implement the P4 medicine, technological development needs to take into account
environmental factors like socio-economic, lifestyle and the molecular determinants of
health which all affect molecular interactions. Also, healthcare systems need to be taken
into account while developing the technology. The Learning-Adapting-Leveling model
addresses the issue of healthcare systems as well.
· Using the EU flagship pilot project ICT Future of Medicine (ITFoM, www.itfom.eu) as example of
European research project where the Learning-Adapting-Leveling model is being implemented
The ITFoM project does indeed take into account the environmental factors mentioned
above, however it is still to be seen how it will be utilized. ITFoM aims to develop a virtual
human on the computer, on which simulations like drug reactions and treatments can be
done. Thereafter it can be transferred to the actual individual. The Learning-Adapting-
Leveling model has been implemented in the ITFoM project to ensure that the required
unseen assessment through the technology transfer pipeline namely HNA, HTA and HIA is
being done to ensure that the technology conforms to the national and regional
healthcare requirements. Also, the model is being used to assess throughout the
development of the technology the value of information and to ensure the 10 essential
public health tasks for integration is implemented. The Learning-Adapting-Leveling model
is also being lobbied with relevant stakeholders. This will ensure that by the time the
technology (here the simulation tool) is rolled out, it can be readily taken up by the
healthcare system.
With  regard  to  specific  objectives  of  Part  B,  with  respect  to chapter VI, the thesis completed and
answered the questions pertaining namely:
· Applying it to Chlamydia trachomatis as the leading cause in tubal pathology and infertility
In this chapter Chlamydia trachomatis has been reviewed as the leading cause in tubal
pathology. The chapter reviews all relevant data on chlamydia trachomatis and provides
an overview of the current state of the art on host genetic markers in relation to infection
and the subsequent late complications it can cause in susceptible people. The chapter
proposes a new clinical diagnostic approach in subfertility diagnostics based on this
overview. The potential translational and clinical value of adding diagnostic host genetic
marker profiles relating to infection and inflammation was proposed to be added to the
current diagnosis techniques which are in the case of subfertility triage in women,
Chlamydia serology. Reason being there is significant amounts of misdiagnosis as several
women without tubal pathology have to go through the invasive and expensive
laparoscopy with the traditional Chlamydia trachomatis serology tests.
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· Demonstrating the implementation of the Learning-Adapting-Leveling model to potential SMEs
Based on the above mentioned problem, it has been considered to develop for example a
potential SME based diagnostic kit for genetic markers in tubal pathology and infertility
to be used in conjunction with Chlamydia trachomatis serology. In order to realize this
endeavor large scale SNP typing and SNP identification in parallel to cohorts is required.
This is currently ongoing. It is hoped that this work will provide insight into what type of
host genetic profile can help improve subfertility diagnoses and whether the added
sensitivity, specificity, and positive and negative predictive value will realize the hope
that carrier traits will significantly increase the ability to predict and identify those at
greatest risk of severe complications from C. trachomatis infection. The Learning-
Adapting-Leveling model will be used and applied here as an overarching framework to
answer that question. As the potential development of the SME and the identification of
genetic markers are being evaluated, the Learning-Adapting-Leveling model will closely
follow the whole process. Early on assessments can be evaluated starting with HNA
through the technology transfer pipeline of this potential diagnostic kit. As a result it is
hypothesized that by the time the diagnostic kit is rolled out it would have conformed to
the healthcare requirements and can be readily taken up in daily practice through
lobbying.
With regard to specific objectives of Part B, with respect to chapter VII, the thesis completed and
answered the objectives pertaining namely:
· Contributing to the development of the European best practice guidelines for genome-based
information and technologies (PHGEN II)
Adapted and shortened from:
Brand A, Lal J, Malats N, Gutierrez-Ibarluzea I.
The Public Health Genomics Network (PHGEN).
The Newsletter of the British Society of Human Genetics 2013, (48):53-54.
Genomics is a highly dynamic field and, as such, represents a moving target for public
health. Public health is shifting from a focus on the population towards an emphasis of
the individual as a means of supporting the wellbeing of the population. In particular, we
are entering the era of predictive, personalized, preemptive and participatory (P4)
medicine supported by advanced technological infrastructure. These changes represent a
paradigm shift in our approach to healthcare and will go hand in hand with a major
reclassification of disease. The challenge now is to understand how all of these changes
will impact public health and how to ensure that they are translated effectively into
benefits for individual citizens and society as a whole. Thus, there is a need to develop
guidelines aiming not to close doors. Instead, the goal is to create a vision that allows for
flexibility and adaptability in their implementation in order to have a maximum impact
on health, the health care infrastructure, health technologies and economic growth in the
health sector. Therefore, the European Commission asked to develop “European Best
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Practice Guidelines for Quality Assurance, Provision and Use of Genome-based
Information and Technologies” to support the Member States (and other relevant
stakeholders) to more efficiently and effectively work together at European level in
addressing the challenges deriving from emerging genome-based information and
technologies and to prepare for the paradigm shift of personalized healthcare in time.
The implementation of the concept of public health genomics being the responsible and
effective translation of genome-based knowledge and technologies for the benefit of
population health requires modifications of public health and health governance systems
on all levels. The Public Health Genomics European Network (PHGEN II) fulfills this task. It
is an EU DG SANCO funded and European Agency for Health and Consumers (EAHC)
issued project (EU Project No. 20081302, 2009-2012), which produced recently the first
edition of "European Best Practice Guidelines for Quality Assurance, Provision and Use of
Genome-based Information and Technologies". The guidelines will assist all EU Member
States, Applicant and EFTA-EEA countries with evidence-based guidance on the timely
and responsible integration of genome-based information and technologies into
healthcare systems for the benefit of population health. They build on the extensive work
of the Public Health Genomics European Network (PHGEN, www.phgen.eu) being the
cornerstone in the development of public health genomics in Europe. In this concept,
genome-based information is very holistic and includes not only all ‘omics’ data, but also
environmental, socioeconomic, and lifestyle factors as well as information on health
systems. The process of the guidelines development was in line with international
standards and acknowledges the diversity and cultural differences in Europe. Key experts
such as public health experts, EU lawyers, human geneticists, ethicists, systems
biologists, Health Technology Assessment (HTA) experts, representatives from the private
sector and patient groups as well as key policymakers had been involved in PHGEN II. On
the 19th and 20th of April 2012, experts from across the field of public health genomics
representing key European and national organizations and institutions from policy-
making, academia and private sector as well as the representatives from all EU Member
States came together at the final PHGEN II meeting in Rome to discuss the future of
public health genomics and to endorse the Declaration of Rome on 19 April 2012, a
summary of the “"European Best Practice Guidelines for Quality Assurance, Provision and
Use of Genome-based Information and Technologies" (Declaration of Rome,
www.phgen.eu). PHGEN II builds on the definitions that were developed and agreed in
PHGEN I, such as the glossary on public health genomics and the status of genetic
information and genetic testing. The definitions provided by PHGEN II take into account
the most recent developments in the fields of genomics, systems biology, and systems
medicine, which provide the evidence base for the “European Best Practice Guidelines for
Quality Assurance, Provision and Use of Genome-based Information and Technologies”.
The terms genome-based information (GBI) and genome-based technologies (GBT) are
encompassed by the term genome-based information and technologies (GBIT). The
ultimate objective of PHGEN II is to enable informed decisions at the macro, meso and
micro levels regarding quality assurance, provision and use of emerging GBIT. The means
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chosen by PHGEN II to achieve this is the preparation of European best practice
guidelines to support this decision-making process now and in the future. However, meta
level guidance is also needed. This meta level guidance can be achieved by ensuring that
the 10 essential public health tasks, as described within the public health wheel or public
health trias (assessment, policy development, assurance) can be adequately fulfilled in
each jurisdiction on the basis of a common understanding of best practice guidelines for
each task Within these best practice guidelines, translational research considerations are
combined with system management under the concept of public health genomics.
· Integration of the Learning-Adapting-Leveling model into these guidelines
It can be seen from this chapter that the best practice guidelines is based around the 10
essential tasks of the public health wheel. This wheel synonymously called the public
health genomics wheel is an essential part of the Learning-Adapting-Leveling model.
Furthermore, the Learning-Adapting-Leveling model has been explicitly mentioned to be
integrated in the best practice guidelines as demonstrated in this chapter. Therefore
compatibility of the Learning-Adapting-Leveling model with the best practice guidelines is
ensured. This also resolves the issue of currently existing guidelines which do not take
into account genomics as a moving target and emerging technologies as previous
guidelines mostly focused on clinical guidelines.
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Section	3	
	General	Discussion	
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Discussion	
Through genome-based technologies and systems biology, personalized healthcare including
personalized medicine has taken an exponential leap in its demand. For example, the market for
personalized medicine is expected to reach $454 billion by 2015 for the US market alone. However,
depending upon the type of technology being implemented, a gap is noticed from time to market to
daily practice of these genome-based technologies in healthcare systems. In other words, it is seen
although a translation from the lab to industrial application (phase I) and also from the industrial
application to market penetration (phase II), there seems to be an apparent delay in the uptake from the
market to healthcare integration (phase III). By the time the delayed relevant technology is taken up in
daily practice is can be considered less relevant as a more effective and efficient technology emerges
onto the market. This plays out repetitively which was defined as the circle of destination in chapter II.
As was also indicated, issues like lack of funding to research institutes and limited return of investments
are hindrances which play a role. The latter however can be attributed to failure of the product and
inaccessible markets or untimely interventions. The lack of funding is more of an inherent problem to the
research institute and it’s funders and does not compute with the delay in uptake of existing
technologies on the market. Although the right timing of the introduction to market does play a role, but
still even if this is properly addressed, the issue of timely uptake remains. Therefore these are not major
reasons for the backlog.
This problem completely relates to the field of Public Health Genomics, which is defined as the
responsible and effective translation of genome-based knowledge and technologies into public policy
and health services for the benefit of population health. The sub-specialty of the field within public
health to address the problem was elaborated and defined in chapter I as ‘valorization in public health
genomics’. It can be seen as the ‘process of realization’ of relevant added value ‘bioproducts’, i.e.
technologies, in the domain of public health for benefit of the population and healthcare systems.
Bioproducts are sustainable novel products or products satisfying novel health applications derived or
inspired from genome-based information or technologies. Genome-based derives everything coming out
of the human genome i.e. genomics, proteomics, metabolomics, etc. genome-based information
includes the interactions with environmental factors such as lifestyle, climate, etc. Technologies can
include a technique, process, methodology, tool, activity, diagnostic kit, application and technology in
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the general sense. There seems to be quite an overlap between the definition of ‘bioproduct’ and
‘technology’. In essence the bioproduct is the technology developed.
The Proposed Solution
In this thesis the main reason for the bottleneck or backlog of effective and efficient real-time uptake of
genome-based health applications was identified as the non-synergy and lack of communication
between the academic-industrial complex and the decision makers of healthcare systems (as indicated in
chapter  I). The latter includes the agencies which assess the technologies and develop the
recommendations for decision makers. This bottleneck also affects the return on investment mentioned
partially due to making the market (in this case healthcare) time-wise inaccessible. Also, the academic-
industrial complex mainly involved in the first 2 phases mentioned above use different tools than the
healthcare systems (phase III). A cross-integration of different concepts (mainly in phase III) has been
suggested to address translation from bench to healthcare.
Within the concept of valorization in public health genomics, in order to resolve this bottleneck, the
Learning-Adapting-Leveling model (figure 1 below) was created bringing in for the first time the
academic-industrial complex and decision makers of healthcare systems on the same platform moving
together relatively parallel. Technology transfer is generally used with the first two phases mentioned in
the paragraph above and chapter I. For the third phase mentioned above, the public health assessment
tools are used. It is hypothesized that through the interactions between technology transfer and the
public health assessment tools (HNA, HTA, HIA) through the development of the technology, academic-
industrial complex will adapt their technology to conform to the healthcare needs taking into account
the value of information and the public health genomics wheel as reference points. The process starts
with basic research and development in the lab leading to an idea which can develop or address a need.
As mentioned in chapters I and III, after some feasibility studies, the TT professionals approach the HNA
professionals which in turn assess the developing technology based on needs and give feedback. The TT
professionals go back to the drawing board and adapt the technology. Thereafter they approach the HTA
professionals. The HTA professionals assess the technology as such and give feedback, with the TT
professionals going back to the lab and adapt the technology. Lastly, the same process is addressed with
HIA professionals. This can involve several feedback loops.
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Figure 1: The Learning-Adapting-Leveling Model as the solution overarching framework.
During the whole process the value of information (VoI, as one of the two reference points) is seen from
three perspectives, namely, the processing ability or understandability of the end user regarding the use
of the technology, relevance to the target need and exclusivity (patents, etc.), which restrict its wide
usage. These three perspectives are analyzed from two different fields of work. As indicated in chapter
II, the value of information is analyzed from the business aspect as well as the HTA’s VoI concept. This
ensures that the technology covers business as well as public health aspects and some form of HTA
requirements are fulfilled early on before feedback. On the other hand the public health genomics wheel
defines the 10 essential tasks of public health needed to be addressed for successful integration of
genome-based technologies into public health. These reference points are kept throughout the process
when technology transfer professionals interact with the HNA, HTA and HIA professionals adapting and
conforming their technologies to ensure no loop holes remain.
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As a result through feedback loops of interactions and improvements by the time the technology is ready
to be rolled out it will have been conformed to the previously unseen requirements of policy.
Consequently, it can be readily taken up by the relevant healthcare system and potential broadly defined
public-private partnerships could be realized in the process. This also takes into consideration of
lobbying of relevant technologies in the pipeline based on their assessments (by HNA, HTA and HIA) and
conformity requirements addressed. The important part here being the early-on involvement of all
stakeholders (patient groups, insurance, doctors, decision makers, etc.) through the interaction between
the academic-industrial complex (through technology transfer) and the PHAT (HNA, HTA and HIA
professionals). It is presumed logical that through this interaction other stakeholders will be eventually
consulted early-on as the conformity analysis issue does take these stakeholders into account based on
the need.
Initiatives like early HTA aiming to facilitate pre-market assessment of upcoming new technologies have
been introduced. However they lack the technology transfer aspect of the academic-industrial complex.
It is well known that modern HTA constitutes horizon scanning and/or constructive technology
assessment for early on assessment of dynamically moving technologies. However, the true sense of
these tools is not realized. Reason being that horizon scanning and constructive technology assessment
can only assess early on or in real-time only those upcoming technologies whose knowledge is in the
public domain or recently introduced on the market. Through the Learning-Adapting-Leveling model, the
interaction between the academic-industrial complex and the HTA professionals early on in the
development of the technology, a true sense of horizon scanning and/or constructive technology
assessment can be realized as the early on evaluation will comprise of assessment through the pipeline
of the technology development prior to its official release to the market or public domain. This also
ensures that relevant technologies are not missed out as the technology developers will be approaching
the HTA professionals.
As an outcome of this interaction through the innovation network in chapter I of this thesis, it has been
stated that the progress and development can lead to the advantage of the industry to come to an early-
on decision on the technology being developed, whether to conform it further if feasible, or kill it
entirely, thus saving on resources like time and money. Also, they could still continue with the
technology not conformed, targeting the traditional market. On the other hand, mainly mentioned in
chapters II and III, this can also possibly help decision makers to timely diffuse relevant technologies into
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health care and develop related policy-wise guidelines. One of the possible outcomes is that this can
reduce the burden of disease as when the technology reaches the patient on time, it can help in a more
effective and efficient manner to diagnose or treat the disease and possibly prevent it early on.
Economically, this will seem more advantageous, therefore delayed integration of relevant technologies
is indeed a problem.
Figure 2: The absorption capacity as a function of the innovation network through time.
In chapter I, it has been stated that the higher the absorption capacity, the higher the possible success of
this proposed model. In other words, the more cases or technologies which go through these
interactions in the innovation network eventually will lead to broadly defined public-private partnerships
for future cases. Each time a new technology goes through the now existing partnership/network,
through experience, the better the interactions will be optimized in terms of efficiency and effectiveness.
It can then be said the more optimized the interaction, the better the chance of success both in time and
resources.  This  absorption  capacity  (see  figure  2  above  on  threshold  capacity)  will  never  be  100%  as
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there will be always room for improvement and unforeseen issues. Also the timeline of integration is
dependent on the type of technology being developed and where. For example, pharmaceuticals can
take more time than general technologies. In chapter I we have given an example on how this
progressed and in chapter III,  we  elaborate  on  this  developing  the  step-by  step  methodology  of  the
framework as stated previously above.
Coverage of the Model
In chapter II, based on the definition of technology transfer it was proven that technology transfer
covers all aspects of translational research from the lab till the market and return on investments. This
includes technology transfer’s coverage (see figure 3) of the concepts of valorization, spin-offs, regional
valorization systems, drug discovery and open innovations, although can still be considered subjective.
Given that technology transfer covers the complete spectrum from the lab to bringing the technology
onto the market including return on investment, and since is it widely used in a variety of forms, it is the
best representation of the academic-industrial complex. Therefore, it was considered one of the two
core components of the Learning-Adapting-Leveling model.
Figure 3: Technology Transfer (TT) as the overarching framework from bench to market. The third row indicates a
subjective vew on the TT process, the fourth row is the drug discovery pipeline. The last two rows indicate the
ovearching framework of TT.
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Similarly, for HNA, HTA and HIA were considered well defined popular methodologies important for
decision making. Thus, their usage in the model as the public health assessment tools was the second
core of the Learning-Adapting-Leveling model. The model considered to keep out certain other tools like
ACCE, EGAPP, T1-T4 and PHG enterprise due to their limited scope and/or overlaps with the public
health assessment tools as was demonstrated in chapter II. Importantly, the public health genomics
wheel or the public health wheel was considered quite important for its inclusion in the model as a
reference point. In the chapter it was demonstrated based on the definitions of the rejected tools with
comparison with the definitions of the components of the public health genomics wheel, the latter
covered all aspects of the rejected tools ensuring that possible gaps can be avoided and that extensive
coverage is ensured. Furthermore, it was stated that the public health assessment tools (HNA, HTA and
HIA) are also covered in a way over the public health genomics wheel; this being due to the reason that
HNA, HTA and HIA are methods used to fulfill or to do some of the ten essential public health tasks of the
wheel. However, the wheel itself was not considered the core component rather a reference point due
to the fact that the public health genomics wheel defines the 10 essential tasks of public health which
have to be considered for successful integration of genome-based technologies into public health and
healthcare without a defined method. On the other hand the public health assessment tools in the form
of HNA, HTA and HIA are well defined and proven popular methodologies referred to by decision makers
for recommendations. In addition to the above the model also takes into consideration the value of
information as the other reference point. As a consequence the Learning-Adapting-Leveling model is
quite comprehensive in its approach and coverage of relevant tools for translation and implementation
from the lab through the market to the implementation in healthcare. Therefore it can be considered an
overarching framework.
As mentioned in chapter II, the coverage of the Learning-Adapting-Leveling model can also be
considered addressing also the concept of ‘diffusions of innovations’ however the scope of the model is
to utilize and incorporate it as opposed to studying the concept. In the Learning-Adapting-Leveling
model’s innovation network, these interactions amongst the technology transfer professionals and the
HNA, HTA and HIA professionals including early on involvement of all stakeholders, address the four
main components that impact a concept according to the concept of ‘diffusion of innovations’ namely,
innovation, communication channels, time and the social system are addressed. The ‘innovation’ is
addressed through technology transfer and its interactions with the public health assessment tools
(HNA, HTA and HIA) regarding its spread. ‘Communication channels’ are addressed and established
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through the interactions within the model through the innovation network by the development of
broadly defined public-private partnerships both formal and informal. ‘Time’ in the form of the
bottleneck of effective and efficient real-time integration is the basis from which the LAL model was
developed. ‘Social system’ is incorporated through these interactions in the innovation network with
technology transfer conforming to the requirements of public health and health care systems via these
assessments. Also the involvement of all stakeholders including patient groups, insurance companies,
doctors, academicians, decision makers, HTA professionals, industry among others throughout the
process of the model ensures that the ‘social system’ the Learning-Adapting-Leveling model works within
is addressed. Furthermore, the ethical, legal, social and economic implications are addressed through
tools in the public health assessment tools.
In addition, human capital is an important aspect of the model as it is according to the concept of
‘diffusion of innovations’. Also, the categories of adopters (from diffusion of innovations), namely
innovators, early adopters, early majority, late majority and laggards are encompassed within the
Learning-Adapting-Leveling model. The motive in the model is to shift towards early adopters through
the conformity requirements and stakeholder involvement during the implementation phase of an
innovation early on. In addition, the concept of ‘critical mass’ in ‘diffusions of innovations’ can draw
parallel with the ‘absorption capacity’ of the Learning-Adapting-Leveling model. Using the concept of
‘diffusion of innovations’, the LAL model can develop the required interactions for effective and efficient
real-time uptake of genome-based technologies within its innovation network. In other words, even if
the actors utilizing the model are not familiar with ‘diffusion of innovations’ they are bound to use those
concepts knowingly or unknowingly as a result of the complex interactions of stakeholders within the
model as concepts like social, change, mentality and organizational issues will be addressed in the
model. On the other hand however, although adaptions since the original concept of diffusion of
innovations (in 1990) has been done, it was the rationale behind the idea of the need of a systematic
approach like HTA which is incorporated as one of the core components of the Learning-Adapting-
Leveling model.
The Model in Action
Chapter  V demonstrates that the Learning-Adapting-Leveling model is being piloted in the EU flagship
pilot project ICT Future of Medicine (ITFoM). ITFoM aims to develop a virtual patient of a human taking
all information from molecular to family history among others into account. The idea is that doctors,
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patients and healthy individuals can simulate the reaction to a drug for example before using it on the
patient. Although ITFoM covers the environmental factors of genome-based information and
technologies and all possible data, healthcare integration will be a bottleneck. Here the Learning-
Adapting-Leveling model is being used to ensure all needed interactions and assessments of HNA, HTA
and HIA keeping in mind the two reference frames namely value of information and the public health
genomics wheel are accomplished through the technology transfer pipeline. As a result, once the ITFoM
technology being a simulation tool is ready to be rolled out into the market, given the conformity issues
addressed and through the developing public-private partnerships as well as the currently ongoing
lobbying of the relevance of the technological development, it in principle should be ready for uptake in
real time by healthcare systems.
In chapter VI, it was described the significant contribution of Chlamydia trachomatis to tubal pathology
and infertility. Here again the ongoing application of the Learning-Adapting-Leveling model is described.
Generally, there is a misdiagnosis in the currently available diagnostic test known as the Chlamydia
Antibody Test (CAT). The chapter builds the case for adding host genetic marker profiles as a supplement
to the currently existing CAT. Through the possibility of a new spin-off company (TubaScan Ltd.) the aim
is to develop a diagnostic kit based around this principle by currently working on large scale single
nucleotide polymorphism typing and identification. This most likely will increase the sensitivity,
specificity and positive & negative predictive value of diagnosis of tubal pathology in women with
subfertility such that clinical utility can be defined properly. The Learning-Adapting-Leveling model is
planned to be applied as an overarching framework within this project through the development of the
diagnostic kit. This will ensure that health policy aspects are covered early on through the process. Using
the framework of interactions between technology transfer and HNA, HTA and HIA, it is aimed to ensure
real-time uptake by the time the technology has been developed. Here again the true sense of horizon
scanning or constructive technology assessment as early stated can be realized.
As  stated  in chapter VII, the Learning-Adapting Leveling model has been incorporated into the EU DG
SANCO “European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based
Information and Technologies” to be used by all EU member states i.e. by the key stakeholders on
European and national level. These guidelines have been developed around the 10 essential tasks of the
public health genomics wheel (see figure 4), which form an essential part of the Learning-Adapting-
Leveling model reference frame, therefore again shows the importance of the wheel. The Learning-
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Adapting-Leveling model has been explicitly mentioned in these European best practice guidelines. The
final aim of the guidelines was to inform decision makers at the macro, meso and micro-levels. The
guidelines are more of a guideline for guidelines. The proposed list of guidelines can be considered
crucial for the implementation of genome-based information and technologies amongst European
Member States in order to improve public and personal health. Based on the current guidelines, as the
next step, a DG SANCO Joint Action is planned on ‘public health genomics and personalized healthcare:
implementing the European best practice guidelines for quality assurance, provision and use of genome-
based information and technologies in rare diseases and cancer’. The planned JA fully supports and
implements the Innovation Partnership Flagship Action of Active and Healthy Ageing. It covers not only
Innovation/Genomics and Health in All Policies (HiAP) in the current program “Together for Health”
(2008 – 2013), but it also highly prepares for and contributes to the new program “Health for Growth”
(2014 – 2020) by applying innovative solutions for improving the quality, efficiency and sustainability of
health systems, putting the emphasis on human capital and the exchange of European best practices.
Figure 4: The 10 essential tasks of the PHG
Wheel  distributed  over  the  3  domains  of
assessment, policy development and
assurance.
Coming back to these guidelines as given in chapter VII, apart from the model being incorporated in the
specific sub-category of the category ‘Mobilize community partnerships’, the model due to its
involvement with HNA, HTA and HIA including P4 medicine, as well as the guidelines developing the basis
from the public health genomics wheel, ensures that the model is covered through all the guidelines
mentioned. Examples of which are given below from the developed guidelines of the 10 categories
(coverage of the model given in italics)
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1. Research
- Keep up with new insights from the basic sciences
The Learning-Adapting-Leveling model revolves around the concept of true horizon scanning
and constructive technology assessment through early on involvement of these agencies
(HNA, HTA and HIA) with technology transfer professionals or basic scientists working in
applied research. Such basic scientists can be considered as entrepreneurs generating spin-
offs as a result. Alternately they can just be applied researchers with potential applications
another picks up for commercialization. This can be realized through the public-private
partnerships of the model.
- Develop trans-disciplinary agendas for translational research.
The Learning-Adapting-Leveling model is trans-disciplinary as it involves a lot of actors from
basic scientists, systems biologists, omics scientists (academia), industry, health research and
policy through HNA, HTA and HIA, government through decision making, regulatory bodies,
regional administration, medicine through doctors, patients and health professionals,
insurance and reimbursements, etc. Again through the public-private partnerships in the
innovation network of the model these agenda for translational research can be set.
- Promote sustainable funding for translational research to produce neutral and trustworthy
information.
The recent EU DG SANCO call (tender) of a half a million Euros on dialogue between HTA
professionals and technology developers indicates to answer this guideline (the tender of
which completely is the Learning-Adapting-Leveling model). Future grants seem to be likely.
- Generate evidence to demonstrate when the use of GBIT in public health can improve health
outcomes in a safe, effective and cost-effective manner.
The interactions between the academic-industrial complex and the public health assessment
tools resulting in adaptions to technological conformity and the lobbying based on generated
evidence is within the framework of the model. The technology transfer professionals have to
demonstrate the evidence of the benefit of GBITs (their developing technologies) to
healthcare in the Learning-Adapting-Leveling model.
- Engage community members and foster trust by supporting research collaborations and
partnerships between academics and the public.
Early on involvement of all stakeholders and public-private partnerships are a basic principle
in the Learning-Adapting-Leveling model, therefore this is taken into consideration.
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2. Monitor Health
- Develop prospective surveillance systems for personal health data that facilitate accurate
and ongoing assessment of highly dynamic health information across the life course.
- Promote the use of personal files that contain comprehensive personal health information
including ‘omics’ data and their interaction with all other health determinants.
The above two fall within the perspective of personalized healthcare. The model was
developed with omics research (combined with its interactions with environmental factors)
and systems biology in mind giving the output into personalized healthcare. The basic
principle of monitor health falls within the reference frame of the PHG wheel of the Learning-
Adapting-Leveling model.
- Ensure that data obtained from different sources and for different purposes can be securely
linked.
This brings in the ELSI (ethical, legal, social implications) model of HTA within the LAL model
(e.g. data protection) as well as HIA. Again this falls within our reference frame.
- Maintain the locus of control for health information with the individual citizen.
- Support self-monitoring using ICT tools.
The above two fall in the category of personalized healthcare and personalized medicine on
which the model was developed.
- Develop new strategies for the use of GBIT within the public domain.
- Maintain an infrastructure for the sharing of GBIT data in public health settings.
The above two fall again within the promotion or execution of the model through the
interactions in the innovation network.
- Increase the use of Health Needs Assessment (HNA), HTA and Health Impact Assessment
(HIA) tools for the evaluation of GBIT in public health.
This becomes quite self-explanatory in the Learning-Adapting-Leveling model being the core
components.
3. Diagnose and Investigate
- Move from symptom- and phenotype-based approaches to pathway-based cloud diagnostics
for the early identification of health problems in individual patients.
- Move from clinical utility to personal utility.
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The above two again fall in the category of omics research (with its interactions with
environmental factors) and systems biology (giving way towards personalized healthcare)
which are the tools being translated into public health through the model.
- Identify which information is relevant to an individual, when, and for what purpose across
the life course.
This falls for example, within the Value of Information reference frame of the Learning-
Adapting-Leveling model.
- Use GBIT to identify hazards to population health.
- Identify and assess new GBIT for proactive and timely decision-making.
- Ensure that the assessment of GBIT is comparative, comprehensive and constructive.
- Again the above three are quite self-explanatory given the scope of the developed model
(Learning-Adapting-Leveling) using HNA, HTA and HIA through the technology transfer
pipeline for true horizon scanning and constructive technology assessment.
4. Inform, Educate, Empower
- Promote health literacy amongst all stakeholders: enable citizens (including health
professionals), individually and cooperatively, to access, understand, appraise and apply
information that will facilitate the application of GBIT for the benefit of individual citizens
and their communities.
- Promote person-centered healthcare.
- Promote social media to enable proactive consumers (“prosumers”) to manage their own
health.
- Establish online platforms dedicated to informing users about validated GBIT as well as
available related health services.
- Support participatory and personalized healthcare through the implementation of decision
support tools that link the values and preferences of citizens to the best available evidence
on GBIT.
Here time and again, the above mentioned six points fall within the core principle of the
Learning-Adapting-Leveling model’s “early-on” involvement of all stakeholders through the
innovation network.
- Ensure that potential users receive guidance on when and how to use public health
assessment tools (HNA, HTA, HIA) applicable to GBIT.
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This comes through the iterations of the feedbacks on using the defined methodology of the
Learning-Adapting-Leveling model as given in chapter III.
5. Mobilize Community Partnerships
- Support the establishment and maintenance of national task forces (NTFs) on public health
genomics. NTFs provide a platform for public health practitioners, basic scientists in
genomics, HTA officials and policy makers to listen to, learn from and contribute to public
health genomics, and to define the policy questions regarding GBIT as well as to assess GBIT
at different stages in their life cycle.
- Promote public-private partnerships by establishing mechanisms, tools and models to link
the needs of healthcare systems to those of the private sector and to foster the
development of individualized technologies (e.g., learning adapting leveling model).
The above two mentioned guidelines again fall within the broadly defined concept of public-
private partnership as mentioned in the Learning-Adapting-Leveling model.
- Reinforce the key role of institutes of public health in community engagement.
- Promote patient- and citizen-oriented social media activities as a new form of community
partnership.
The above two guidelines apart from being part of the public-private partnerships as
mentioned in the Learning-Adapting-Leveling model also involves the model’s core principle
of early-on involvement.
6. Develop Polices
- Reinforce the collaboration between PHGEN NTFs, national HTA agencies and parliamentary
technology  assessment  groups  to  develop  strategies  to  inform  policy  makers  on  the
introduction and iterative assessment of GBIT in an effective, efficient and timely manner.
This falls within the public-private partnership category of the model.
- Promote policies that cover all phases of the innovation pipeline by combining technology
transfer activities with health policy processes: laboratory–enterprise, enterprise–regulation,
regulation–reimbursement, and reimbursement–disinvestment.
In chapter  I, it was stated that government driven regulatory requirements would greatly
benefit the execution of the model, this becomes apparent with this statement as well as
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given current EU calls of which the model answers (including the EU tender previously
mentioned).
- Improve the implementation of promising GBIT under conditions that safeguard the
wellbeing of citizens.
The ELSI of HTA and HNA assessment as well as the public-private partnerships answer this
guideline within the model.
- Support health policies related to GBIT based on good governance and trust.
The government driven regulatory requirements are favorable to the model.
- Treat GBIT as the most holistic approach to health information when developing health
policies.
This guideline is what the model wishes to translate.
- Ensure that public health genomics works towards health in all policies.
This again answers the government driven regulatory requirements
- Support health policy making that takes into account the best available evidence, real-world
context, resources and population characteristics as well as the needs, values and
preferences of stakeholders.
This is answered by HNA, value of information as well as early on involvement of all
stakeholders as mentioned in the model.
- Translate knowledge in a timely manner from basic sciences into healthcare applications.
The final objective of the Learning-Adapting-Leveling model.
7. Enforce Laws
- Use the dynamics of GBIT as a unique opportunity to frame and enforce laws and regulations
proactively.
This guideline works well with the model as the model also aims to develop policies on GBITs
through the interactions between the academic-industrial complex and the decision makers
through the public health assessment tools (HNA, HTA and HIA).
- Ensure that GBIT and their use in public health meet applicable legal standards. In this
regard, the privacy and security of personal health information should be safeguarded in
accordance with applicable law.
This falls within the category of ELSI of the model.
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- Work to correct perceptions of genetic exceptionalism and promote laws and regulations
that address personal health information as a whole.
- Use modern ICT to protect personal health data.
Data protection, health literacy (reference frame) and personalized healthcare are addressed
through this thus alleviating the model.
- Assess existing legal frameworks applicable to public health genomics on a regular basis and
adapt them when necessary to ensure the consistency and visibility of enforceable rules on
the use of GBIT in different contexts.
The constant adaptions and iterations in the Learning-Adapting-Leveling model will also
promote the upgrade or revisions in health policies and legal frameworks to accommodate
the requirement of GBITs by the interactions in the innovation network including its
consequential lobbying.
- Support implementation of the EU Data Protection Directive amongst European Member
States to allow the use of personal health data for personal and public health purposes and
to improve the outcome of health interventions.
The statement of this guidelines again works towards the positive usage of the model.
8. Link to/provide care
- Reduce inequalities in health through sustainable access to and use of GBIT.
- Develop systems that support interoperability between personal and public health
management.
The above two mentioned guidelines are addressed through the interactions of the Learning-
Adapting-Leveling model developed potentially into public-private partnerships. As a
consequence, timely interventions can reach the patient reducing inequalities and
management can be made consistent over time.
- Support the integration of P4 medicine into healthcare provision.
The Learning-Adapting-Leveling model also addresses P4 medicine.
9. Ensure a Competent Workforce
- Integrate GBIT into the professional training and lifelong learning curricula of health
professionals.
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This involves the ‘processing ability’ or understandability, one of the three components of the
value of information reference frame in the model. In addition, the PHG wheel reference
frame’s ‘educate’ covers this as well. This can be achieved through lobbying.
10. Evaluate
- Establish and support a holistic and systems-based evaluation of the impact of GBIT, taking
into account economic issues and the different European health systems.
This directly relates to HIA of the model as well as partly HTA.
- Promote a system in which technology transfer activities and policy-based public health
assessment tools (HNA, HTA, HIA) run in parallel for the timely, effective and efficient
evaluation of GBIT.
This is the government driven regulatory requirement which supports the functioning of the
model.
The Learning-Adapting-Leveling model has been lobbied through self-citations, other citations, high level
policy reports, grants and presentations internationally. Below the list as a result of this lobbying and
promotion of the model is given:
Related Publications (citing the original)
· Brand A, Lal JA. European Best Practice Guidelines for Quality Assurance, Provision and Use of
Genome-based Information and Technologies: the 2012 declaration of Rome. Drug Metabolism
and Drug Interactions 2012, 27(3):177-182.
· Lal JA. Addressing the backlog of genome-based technologies in healthcare. The Newsletter of
the British Society for Human Genetics 2013, 48:59-60.
· Lal JA, Malogajski J, Verweij SP, de Boer P, Ambrosino E, Brand A, Ouburg S, Morré SA. Chlamydia
trachomatis Infections and Subfertility: Opportunities to Translate Host Pathogen Genomic Data
into Public Health. Public Health Genomics 2013, 16:50-61.
· Lal  JA,  Sudbrak  R,  Lehrach  H,  Brand  A.   Functional  Dynamics:  From  Biological  Complexity  to
Translation and Impact in Healthcare Systems. Journal of Computer Science and Systems Biology
2013, 6(2): 088-092.
· Brand A. Personalisierte Medizin: Von der Vision zur Realität. Bulletin SAMW 2012, 3112:2-4.
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· Brand A, Morré, SA. Public Health Genomics – public health goes personalized. Tijdschrift voor
Gezondheidswetenschappen 2013, 91(2):86-87.
· Brand A. Public Health Genomics and Personalized Healthcare: a pipeline from cell to society.
Drug Metabolism and Drug Interactions 2012, 27(3):121-123.
· Brand A. Public Health Genomics – from cell to society. The Newsletter of the British Society for
Human Genetics 2013, 48:51-52.
· Lal JA, Vaidya A, Gutiérrez-Ibarluzea I, Dauben HP, Brand A. The LAL Model: from theory to
hypothesis of steps for implementation of basic genome-based evidences in personalized
medicine. Personalized Medicine 2013, 10(7):683-701.
· Lal JA, Morré SA, Brand A: The overarching framework of translational and integration: a case for
the LAL model. Personalized Medicine 2013, In Press.
Other articles/publications citing the original article
· Malogajski J, Brankovic I, Verweij SP, Ambrosino E, van Agtmael MA, Brand A, Oudurg S, Morré
SA. Translational Potential into Health Care of Basic Genomic and Genetic Findings for Human
Immunodeficiency Virus, Chlamydia trachomatis, and Human Papilloma Virus. Biomedical
Research International 2013, 2013:1-10
· Lotte S, van de Wetering G, Groothuis-Oudshoorn K, Retel V. A Systematic and Critical Review of
the  Evolving  Methods  and  Applications  of  Value  of  Information  in  Academia  and  Practice.
Pharmacoeconomics 2013, 31(1):25-48.
· Joly Y, Dove ES. Moving Beyond Commercialization: Strategies to Maximize the Economic and
Social Impact of Genomics Research. Policy Brief No. 5, Genome Canada April 2012 pages 1-13.
· Anzenbacher P, Nekvindová J. Perzonalizovaná medicína – současná praxe a přísliby do
budoucna. Klinická farmakologie a farmacie2012, 26(3):123-125
· Sanders MS. Host genetic variants in susceptibility, severity and outcome of bacterial meningitis.
Chapter 9, Doctoral Thesis – Medicine. Vrije Universiteit Amsterdam. 27-02-2013.
High level policy reports incorporating the model
· European Science Foundation Forward Look: Personalized Medicine for the European citizen.
Towards more precise medicine for the diagnosis, treatment and prevention of disease (iPM),
2012, pp. 17, 41.
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· European Alliance for Personalized Medicine: Innovation and Patient access to personalized
medicine. Report from Irish Presidency Conference March 20th/21st 2013.
· ICT Future of Medicine Pilot Flagship Final Report. 30 April 2012, Pages 25, 26, 69, 70, 76.
· Das war die Amgen Science Lounge 2013. AMGEN.
Related published conference proceedings
· Lal J. Valorization of genome-based technologies in public health. In proceedings of the 4th
European Public Health Conference. European Journal of Public Health 2011, Vol. 21,
Supplement 1. 10 November, Copenhagen.
· Vondeling  H,  Lal  J,  Douw  Karla,  Cassiman  JJ,  Brand  A.  Public  Health  Genomics  and  Health
Technology Assessment. In proceeds of the 9th HTAi Annual Meeting. Gac Sanit. 2012, 26(Espec
Congr 2):6.
· Lal  JA.  Valorization  of  Genomics  in  Public  Health.  Biomedica  Life  Science  Summit  2011,
Eindhoven Netherlands.
· Lal  JA,  Schulte  in  den  Bäumen  T,  Morré  SA,  Brand  A.  Valorizing  Genomics  in  Public  Health.
Genetica Retraite 2011, Kerkrade Netherlands.
Grants incorporating the model
· EU Framework Program 7 (FP7)
o COST - European Cooperation in the field of Scientific and Technical Research
§ Title: An integrated European Platform for Pancreas Cancer Research: From Basic
Science to Clinical and Public Health Interventions for a rare disease
· Duration: 2013-2016
o FP7-Helath-2012-Innovation
§ Title: RARE Best practices – Best Practice and knowledge sharing in the clinical
management of rare-diseases
· Duration: 2013-2016
o FP7-ICT-FET-F
§ Title: Information and Communication Technology Future of Medicine /ITFoM
· Duration: 2011-2012
· EU DG SANCO
o European Agency for Health Consumers
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§ Public Health Genomics European Network II  (PHGEN II),
· Title: European Best Practice Guidelines on Quality Assurance Provision
and Use of Genome-based Information and Technologies.
o Duration: June 2009 to November 2012
· Canadian
o APOGEE Net CanGeneTest – A Research and Knowledge Network on Genetic Health
Services and Policy.
§ Pilot Project Title: Efficient integration of genome-based technologies into the
healthcare system.
· Duration: March 2011 to March 2015
Other related articles/conference proceedings
· Brand A, Lal J, Malats N, Gutierrez-Ibarluzea I. The Public Health Genomics European Network.
The Newsletter of the British Society for Human Genetics 2013, 48:53-55.
· Brand A, Lal J. Declaration of Rome-European guidance on Public Health Genomics. 5th European
Public Health Conference. European Journal of Public Health 2012, 22(2):16.
Interviews related to the model
· TV Interview sporting a discussion along with colleagues regarding Public Health Genomics (15-
05-2012, 11:30-14:00) for the ARTE TV network.
· Thirty minutes telephonic interview on the harmonization strategies for HTA reimbursement and
regulatory approval by Prof. Ron Goeree (McMaster University, Canada) and Michael Drummond
(University of York). (06-12-2012, 15:00-15:30)
The Learning-Adapting-Leveling model has also been incorporated in other currently submitted FP7s as
well  as  other  grants  including  the  current  DG  SANCO  ‘Call  for  tender  n°  EAHC/2013/Health/09
concerning pilots on early dialogue between health technology assessors and healthcare product
developers during the development phase of medicinal products and medical devices’ which directly
relate to the interactions of the model. Furthermore, a Universiteitsfond Limburg SWOL grant to
organize a workshop around the Learning-Adapting-Leveling model has been accepted. This workshop
will involve high level stakeholders to familiarize themselves with the model and to implement it. In
addition, other papers in submission and preparation emphasis the model. In particular from the reports
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listed, the report from the Irish Presidency of the EU incorporates the model. Also the incorporation of
the model in the European Science Foundation’s Forward Look report and the developed European best
practice guidelines of PHGEN II at EU level emphasize the extensive proliferation of the model in the EU.
Ongoing Adaptions
On the other hand, there are issues which still have to be addressed. Preferentially, government driven
regulatory requirements concerning the Learning-Adapting-Leveling model would be stimulating for the
adoption of the model, however may turn out as stated in the EU best practice guidelines above.  Also,
having the push of the technology from the market and the pull is from the society or healthcare based
around the need is ideal. Therefore, it is up to the academic-industrial complex to voluntarily implement
the model in their setting. It can be said here, that the broadly defined public-private partnerships are an
important component to spread this voluntary implementation to a standard eventually as these
partnerships convey the momentum from on section to another. As a consequence, this can bolster
possible future government driven regulatory requirements. However, as mentioned in chapter II, the
EU DG SANCO has placed a call for these early interactions understanding the importance of it. The
Learning-Adapting-Leveling model is an applicant in that call.
The model seems simply straightforward. Nevertheless, the public health assessment tools (HNA, HTA
and HIA) have to be compatible to each other as well as technology transfer as mentioned in chapters I
and II. These tools have their own timeframes and subjective methodologies. This can lead of redefining
the roles of these tools. This will only be achieved through the interactions within the Learning-Adapting-
Leveling model possibly leading to organizational and policy-wise changes to synergize the approach.
Coming back to HTA, it should be noted like HNA and HIA, although quite widely used in several
countries, there are regions where agencies with alternate names and functions carry out the
assessments. It goes without saying that in that case within the Learning-Adapting-Leveling model those
agencies will replace the public health assessment tools mentioned for the assessment. Nonetheless, the
technology transfer professionals will most likely have to always approach the HNA, HTA and HIA
professionals to activate the model. Given its wide lobbying, the model could be eventually considered a
standard in some regions whereas in other regions it may take time or be rejected.
However, the model can still be applied internally by technology transfer professionals, if the current
landscape does not allow the development of the innovation network. Through this the academic-
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industrial complex can ensure that even though an innovation network or public-private partnership
does not exist, they nonetheless are able to conform to perceived health policy needs. Internal
assessments should be not considered a replacement to the original design as it is important that health
policy is on board for real-time acceptance. Furthermore, development of public-private partnerships is
beneficial in the long run. Importantly, the core problem of delayed uptake or lack of effective and
efficient  real-time  uptake  of  genome  based  (information  and)  technologies  is  in  fact  the  lack  of
communication or non-synergy between the academic-industrial complex and health policy. Therefore,
internal assessments should be not a replacement.
The term technology transfer can be described in simplistic terms as to transfer the technology from one
setting  to  another  setting.  However,  the  term  itself  is  mostly  used  in  the  valorization  and
commercialization of technologies, therefore does not constitute healthcare implementation. Although
there may be issues between the players of technology transfer, given its extensive usage and
popularity, the problems are minor and can be neglected. Also within technology transfer the drug
discovery phase timeline issues as mentioned in chapter I are not due to the organizational issues of
technology transfer rather the proof of concept of the drug being developed. It should also be noted as
stated in chapter III that technology transfer professionals should present the best or few of the best
options to health policy rather than showing all on the table for assessment as this can result in
rejection.
Regional valorization systems as indicated in section 1 seem to have some of the ingredients from
industry to policy, which can bring in the question, why it was not considered an overarching framework.
The system itself apart from being not popular and not proven importantly has no defined method or
defined actors. Furthermore this system works on the policy aspect for development for only business
conditioning or favorable conditions. Also it does not cover the whole pipeline (from bench to
healthcare) and is only focused on regional structures. In addition, it does not have any systematic
proven approaches like HTA. Conclusively, it is far away from being useful as the healthcare perspective
is completey lacking. The Learning-Adapting-Leveling model does in fact take these aspects into
consideration and goes beyond business conditioning for conditioning of the healthcare benefits. Also
the regional valorization system is in fact covered within the Learning-Adapting-Leveling model with
regard to its interactions.
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The mentioned reference frames of the Learning-Adapting-Leveling model should be considered more
indicative than absolute as stated in chapter III. With respect to the applicability of the technology and
relevance to the end user and the actor implementing the model, certain criteria of the business aspect
of the value of information can be overlooked. Also the process of answering the reference frames in the
positive will make the chances of success more likely; however the process itself is not defined in the
thesis. Again this is dependent on the actor using the model. The reference frames can be considered as
a prelude to the actual development of the innovation network.
Timelines are currently hypothetical in chapter III as the model has only started its proof of concept yet
which is currently ongoing. Although the ideal of 5-10 years seem good, it may not be the case when the
model is executed. In fact, the initial timeframe could be much longer. However, in the long run over
iterations the timeframe can be reduced and optimized. Even for the technology transfer pipeline, the
timeframe could increase due to the additional consultations and feedback loops with the HNA, HTA and
HIA professionals. Also structural conformity issues between the different agencies and professionals
involved may take its initial toll. Nonetheless, real-time uptake by healthcare systems should be more
likely once the technology is rolled out and is more advantageous when compared to the time lost from
market to healthcare. Another issue is that relevant lobbying in the Learning-Adapting-Leveling model
brings in ethical issues of varied interests of stakeholders. As indicated in chapter I, the decision makers
should apart from the lobbied case of the academic-industrial complex and their own perceived point of
view, use opinions of third parties like patient groups and ethical boards to ensure only relevant
technologies reach the end user.
Coming back to the structural conformity mentioned in the previous paragraph, apart from the issues of
conformity amongst the different agencies, HTA for example is mainly focused on a population level as
mentioned in chapter VI, given the new development of the European best practice guidelines as in
chapter VII, the shift seems to move from clinical utility to personal utility. As a consequence, HTA will
have to shift from assessment at a population level to an individual level. Although currently this seems a
long term organizational tour, it is required to shift to personalized medicine as given in the guidelines.
Nonetheless, HTA analysis can still happen for personalized interventions however will be at a more
stratified level than individual which is feasible for the near future and for the model. Nonetheless,
conformity issues between agencies remains.
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Also as mentioned in chapter I, the model does not address the phasing out of the technology although
it is pointed out that the same model can be used to phase out as it is used to phase in. This is
dependent on who is the user, for example, the healthcare professional or industry. The prior would be
more concerned with the phasing out. Nevertheless, it would be advantageous for the academic-
industrial complex to also pay attention to the phasing out of the technology as it would present a better
case for simultaneously phasing in a technology. Although this has not been expanded upon in the
chapter, it can be briefly emphasized. The interactions between technology transfer and the public
health assessment tools through the development of the innovation network will eventually lead to
public-private partnerships. In parallel to introducing a technology through the assessments, the
technology transfer professionals should build a case based on those assessments or based on the early
assessment of that integrated technology, why it should be made obsolete while introducing their
technology. A SWOT (Strengths, Weaknesses, Opportunities and Threats) analysis and comparative
analysis can build a case in a broad and quick way for the phasing out of a technology. This can be done
simultaneously while developing their technology through the framework of the Learning-Adapting-
Leveling model. Another aspect of this model is that it can be used in an adapted form to propel relevant
non-genome-based technologies into healthcare or other organizations.
Although the issue of bottleneck of delay is the problem on the major part, the model in some instances
is not required in a smaller setting. For example, some university medical centers develop technologies
within their own settings and implement it into their own settings directly without going through the
general approval protocols. Some of such developed technologies go as far as not applying for a CE
marking as the technology is not being officially categorized as diagnostics. These technologies are
diffused readily into that healthcare settings and related networks. These developed technologies are
generally built in collaboration with industry. On the other hand sometimes, industry developing
prototypes and using their contacts let these university medical centers test the feasibility of the
technology and adapt the technology in-house. However with current ongoing scenarios, the CE marking
is being discussed with industry regarding its possibility of potential mandatory application, which may
change the approach of such university medical centers making it more feasible for the Learning-
Adapting-Leveling model. However, if willing the medical centers, the model can be differentially applied
in these settings to broaden the scope and reach of these developing technologies also making it easier
for future official assessments. In the current status, the assessments can be more internal than official
and later on approached to the official channels as per requirement, for example if they want to move
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from related networks usage to wide implementation. Another perspective to this issue is that quality
assurance is becoming very important. In the near future, also technologies applied in hospitals (medical
centers) need to have an HTA and systematic assessments. Thus, no in-house testing will be possible
eventually. This is a consequence of EU talks after recent scandals (like silicon implants) and is part of the
new EU directive on medical devices and IVD new directive. This contributes to the importance of the
model.
The concept of the game theory has been widely used in several fields of applications including biology.
The interactions between technology transfer of the academic-industrial complex and public health
assessment tools of the decision makers does involve complex interactions. Therefore a game theory
approach to study this will be an interesting endeavor. With regard to the interactions between
technology transfer and the public health assessment tools as two separate units, the concept of non-
cooperative game theory would be interesting to investigate. Furthermore, the interactions of the
academics with industry (academic-industrial complex) and the internal interactions between HNA, HTA
and HIA within the public health assessment tools will be interested to analyze with cooperative game
theory.
The Learning-Adapting-Leveling model has not been completely tested although is being tested on
different projects for the proof of concept. Until the proof of concept is accomplished, the scenarios and
probabilities mentioned above although seem likely are still hypothetical. Therefore, it is very important
for the sustainability of the model to have results on its first run which is currently an ongoing process
for the next few years.
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Chapter-wise Addressed Thesis Objectives
The general objectives of the thesis can be summarized as have been answered in the mentioned chapters
(when compared to the specific objectives and conclusions of Part A and Part B):
· PART A
o Chapter I
§ Identify the reason behind the backlog or bottleneck of effective and efficient
real time integration of health innovations/interventions (genome-based
technologies)
§ Address the issue of this bottleneck by proposing a framework covering the
whole spectrum of translational research possibly through integration and
development of (new) concepts
§ Defining the concept of valorization in public health genomics
o Chapter II
§ Demonstrating reasons why certain tools are not relevant to the framework
§ Addressing the confusion behind different concepts in translational research and
showing the relations between them including conceptual development of the
placement of tools within the translational research pipeline
o Chapter III
§ Developing the protocol of the developed framework
· PART B
o Chapters V and VI
§ Giving examples where the new framework can be implemented
o Chapter VII
§ Contribution to the development of the European best practice guidelines on
genome-based information and technologies
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Conclusions	
Personalized healthcare sets off a new era of healthcare that currently focuses on the individual genomic
signature of patients interacting dynamically with other health determinants such as environmental and
lifestyle factors to create a more personalized approach at a much earlier stage to healthcare. The core
diagnostic/therapeutic segment of the market comprised primarily of drugs, medical devices and
diagnostics is expected to reach £26 billion by 2015. Improvements in genome-based technologies are
primarily responsible for this staggering growth. The market is pioneered by small to medium enterprises
(SMEs) regarded as the true innovator of personalized diagnostics market, highly contributing to benefits
for society as stated in Europe’s growth strategy EU 2020. However, both historically and currently we
see that the timely uptake and implementation of these relevant SME-based genomics-related
applications in real time is negligible. The average time to diffusion in healthcare systems is over 10-20
years even with marketing approval (FDA, CE, CE-IVD, etc.). As a result and given the exponential fast
pace of technological development, by the time a relevant application is integrated into the healthcare
system, it is considered less relevant as a more effective and efficient application becomes available on
the market. Subsequently, both businesses and the population (e.g., patients in need of new and more
accurate clinical diagnostics) are at a disadvantage. This can increase the burden of disease as well as
become a development hurdle for companies in the diagnostics market causing significant problems, i.e.
product failure connecting to loss of employment, capital and IP.
Based around this bottleneck of healthcare integration the unique Learning-Adapting-Leveling model
was developed at the Institute for Public Health Genomics (IPHG) at Maastricht University. The
innovative nature of this model is that for the first time it brings together in parallel two never before
connected yet seemingly striking activities or worlds. The first being technology transfer, which is used
by industry to translate academic knowledge, patents and applied research into marketable products
and the second being the public health assessment tools. The latter is used by decision makers to assess
technologies on the market for healthcare implementation/acceptance, guidelines and reimbursement.
The Learning-Adapting-Leveling model identifies non-synergy between these two different entities as the
reason for the bottleneck of technological integration. The model assesses the feasibility of the
developing technology from the start to near the end of the technology maturation process for real-time
uptake by healthcare systems and policy guidelines, thereby give real-time recommendations to
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compensate for any gaps in the process prior to launching the product and to build contact with policy.
This model encourages early-on involvement of all stakeholders including doctors, industry, patient
groups, investors, insurance companies, HTA professionals, etc. leading towards a possible cross-talk and
public-private partnership. The model also takes into account and assesses the Value of Information and
does control analysis of possible gaps defined through the 10 essential public health tasks defined by the
Institute of Medicine (IoM) in 1988 and adapted to public health genomics within the Public Health
Genomics European Network (PHGEN). As a consequence it can be considered an overarching
framework given its extensive coverage of various widely regarded tools.
The model has been officially integrated in the European best practice guidelines for QA, provision and
use of genome-based information and technologies, FP7s and a few SMEs as well as the EU flagship pilot
project ICT Future of Medicine (www.itfom.eu). The model is also being used with SMEs and other
projects as well as grants and publications. Also a Joint Action is being planned for PHGEN II for the
implementation of the European best practice guidelines or in other words the implementation of the
model. Furthermore, the model has been published in high level reports like the Cyprus and Irish
Presidency and the European Science Foundation’s Forward Look report among others. The model has
been presented in the form of talks and poster presentations at international conferences and lectures.
Approaches even by contacts outside the EU (US and Australia) with people interested in the model have
been seen. Moreover, a grant from Limburg Fond has been obtained to organize a workshop on the LAL
model with participants from the academic-industrial complex, policy makers, hospitals and health
services on the regional level. The model has been lobbied for in the EU member states. Recently, the EC
has come up with a very specific tender on HTA interactions with technology developers as mentioned in
the general discussion section, which completely fits to the model showing the direction the EU is
interested in. Therefore, the sustainability of the model seems feasible and possibly could become the
standard for implementation of technologies to public health and healthcare. The next step of the model
is to test its proof of concept with pilot studies.
Although the model still may have adaption issues as mentioned in the general discussion section, it is
nonetheless the first translational model created within Public Health Genomics and the only one being
used at the Institute for Public Health Genomics for valorization concepts. Also, this model fulfills
accurately the definition of Public Health Genomics. The model creates translational research from basic
sciences to public health and from technology development to technology transfer. Most importantly,
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the model is a new specialization (valorization) within the field of Public Health Genomics. As the field of
Public Health Genomics is more into ‘the responsible and effective translation…’ the sub-specialization of
valorization in public health genomics is more into the ‘process of realization of added value bioproducts
(genome-based technologies) in the domain of public health…’. Realization is from the perspective of
identifying and understanding the importance and relevance of the bioproduct, i.e. any kind of
technology, for public health and healthcare purposes, thereby implementing them.
The Learning-Adapting-Leveling model based on the previous chapters has been proposed to be the
overarching framework in translational research for integration and implementation from bench to
bedside and beyond, i.e. into healthcare, through early-on interactions of all stakeholders. Through the
process the stakeholders ‘learn’ from each other,  ‘adapt’  or conform to each other’s requirements and
through the innovation network and developed public-private partnerships ‘level’ the modes of
communication to a single platform. This is the essence of the Learning-Adapting-Leveling model. The
model conceptually answers the original objective of the thesis regarding the bottleneck of the effective
and efficient real-time integration of genome-based information and technologies into healthcare.
Conclusively the thesis has developed a conceptual framework for the whole pipeline of translational
research i.e. from technology transfer to healthcare integration, using the concept of valorization in
public health genomics and demonstrated it with examples of potential applications. However the proof
of the model is an ongoing endeavor with various partners over the next few years.
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Summary	
Public Health Genomics is the responsible, effective, efficient and timely translation of genome-based
information and technologies into health policies and practice for the benefit of population health. Being
complementary to the interventions in health protection and health promotion, public health genomics
also demonstrates that the current public health interventions move towards personalized healthcare
including personalized medicine. In the past decade we have seen an exponential growth of personalized
medicine applications onto the market with the US market alone estimated to be at $454 billion by 2015.
The advent of personalized medicine and healthcare can find its roots in computational power through
‘omics’ research as well as systems biology and systems biomedicine. Importantly this push has been
from active participation of individuals through social media and the internet. However, it is noticed that
the implementation into healthcare systems of such personalized applications in the form of genome-
based information and technologies seems to have a huge backlog. Consequently both industry and the
citizens are at disadvantage. The thesis aims to address the issue of the backlog and bottleneck of the
effective and efficient integration of genome-based information and technologies (including
personalized medicine applications) from the bench (lab) through the market to the bedside and beyond
(healthcare) covering the whole spectrum of translational research of (personalized) healthcare. The
hypothesis is that given the exponential increase in genome-based technological innovation, systems in
place for technological integration into the healthcare practice still have a backlog in real time. The thesis
therefore projects to gain knowledge about current methodological apparatuses in place, identification
of gaps/problems and issues in healthcare systems, see possible integration of relevant tools and give
recommendations as well as potential application of the recommendations. Furthermore, certain
existing concepts and ideas have overlaps, and the thesis also aims to develop a consistency of the
relation of different tools to avoid confusion thereby bringing in new concepts in valorization. In
addition, the current existing European guidelines are not compatible for implementation of genome-
based technologies; therefore the thesis also contributes to the recently developed and endorsed
European best practice guidelines (PHGEN II), which will be implemented in the next few years in all EU
member states.
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With respect to the aims mentioned above, section 1 describes and builds the case for the above
mentioned problem statement and reviews the state of the art. In section 2, PART A of the thesis deals
with the development of theoretical concepts.
Within PART A, chapter I deals with setting the stage of the issue as the lack of communication or non-
synergy between the academic-industrial complex and decision makers. It was identified that both use
different tools for commercialization and implementation respectively, namely technology transfer (TT)
and the public health assessment tools (PHAT) in the form of health needs assessment (HNA), health
technology assessment (HTA), and health impact assessment (HIA). Furthermore, the chapter defined
the concept of valorization in Public Health Genomics as the process of realization of added value
(bio)products in the domain of public health for benefit of the population and healthcare systems. The
chapter addressed the bottleneck by developing a conceptual framework known as the Learning-
Adapting-Leveling model. This model brings for the first time technology transfer and the public health
assessment tools for cross talk to conform to each other’s needs.
Chapter II elaborates on all the widely used concepts of translation and implementation of genome-
based technologies such as personalized health applications. These include valorization, regional
valorization system, open innovation, technology transfer, drug discovery, spin-offs from the commercial
perspective  from bench  to  market.  From market  to  healthcare  concepts  include  HNA,  HTA,  HIA,  ACCE,
EGAPP, T1-T4, PHG Enterprise and the PHG wheel. The chapter clarifies the concepts of different tools
and demonstrates the place of different tools within other concepts and clears the confusion. It
elaborates that for the commercialization technology transfer covers all aspects of translation to the
market including valorization, regional valorization system, open innovation, drug discovery and spin-
offs. It also demonstrates why certain tools were left out of the developed framework (ACCE, EGAPP, T1-
T4, PHG Enterprise) due to limited scope and overlaps with existing widely regarded tools.
Chapter III develops the complete detailed protocol on how to use the Learning-Adapting-Leveling
model. This was stated as after initial research and development the technology transfer professionals
contact the HNA, HTA and HIA professionals in the same order involving feedback loops and going back
to the drawing board before going to the next professional (HNA to HTA to HIA). Throughout the process
the reference frames of value of information and the public health genomics wheel is taken into account.
This could lead to broadly defined public-private partnerships and can be optimized over time. Also this
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chapter addresses issues of timeframe as well as compatibility issues. Chapter IV gives the general
conclusion of Part A based on the specific objectives defined.
PART B deals with the potential implementation scenarios of the developed framework.
Within Part B, chapter V describes the complexity of biology as a result of ‘-omics’ and the introduction
of systems biology and its relation to personalized medicine and healthcare. It proposes the
implementation of the developed framework using an example of a current EU flagship pilot project ICT
Future of Medicine (ITFoM).
Chapter VI gives  an  overview  of  the  current  state  of  the  art  of  host  genetic  markers  in  relation  to
Chlamydia trachomatis infection.  The potential translational and clinical value of adding diagnostic host
genetic marker profiles on the basis of infection and inflammation to the current clinical management of
subfertility was investigated. The chapter proposes a new clinical diagnostic approach supplementing
traditional Chlamydia trachomatis serological tests, and investigates how the Learning-Adapting-Leveling
model can be of value and provide insight to see whether these host genetic markers can be translated
into public health
Chapter VII contributes to the development of the European best practice guidelines for quality
assurance, provision and use of genome-based information and technologies (PHGEN II) and clears
certain concepts. Here the thesis demonstrates the incorporation of the developed framework in the
European policy guidelines. Chapter VIII gives the general conclusions of Part B based on the specific
objectives defined.
Section 3 discusses in detail the conceptual development of the framework and discusses the issues of
the previous chapters and conceptualizes beyond the status quo and concludes the model’s overarching
reach and the development of the conceptual framework from technology transfer to healthcare
integration. Section 4 derives the final conclusion over the complete thesis and states that the
framework developed answers the objectives of the thesis regarding the bottleneck of real-time
effective and efficient integration of genome-based information and technologies, although the proof of
concept is a currently ongoing project over the next few years with collaborators. Section  5 gives the
summary of the thesis, the CV of the thesis author as well as list of publications and acknowledgements.
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Samenvatting	(Dutch	Summary)	
Public Health Genomics is de verantwoordelijke, effectieve, efficiënte en tijdige vertaling van
genoomgebaseerde informatie en technologie naar gezondheidsinstellingen en gezondheidszorg ter
bevordering van de volksgezondheid. Terwijl Public Health Genomics bijdraagt aan de interventie in
gezondheidsbescherming en bevordering van de gezondheid, laat het ook zien dat de hedendaagse
interventies in Public Health veranderen in gepersonaliseerde gezondheidszorg, en daarmee
gepersonaliseerde geneeskunde. In de afgelopen tien jaar was er op de markt een exponentiële groei
waarneembaar in gepersonaliseerde geneeskundige toepassingen, met de markt van de Verenigde
Staten  alleen  al  geschat  op  een  waarde  van  $454  miljard  tegen  het  jaar  2015.  De  komst  van
gepersonaliseerde geneeskunde en gezondheidszorg vindt zijn oorsprong in zowel rekenkracht door
onderzoek naar ‘omics’, alsmede systeem biologie en systeem biomedische wetenschappen. Het is
belangrijk te weten dat de aanzet daarvan afkomstig is uit de actieve betrokkenheid van individuen door
sociale media en internet. Er is echter bemerkt dat de implementatie in gezondheidszorgsystemen van
dergelijke gepersonaliseerde toepassingen, in de vorm van genoomgebaseerde informatie en
technologie, een enorme achterstand heeft. Als gevolg worden zowel de industrie als de bevolking
benadeeld. Deze thesis heeft als doel het ter sprake brengen van het probleem van de achterstand en
het knelpunt van de effectieve en efficiënte integratie van genoomgebaseerde informatie en technologie
(inclusief gepersonaliseerde geneeskundige toepassingen) vanaf de onderzoekstafel (laboratorium) via
de markt naar het ben van de patiënt en verder (gezondheidszorg), om het gehele spectrum aan
translationeel onderzoek naar (gepersonaliseerde) gezondheidszorg te behandelen. De hypothese is dat
gezien de exponentiële toename in genoomgebaseerde technologische innovatie, de bestaande
systemen voor technologische integratie in de praktijk van gezondheidszorg een voortdurende
achterstand hebben. Deze thesis stelt zich ten doel om kennis te verwerven van hedendaagse
methodologische systematiek, missende informatie of problemen binnen gezondheidszorgsystemen te
identificeren, mogelijke integratie van relevante hulpmiddelen in kaart te brengen en zowel
aanbevelingen als potentiële toepassing van de aanbevelingen te doen. Verder hebben bepaalde
bestaande concepten en ideeën overlap, en de thesis heeft tevens als doel om éénduidige hulpmiddelen
te ontwikkelen, en zal daarbij nieuwe concepten van valorisatie introduceren. Bovendien zijn de huidige
bestaande Europese richtlijnen niet compatibel voor implementatie van genoomgebaseerde
technologie; daarom draagt de thesis ook bij aan de recent ontwikkelde en doorgevoerde European best
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practice guidelines (PHGEN II), welke gedurende de komende jaren geïmplementeerd zullen worden in
alle EU lidstaten.
Met betrekking tot bovengenoemde doelstellingen, beschrijft en onderbouwt sectie 1 van de thesis de
eerst genoemde probleemstelling, en beoordeelt de huidige stand van zaken. In sectie 2 behandelt DEEL
A de ontwikkeling van theoretische concepten.
Binnen DEEL A behandelt hoofdstuk 1 het introduceren van het probleem van gebrek aan communicatie
en non-synergie tussen het academisch-industriële complex en de besluitvormers. Analyse liet zien dat
beiden verschillende hulpmiddelen gebruikten voor commercialisatie en implementatie, namelijk
technology transfer (TT) en de public health assessment tools (PHAT) in de vorm van health needs
assessment (HNA), health technology assessment (HTA), en health impact assessment (HIA). Verder
stelde het hoofdstuk het concept van valorisatie in Public Health Genomics vast als het realisatie-proces
van (bio)producten met toegevoegde waarde in het domein van volksgezondheid ten behoeve van de
bevolking en gezondheidszorgsystemen. Het hoofdstuk benoemt het knelpunt door het ontwikkelen van
een conceptueel kader dat we kennen als het Learning-Adapting-Leveling model. Dit model brengt voor
het eerst technologische overdracht en de beoordelingshulpmiddelen van de volksgezondheid samen om
elkaar aan te vullen.
Hoofdstuk II gaat dieper in op alle veel gebruikte concepten van translatie en implementatie van
genoomgebaseerde technologieën zoals gepersonaliseerde toepassingen in de gezondheidszorg. Hiertoe
behoren valorisatie, het regionale valorisatiesysteem, open innovatie, technologische overdracht,
farmaceutisch onderzoek, en spin-offs vanuit commerciële perspectief van de onderzoekstafel tot de
markt.  Concepten  van  de  markt  naar  gezondheidszorg  omvatten  HNA,  HTA,  HIA,  ACCE,  EGAPP,  T1-T4,
PHG Enterprise en het PHG wiel. Het hoofdstuk verduidelijkt de concepten van verschillende
hulpmiddelen en demonstreert de plaats die verschillende hulpmiddelen innemen binnen andere
concepten. Het gaat verder in op het feit dat voor commercialisatie, de technologische overdracht alle
aspecten van vertaling naar de markt beslaat, inclusief valorisatie, het regionale valorisatiesysteem, open
innovatie, farmaceutisch onderzoek en spin-offs. Het toont ook aan waarom bepaalde hulpmiddelen
werden weggelaten uit het ontwikkelde kader (ACCE, EGAPP, T1 - T4 , PHG Enterprise) vanwege de
beperkte reikwijdte en overlappingen met bestaande, alom bekende hulpmiddelen.
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Hoofdstuk III ontwikkelt het complete gedetailleerde protocol rond de vraag hoe het Learning-Adapting-
Leveling model gebruikt moet worden. Dit werd opgesteld aangezien de professionals in de
technologische overdracht, na het beginnende onderzoek en ontwikkeling, contact opnamen met de
HNA, HTA en HIA professionals in dezelfde volgorde, waarin zij feedback rondes betrokken en
terugkeerden naar de eerste fase voordat zij verder gingen naar de volgende professional (HNA naar HTA
naar HIA). Gedurende dit proces werden de referentiekaders informatie-waarde en het Public Health
Genomics Wheel in acht genomen. Dit zou kunnen leiden tot breed gedefinieerde publiekprivate
partnerschappen, hetgeen later  steeds verder geoptimaliseerd kan worden. Dit hoofdstuk behandelt
ook de problemen van het tijdskader, alsmede compatibiliteitsproblemen. Hoofdstuk IV geeft  de
uiteindelijke conclusie van DEEL A, gebaseerd op de specifiek gedefinieerde doelstellingen.
DEEL B behandelt de potentiële implementatie scenario’s van het ontwikkelde kader.
Binnen DEEL B omschrijft Hoofdstuk V de complexiteit van biologie als resultaat van ‘-omics’, en de
introductie van systeem biologie en haar relatie tot gepersonaliseerde geneeskunde en gezondheidszorg.
Het stelt de implementatie van het ontwikkelde kader voor door het voorbeeld van het belangrijke
huidige EU proefproject ICT Future of Medicine (ITFoM) aan te halen.
Hoofdstuk VI geeft een overzicht van de huidige stand van zaken wat betreft de genetische merker in
relatie tot de Chlamydia trachomatis infectie. De potentiële translationele en klinische waarde van het
toevoegen van diagnostische genetische merker profielen, op basis van infectie en ontsteking, aan het
huidige klinische management van verminderde vruchtbaarheid werd onderzocht. Het hoofdstuk stelt
een nieuwe klinisch diagnostische benadering voor ter aanvulling op de traditionele serologische test op
Chlamydia trachomatis, en onderzoekt hoe het Learning - Adapting - Leveling model van waarde kan zijn
en inzicht kan geven om te zien of deze genetische merkers naar de volksgezondheid kunnen worden
vertaald.
Hoofdstuk VII draagt bij aan de ontwikkeling van de Europese richtlijnen voor kwaliteitsborging, levering
en het gebruik van het genoomgebaseerde informatie en technologieën (PHGEN II) en verduidelijkt
specifieke concepten. Hier laat de thesis de incorporatie van het ontwikkelde kader in de Europese
richtlijnen zien. Hoofdstuk VIII geeft de algemene conclusies van DEEL B, gebaseerd op de specifiek
gedefinieerde doelstellingen.
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Sectie 3 gaat uitgebreid in op de conceptuele ontwikkeling van het kader en benoemt de problemen uit
de voorgaande hoofdstukken, conceptualiseert verder dan de status quo, en concludeert het
overkoepelende bereik van het model en de ontwikkeling van het conceptueel kader van de overdracht
van technologie tot integratie in gezondheidszorg. Sectie 4 trekt de uiteindelijke conclusie vanuit de
gehele thesis en stelt dat het ontwikkelde kader de doelstellingen van de thesis, betreffende het
knelpunt van werkelijk effectieve en efficiënte integratie van genoomgebaseerde informatie en
technologieën, beantwoord, hoewel het bewijs van het concept momenteel work-in-progress is. Sectie 5
geeft een samenvatting van de thesis, de CV van de auteur van deze thesis alsmede een lijst van
publicaties en dankwoord.
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सारांश	(Hindi	Summary)	
tu LokLF; thuksfeDl] turk ds LokLF; ykHk ds fy, LokLF; uhfr;ksa vkSj O;ogkj eas thukse vk/kkfjr lwpuk
vkSj izkS|ksfxdh ds ftEesnkj] izHkkoh] dq'ky vkSj lkef;d vuqokn gSA LokLF; lqj{kk vkSj LokLF; dks c<+kok nsus
esa gLr{ksi djus ds fy, iwjd gksus ds ukrs] tu LokLF; thuksfeDl Hkh ekStwnk tu LokLF; mik;ksa] O;fDrxr
nok lfgr O;fDrxr LokLF; dh fn'kk es ,d izHkkoh dne n'kkZrk gSA fiNys ,d n'kd esa  geus vesfjdk ds
cktkj es vdsys 2015 rd $ 454000000000 esa gksus ds vuqeku ds lkFk cktkj ij O;fDrxr fpfdRlk vuqiz;ksxksa
dh ,d O;k[;kRed o`f) ns[kh gSA O;fDrxr fpfdRlk i)fr vkSj LokLF; lsok ds vkxeu ls vksfeDl vuqla/kku
ds lkFk gh tho foKku iz.kkyh vkSj iz.kkfy;ka] ck;ksesfMflu ds ek/;e ls ys[kkO;fDr es viuh tM+ks dks ik
ldrk gSA ;g egRoiw.kZ dk;Z lkekftd ehfM;k vkSj baVjusV ds ek/;e ls O;fDr;ksa dh lfdz; Hkkxhnkjh ls
fd;k  x;k  gSA  gkykafd  ;g  thukse  vk/kkfjr  lwpuk  vkSj  izkS|ksfxdh  ds  #i  es  bl  rjg  ds  O;fDrxr
mi;ksx]LokLF; iz.kkyh esa ,d lafpr dk;Z gSA ftlds ifj.kke Lo#i nksuks m|ksx vkSj ukxfjdks dks gkfu gqbZ gSA
bl Fkhfll dk ;g y{; gS fd lafpr dk;Z rFkk vU; #dkoVksa fd leL;k dk lek/kku gks lds] rkfd mi;ksxh
rFkk izHkko'kkyh thukse vk/kkfjr rduhdh lwpuk vkSj vfHk;ksx dk ,dhdj.k gks ldsa] ftlls fd iz;ksx'kkyk ls
LokLF; lsok  cktkj  gsrq  lHkh  rjaxks  esa  LokLF; lsok  vuqla/kku  dk  vuqokn  gks  ldsA  dYiuk  dh  tkrh  gS  fd
thukse vk/kkfjr rduhdh es ?kkrkadh c<+ksÙkjh rFkk rduhdh ,dhdj.k] LokLF; lsok dk;Z iz.kkyh es lafpr dk;Z
gSA blfy, ;g 'kks/k&i= vkt ds le; esa iz.kkyh lacaf/kr midj.kksa] vUrjky@leL;k dh igpku rFkk LokLF;
lsok Øe ekeys] mi;ZqDr midj.kksa dk ,dhdj.k] rFkk laEHkork mi;ksx ds izksRlkgu dks lacksf/kr djrk gS rkfd
Kku dh c<+ksRrjh gks ldsA blds vfrfjDr dqN ,slh ekStwnk fopkj /kkjk,W gS] tks ,d nwljsa ij vfrO;kIr gSA
;g “kks/k i= ewY; of`) esa ubZ vo/kkj.kkvksa esa ykus ds Hkze dh fLFkfr ls cpus ds fy, fofHkUu midj.kksa ds laca/k
es ,d vuqdwyrk fodflr djus dk ,d iz;kl gSA blds vykok ekStwnk ;wjksih; fn'kkfunZs'k  thukse vk/kkfjr
izkS|ksfxdh ds dk;kZUo;u ds fy, laxr ugh gSA blfy, bl Fkhfll ds ifj.kkeksa dks vxys dqN o"kksZ es ykxw
fd;k tk,xk] tks gky es gh fodflr vkSj leFkZu izkIr ;wjksih; lcls vPNk vH;kl fn'kk funsZ'kksa ¼ih,pthb,u
f}rh;½  ds fy, ;ksxnku ds #i es ;wjksfi; la?k ds lnL; ns'kksas@jkT;ksa eas vxys dqN o"kkZs esa ykxw dh tk
ldrh gSA
Åij fn;s x, mYys[k tks [k.M&1 esa of.kZr gS mijksDr leL;kvksa ds c;ku ds fy, ekeys dks etcwr cukrk gS
vkSj dyk dh fLFkfrt dh leh{kk djrk gSA 'kks/k&i= ds [k.M&2] Hkkx v esa lS)kfUrd /kkj.kk ds vfo"dkj dk
o.kZu gSA
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Hkkx&v ds Hkhrj izFke v/;k; esa 'kS{kf.kd vkS|ksfxd ifjlj vkSj fu.kZ; fuekZrkvksa ds chp lapkj ;k xSj rkyesy
dh deh ds :i esa bl eqn~ns dks eap ij LFkkfir djus dk lek;kstu gSA O;oklkf;d vkSj dk;kZUo; ds fy,
nksuksa dk mi;ksx fofHkUu midj.kksa vFkkZr izkS|ksfxdh gLrkUrj.k ¼Vh0Vh0½ vkSj LokLFk ds :i esa lkoZtfud
LokLFk ewY;kadu midj.k ¼QSV½ LokLFk lEcU/kh ¼,p0,u0,0½ rduhdh izkS|ksfxdh vkadyu ¼,p0Vh0,0½ dh
igpku djuk  vko';d gSA blds vykok bl v/;k; esa tksM+ ewY; dh izkfIr ¼tho½ tula[;k vkSj LokLF;
iz.kkfy;kssa ds ykHk ds fy, lkoZtfud LokLF; ds {ks= esa mRiknks dks izfØ;k ds #i esa tu LokLF; thuksfeDl esa
ewY; o`f) dh vo/kkj.kk dks Hkh ifjHkkf"kr fd;k x;k gSA ;g v/;k; yfuZax ,MkifVax ysofyax ekWMy ds #i esa
,d oSpkfjd <kaps ds fodkl dks Hkh lacksf/kr djrk gSA ;g ekWMy] ,d nwljs dh t#jrks ds vuq#i igyh ckj
izkS|ksfxdh gLrkarj.k vkSj lkoZtfud LokLF; ewY;akdu midj.k dh ckr djrk gSA
f}rh; v/;k; esa O;fDrxr LokLF; vuqiz;ksxksa ds #i esa thukse vk/kkfjr izkS|ksfxdh dk vuqokn vkSj dk;kZUo;u
ds lHkh igyqvksa dk O;kid #i ls bLrseky fd;k x;k gSA ;g vo/kkj.kk crkrh gS fd izkS|ksfxdh csap ls cktkj
dks O;kolkf;d utfj, ls ewY;o`f)]{ksf=;ewY;o`f) iz.kkyh] [kqyk uokpkj] izkS|ksfxdh gLrkarj.k nokvksa dh [kkst
miksRikn 'kkfey gSA cktkj ls LokLF; vo/kkj.kkvksa ¼,p0,u0,0½ ¼,p0Vh0,0½ ¼,p0vkb0,0½ ¼,0lh0lh0bZ0½
¼b0th0,0ih0ih0½ ¼Vh1½&¼Vh4½ ¼ih0,p0th0½ m|e vkSj ¼ih0,p0th0½ pØ 'kkfey gSA bl v/;k; es fofHkUu
midj.kksa dh vo/kkj.kkvksa dks Li"V fd;k gS ;g vU; vo/kkj.kks ds Hkhrj fofHkUu midj.kksa ds LFkku dks n'kkZrk
gS vkSj Hkze dh fLFkfr dks lkQ djrk gSA ;g O;kolk;hdj.k izkS|ksfxdh gLrkarj.k ds fy, ewY; o`f) {ksf=;
ewY;o`f) iz.kkyh] [kqyk uokpkj nokvksa dh [kkst vkSj vuisf{kr ykHk lfgr cktkj ds fy, vuqokn ds lHkh
igyqvksa dks 'kkfey djrk gSA ;g bl ckr dks iznf'kZr djrk gSA fd fdl izdkj dqN midj.k fodflr <kaps
¼,0lh0lh0bZ0] bZ0th0,0ih0ih0] Vh01]Vh04] ih0,p0th0 bUVjizkbt½ls vyx dj fn;s x, gS vkSj mldk dkj.k
gSs ladh.kZ iz;kstu rFkk laHkor% midj.kks dk vfrO;kiuA
rr`h; v/;k; yfuZax ,MkifVax ysofyax ekWMy dk mi;ksx djus ij iwjk foLrr` izksVksdkWy fodflr djrk gSA
bl izkjafHkd vuqla/kku vkSj fodkl ds ckn izkS|ksfxdh gLrkarj.k ls tqMs+ O;olkf;d euq"; ds fy, ekSdk gS fd
og M~kabx cksMZ rFkk izfriqf"V Qans dks le>s ftls igys og ¼,p0vkb0,0½dks ¼,p0Vh0,0½dks ¼,p0,u0,0½ esa
¼,p0Vh0,0½ vkSj ¼,p0vkb0,0½ O;olkf;d euq"; ls lEidZ djsaA izfØ;k ds nkSjku lwpuk ,oa tu LokLF;
thuksfeDl pØ ds  ewY; ds  lanHkZ  Qsze  dks  /;ku es  j[kk  tkrk  gSa  ;g eksVs  rkSj  ij  bls  ifjHkkf"kr  lkoZtfud
futh Hkkxhnkjh ds fy, mi;ksx fd;k tk ldrk gSA le; ds lkFk bls vuqdwfyr fd;k tk ldrk gSA blds
vykok ;g v/;k; le; lhek ds eqnnksa ds lkFk gh] laxrrk leL;vksa ds gy dks Hkh izLrqr djrk gSA prqFkZ
v/;k; Hkkx *v* esa ifjHkkf"kr fof'k"V mnns';ksa ij vk/kkfjr lkekU; fu"d"kZ nsrk gSA
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Hkkx c% fodflr <kaps dh {kerk dk dk;kZUo;u ifjn'`;ksa dks lacksf/kr djrk gSA
Hkkx&c ds v/;k; ikap vksfeDl vkSj tho foKku iz.kkyh] O;fDrxr fpfdRlk vkSj LokLF; dks vius fj'rs dh
'kq#vkr dk ,d ifj.kke ds #i esa tho foKku dh tfVyrk dk o.kZu djrk gSA ;g fpfdRlk ¼vkb0Vh0,0,e0½
ds ,d ekStwnk ;wjksih; la?k ds izeq[k ik;yV ifj;kstuk ¼vkb0lh0Vh0½ Hkfo"; dk ,d mnkgj.k dk mi;ksx dj
fodflr <kaps ds dk;kZUo;u dk izLrko djrk gSA
v/;k; N% DySekbfM;k VS~dkseSfVl laØe.k ds laca/k es vkuqokaf'kd ekdZjks dh dyk dh orZeku fLFkfr dk ,d
flagoyksdu nsrk gSA lcQfVZfyVh ds orZeku uSnkfud izca/ku ds fy, laØe.k vkSj iztoyu ds vk/kkj ij funku
vuqokaf'kd ekdZj izksQkby dks tksM+us dh {kerk vuqokfnd vkSj uSnkfud ewY; dh tkap blesa lfEefyr gSA ;g
v/;k; ikjaifjd DySekbfM;k vkSj yfuZax ,MkifVax ysofyax ekWMy ewY; gsrq vkuqoaf'kd ekdZjks dk lkoZtfud
LokLF; esa vuqokn vkSj bl {ks= esa varnf`"V dks n”kkZrk gSA
v/;k; lkr xq.koRrk vk'oklu izko/kku vkSj thukse vk/kkfjr lwpuk vkSj izkS|ksfxdh ¼ih0,p0th0b0,u0½ f}rh;
dk mi;ksx djus ds fy, ;wjksih; lcls vPNs vH;kl fn'kk funZs'kks ds fodkl ds fy, ;ksxnku nsrk gS vkSj dqN
vo/kkj.kkvksa dks Hkh lkQ djrk gSA ;gkW ij 'kks/k i= ;wjksih; uhfrxr fn'kkfunsZ'kksa esa fodflr #ijs[kk ds
lekos'k dks n'kkZrk gSA v/;k; vkB es ifjHkkf"kr fof'k"V mnns';ksa ds vk/kkj ij Hkkx c ds lkekU; dks fu"d"kZ
nsrk gSA
/kkjk 3 esa foLrkj <kaps ds oSpkfjd fodkl dh ppkZ gS vkSj fiNys v/;k;ksa ds eqnnksa ij ppkZ gS vkSj ;FkkfLFkfr
ls ijs dUlsiVqykbt vkSj ekWMy dh O;kid igqap vkSj LokLF; ,dhdj.k ds fy, izkS|ksfxdh gLrkarj.k ls
oSpkfjd <kaaps ds fodkl ds fu"d"kZ dks fudkyk gSA ;g vo/kkj.kk lcwr ds lkFk orZeku esa py jgh gS] gkykfd
/kkjk&4 iwjh 'kks/k i= vkSj <kaps ds tokc thukse vk/kkfjr lwpuk vkSj izkS|ksfxdh ds okLrfod le; izHkkoh vkSj
dq'ky ,dhdj.k ds ckjs es 'kks/k ds mnns';ksa ds fodflr jkT;ks esa vafre fu"d"kZ crkrk gSA lg;ksfx;ksa ds lkFk
vxys dqN o"kkZs es ifj;kstuk /kkjk&5 'kks/k i= ds lkjka'k 'kks/k ys[kd ds ck;ksMkVk ds lkFk izdk'ku vkSj
vkHkkj&iwfrZ dh lwph nsrk gSA
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